

Europäisches Patentamt

European Patent Office

Office européen des brevets



(11) **EP 1 243 648 A1**

(12)

EUROPEAN PATENT APPLICATION

published in accordance with Art. 158(3) EPC

(43) Date of publication:

25.09.2002 Bulletin 2002/39

(21) Application number: 00985985.1

(22) Date of filing: 28.12.2000

(51) Int Cl.7: **C12N 15/09, C12N 1/15,
C12N 1/19, C12N 1/21,
C12N 5/10, C07K 14/705,
C07K 16/28, C12P 21/02,
C12Q 1/02, C12Q 1/68,
A61K 31/711, A61K 48/00,
A61P 43/00, G01N 33/15,
G01N 33/50**

(86) International application number:
PCT/JP00/09408

(87) International publication number:
WO 01/048188 (05.07.2001 Gazette 2001/27)

(84) Designated Contracting States:

**AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU
MC NL PT SE TR**

Designated Extension States:

AL LT LV MK RO SI

(30) Priority: 28.12.1999 JP 37515299

31.03.2000 JP 2000101339

(71) Applicant: Mitsubishi Pharma Corporation
Osaka-shi, Osaka 541-0046 (JP)

(72) Inventors:

- **MATSUMOTO, Shun-ichiro**
Funabashi-shi, Chiba 273-0005 (JP)
- **ODA, Tamaki**
Kisarazu-shi, Chiba 292-0054 (JP)
- **SAITO, Youko**
Kisarazu-shi, Chiba 292-0043 (JP)
- **MORIKAWA, Noriyuki**
Kisarazu-shi, Chiba 292-0833 (JP)

- **YOSHIDA, Kenji**
Kisarazu-shi, Chiba 292-0043 (JP)
- **SUWA, Makiko**
Ota-ku, Tokyo 144-0052 (JP)
- **SUGIYAMA, Tomoyasu**
Kisarazu-shi, Chiba 292-0045 (JP)
- **KISHIMOTO, Toshimitsu**
2-chome, Chuo-ku, Tokyo 103-8405 (JP)
- **KANZAKI, Kouji**
2-chome, Chuo-ku Tokyo 103-8405 (JP)
- **YASUDA, Shin-ichiro**
2-chome, Chuo-ku Tokyo 103-8405 (JP)
- **INOUE, Yoshihisa**
2-chome, Chuo-ku Tokyo 103-8405 (JP)

(74) Representative: Grünecker, Kinkeldey,
Stockmair & Schwanhäusser Anwaltssozietät
Maximilianstrasse 58
80538 München (DE)

(54) **NOVEL GUANOSINE TRIPHOSPHATE-BINDING PROTEIN-COUPLED RECEPTORS, GENES THEREOF AND PRODUCTION AND USES THEREOF**

(57) Nine novel genes sustaining hydrophobic domains, which are estimated to be seven transmembrane domains characteristic to G protein-coupled receptors, are successfully isolated by human tissue cDNA screening. These genes and proteins which are the expression

products thereof are usable in screening ligands, screening agonists or antagonists which are useful as drugs, diagnosing diseases in which these gene participate, etc.

EP 1 243 648 A1

D scripti n

Technical Field

5 [0001] The present invention relates to novel G protein-coupled receptors and genes thereof, and production and uses thereof.

Background Art

10 [0002] G protein-coupled receptor is a generic name for the group of cell membrane receptors transducing signals into cells via the activation of trimer-type GTP-binding proteins. The G protein-coupled receptor has structural characteristic of seven transmembrane domains in a molecule, and thus called also as "a seven-transmembrane receptor". The G protein-coupled receptor transmits the information consisting of various physiologically active substances into cells across the cell membrane via the activation of the trimer-type GTP-binding protein and the change of the intracellular second messengers caused thereby. Well-known intracellular second messengers that are regulated by the trimer-type GTP-binding protein include cAMP mediated by adenylate cyclase, and Ca^{2+} mediated by phospholipase C. Recent studies have shown that many types of intracellular proteins serve as the targets thereof; for example, the regulation of channels and activation of phosphorylation enzymes are mediated by the trimer-type GTP-binding protein (*Annu. Rev. Neurosci.* (97) 20:399). There are a wide variety of substrates (ligands) for the G protein-coupled receptor, for example, protein hormone; chemokine; peptide; amine; substances derived from lipids; and protease, such as thrombin, is also one such example. The number of human G protein-coupled receptors whose genes have been identified recently, is a little under 300, excluding the sensory-type receptors. However, the number of G protein-coupled receptors to which the ligands have been identified is only about 140 types. Thus, there are 100 or more, ligand-unknown, "orphan G protein-coupled receptors". The human genome has been assumed to contain at least 400 types, and possibly up to 1000 types of G protein-coupled receptors (*Trends Pharmacol. Sci.* (97) 18:430). This means that the number of functionally unknown orphan G protein-coupled receptors can be exploding accompanied by the rapid progress of the genome analysis.

[0003] Ninety % or more drugs that have so far been produced by the pharmaceutical companies in the world aim at the interaction in extracellular spaces, and low-molecular-weight drugs comprises the majority of those relating to G protein-coupled receptors. The reason is that the G protein-coupled receptor-related diseases include many types of diseases, such as those of the cerebral nervous system, circulatory system, digestive system, immune system, locomotor system, urinary system, and genital system, including genetic diseases. Thus, in recent years, many pharmaceutical companies retain their orphan G protein-coupled receptors found through the genome analysis, and are competing fiercely with each other to reveal the ligands and physiological functions. Based on this, successful cases of physiological screening of ligands to some novel G protein-coupled receptors have begun to be reported recently. For example, the cases of a calcitonin-related peptide receptor (*J. Biol. Chem.* (96) 271:11325), orexin (*Cell* (98) 92:573), and prolactin-releasing peptide (*Nature* (98) 393:272) gave a great impact to basic studies in the field of life science.

[0004] In particular, as potential new targets to bring about the drug development, the orphan G protein-coupled receptors have become a center of attraction. In general, since there are no specific ligands to the orphan G protein-coupled receptors, it has been difficult to develop agonists or antagonists. However, in recent years, creation of orphan G protein-coupled receptor-targeted drugs by combining the enriched compound libraries and high-throughput screening methods has been proposed (*Trends Pharmacol. Sci.* (97) 18:430, *Br. J. Pharm.* (98) 125:1387). Specifically, in the creation comprises identifying physiological agonists of an orphan G protein-coupled receptor identified by genetic engineering, by functional screening utilizing alterations in the level of an intracellular messenger, cAMP or Ca^{2+} , as an index, and then analyzing the *in vivo* functions. In this method, high-throughput screening achieved by using a compound library allows theoretically to discover surrogate agonists and antagonists specific to the orphan G protein-coupled receptor, and further, to develop therapeutic agents for particular diseases.

50 Disclosure of the Invention

[0005] The present invention was achieved considering the present situation surrounding G protein-coupled receptors, and an objective thereof is to provide novel G protein-coupled receptors and their genes, and a method for producing and uses of them. Another objective of the present invention is to provide these molecules as targets for the study of drug development.

55 [0006] The present inventors studied strenuously to achieve the above-mentioned objectives, and successfully isolated nine novel genes comprising nucleotide sequences encoding hydrophobic regions considered to be seven transmembrane domains, which are characteristic of the G protein-coupled receptors, by polymerase chain reaction using

cDNAs from human tissues as templates. These genes and the proteins as the translation products can be used in the screening of ligand and of agonist or antagonist useful as a pharmaceutical, or can be used for diagnosing diseases relating to these genes.

[0007] Thus, the present invention relates to novel G protein-coupled receptors and the genes encoding them, and the uses and production thereof. More specifically, the present invention provides:

(1) a DNA that encodes a guanosine triphosphate-binding protein-coupled receptor, wherein said DNA is selected from the group consisting of the following (a) to (d):

- (a) a DNA encoding a protein comprising the amino acid sequence of any one of SEQ ID NOs: 1 to 4 and 17 to 21;
- (b) a DNA comprising a coding region of the nucleotide sequence of any one of SEQ ID NOs: 5 to 8 and 22 to 26;
- (c) a DNA encoding a protein comprising the amino acid sequence of any one of SEQ ID NOs: 1 to 4 and 17 to 21 in which one or more amino acids are substituted, deleted, added, and/or inserted; and
- (d) a DNA hybridizing under stringent conditions to the DNA comprising the nucleotide sequence of any one of SEQ ID NOs: 5 to 8 and 22 to 26;

(2) a DNA encoding a partial peptide of a protein comprising the amino acid sequence of any one of SEQ ID NOs: 1 to 4 and 17 to 21;

(3) a vector comprising the DNA of any one of (1) and (2);

(4) a transformant carrying the DNA of any one of (1) and (2) or the vector of (3);

(5) a protein or a peptide encoded by the DNA of any one of (1) and (2);

(6) a method for producing the protein or the peptide of (5), said method comprising the steps of culturing th transformant of (4) and recovering an expressed protein or peptide from the transformant or culture supernatant thereof;

(7) a method of screening for ligands that bind to the protein of (5), said method comprising the steps of:

- (a) contacting a test sample with the protein or the peptide of (5); and
- (b) selecting compounds that binds to said protein or said peptide;

(8) a method of screening for compounds that have activity of inhibiting the binding between the protein of (5) and a ligand thereof, said method comprising the steps of:

- (a) contacting the protein of (5) or a partial peptide thereof with the ligand in the presence of a test sample and detecting a binding activity of said protein or said partial peptide with said ligand; and
- (b) selecting compounds that reduces the binding activity detected in step (a) as compared with a binding activity detected in the absence of the test sample;

(9) a method of screening for compounds that inhibit or enhance activity of the protein of (5), said method comprising the steps of:

- (a) contacting a ligand of said protein with cells expressing said protein in the presence of a test sample,
- (b) detecting an alteration in the cells that results from binding of said ligand to said protein, and
- (c) selecting compounds that suppress or enhance the alteration detected in step (b) as compared with an alteration detected in the cells in the absence of the test sample;

(10) the method of (8) or (9), wherein the alteration in cells is a change in cAMP concentration or calcium concentration;

(11) an antibody binding to the protein of (5);

(12) a compound isolated by the method of any one of (7) to (10);

(13) a pharmaceutical composition comprising the compound of (12) as an active ingredient;

(14) the pharmaceutical composition of (13), wherein said pharmaceutical composition is formulated for the treatment of a disease selected from the group consisting of cancer, cirrhosis, and Alzheimer's disease;

(15) a polynucleotide comprising at least 15 nucleotides, wherein said polynucleotide is complementary to the DNA comprising the nucleotide sequence of any one of SEQ ID NOs: 5 to 8 and 22 to 26 or a complementary strand thereof;

(16) a method for diagnosing a disease selected from the group consisting of cancer, cirrhosis, and Alzheimer's disease, said method comprising the steps of detecting expression of the DNA of (1) in tissues related to th

disease derived from a subject, or mutation in the DNA of (1) in the subject; and
 (17) a agent for diagnosing a disease selected from the group consisting of cancer, cirrhosis, and Alzheimer's disease, said agent comprising the antibody of (11) or the nucleotide of (15).

[0008] As used herein, the term "G protein-coupled receptor" means a cell membrane receptor transducing signals into cells *via* the activation of the GTP-binding protein.

[0009] As used herein, the term "ligand" means a physiological substance binding to the G protein-coupled receptor and transducing signals into cells. Herein, the term "physiological substance" means a compound bound to the G protein-coupled receptor *in vivo*.

[0010] As used herein, the term "agonist" means a compound capable of binding to the G protein-coupled receptor and transducing signals into cells, including biological substances, artificially synthesized compounds, and naturally occurring compounds.

[0011] As used herein, the term "antagonist" means a compound inhibiting the binding of ligand to the G protein-coupled receptor or inhibiting the signal transduction into cells, including biological substances, artificially synthesized compounds, and naturally occurring compounds.

[0012] The present invention provides novel G protein-coupled receptors and the DNAs encoding the proteins. The nine human cDNA clones, isolated by the present inventors and included by the present invention, were named "GPRv8", "GPRv12", "GPRv16", "GPRv21", "GPRv40", "GPRv47", "GPRv51", "GPRv71", and "GPRv72" (as required, these clones are collectively referred to as "GPRv"). The nucleotide sequences of the cDNAs are shown in SEQ ID NOs: 5 to 8 and 22 to 26; the amino acid sequences of the proteins encoded by the cDNAs are shown in SEQ ID NOs: 1 to 4 and 17 to 21.

[0013] A result obtained by BLAST search showed that amino acid sequence of all the proteins encoded by GPRv cDNAs exhibited significant homology to those of known G protein-coupled receptors. Specifically, "GPRv8" exhibited 36% homology to HUMAN VASOPRESSIN V1B RECEPTOR (P47901, 424 aa); "GPRv12" exhibited 27% homology to RAT 5-HYDROXYTRYPTAMINE 6 RECEPTOR (P31388, 436 aa); "GPRv16" exhibited 28% homology to MOUSE GALANIN RECEPTOR TYPE 1 (P56479, 348 aa); "GPRv21" exhibited 30% homology to BOVIN NEUROPEPTIDE Y RECEPTOR TYPE 2 (P79113, 384 aa); "GPRv40" exhibited 34% homology to OXYTOCIN RECEPTOR (P97926, 388 aa); "GPRv47" exhibited 43% homology to GPRX_ORYLA PROBABLE G PROTEIN-COUPLED RECEPTOR (Q91178, 428 aa); "GPRv51" exhibited 37% homology to PROBABLE G PROTEIN-COUPLED RECEPTOR RTA (P23749, 343 aa); "GPRv71" exhibited 45% homology to Chicken P2Y PURINOCEPTOR 3 (P2Y3) (Q98907, 328 aa); "GPRv72" exhibited 30% homology to ALPHA-1A ADRENERGIC RECEPTOR (002824, 466 aa).

[0014] Further, all the proteins encoded by GPRv cDNAs (hereinafter also may be referred to as "GPRv protein"), isolated by the present inventors, contained hydrophobic regions, which were assumed to correspond to the seven transmembrane domains characteristic of the G protein-coupled receptor. Based on these findings, all the GPRv cDNAs can be considered to encode proteins belonging to the G protein-coupled receptor family. The G protein-coupled receptors have the activity for transducing signals into cells *via* the activation of the G protein, which is mediated by the ligand. As described above, the receptor are involved in many types of diseases, such as those of the cerebral nervous system, circulatory system, digestive system, immune system, locomotor system, urinary system, and genital system, including genetic diseases. Accordingly, the GPRv proteins can be used to screen for agonists and antagonists regulating the functions of GPRv proteins, and thus become important targets of drug development for the above diseases.

[0015] The present invention also provides proteins functionally equivalent to the GPRv proteins. As used herein, the term "functionally equivalent" means that a protein of interest has biological properties identical to those of the GPRv proteins. The biological properties of GPRv proteins include the activity of transducing signals into cells *via* the activation of the trimer-type GTP-binding protein. According to the types of activated systems of intracellular signal transduction, the trimer-type GTP-binding proteins are categorized into three classes, namely, Gq type that increases the Ca²⁺ level, Gs type that increases the cAMP level, and Gi type that reduces the cAMP level (*Trends Pharmacol. Sci.* (99) 20:118). Thus, it can be assessed whether the protein of interest has biological properties identical to those of GPRv proteins, for example, by detecting concentration changes of cAMP or calcium in cells depending on the activation.

[0016] In an embodiment, the method for preparing a protein functionally identical to the GPRv protein includes a method of introducing mutations in the amino acids sequence of the protein. Such method includes, for example, site-directed mutagenesis (*Current Protocols in Molecular Biology*, edit. Ausubel et al. (1987) Publish. John Wiley & Sons Section 8.1-8.5)). The amino acid mutations in the protein can be also occurred naturally. The present invention includes mutant proteins, regardless of being generated artificially or naturally, in which one or more amino acids have been substituted, deleted, inserted and/or added in the amino acid sequences (SEQ ID NOs: 1 to 4 and 17 to 21) of GPRv proteins, but the mutant proteins are functionally equivalent to the GPRv proteins. There is no limitation on the number of amino acid mutations and positions of the mutations in the proteins, as far as the functions of GPRv proteins are retained. The number of mutations is assumed to range typically within 10% of the entire amino acids, preferably within

5% of the entire amino acids, further preferably within 1% of the entire amino acids.

[0017] In another embodiment of the invention, the method for preparing a protein functionally equivalent to the GPRv protein includes a method using the hybridization technique or gene amplification technique. Specifically, those skilled in the art can typically isolate a DNA having high homology to the DNA sequence encoding the GPRv protein (SEQ ID NOs: 5 to 8 and 22 to 26) or a partial sequence thereof from a DNA sample derived from a homologous or heterologous using the hybridization technique (*Current Protocols in Molecular Biology*, edit. Ausubel et al. (1987) Publish. John Wiley & Sons Section 6.3-6.4) and then obtain a protein functionally equivalent to the GPRv protein. Thus, the protein of the present invention also include a protein encoded by a DNA capable of hybridizing to the DNA encoding the GPRv protein, which is functionally equivalent to the GPRv protein.

[0018] Organisms to be used for isolating such a protein include, for example, rat, mouse, rabbit, chicken, pig, cattle, and so forth, in addition to human, but not limited thereto.

[0019] Typical stringent hybridization conditions for isolating a DNA encoding a protein functionally equivalent to the GPRv protein are those of "1x SSC, 0.1% SDS, 37°C" or the like; more stringently, those of "0.5x SSC, 0.1% SDS, 42°C" or the like; much more stringently, those of "0.2x SSC, 0.1% SDS, 65°C" or the like. As the hybridization conditions become more stringent, a DNA with higher homology to the probe sequence can be expected to be isolated. However, the above combinations of SSC, SDS, and temperature are only examples, and those skilled in the art can achieve the stringencies equivalent to the above by appropriately combining the above or other factors determining the hybridization stringency (for example, probe concentration, probe length, time of hybridization reaction, and so forth).

[0020] The protein encoded by a DNA isolated by using such hybridization technique typically has high homology of amino acid sequence to those of the GPRv protein. The term "high homology" means the degree of sequence homology of at least 40% or higher, preferably 60% or higher, further preferably 80% or higher (for example, 90% or higher, or 95% or higher).

[0021] Identity of amino acid sequence or nucleotide sequence can be determined with the BLAST algorithm of Karlin and Altschul (Proc. Natl. Acad. Sci. USA 90:5873-5877, 1993). Based on this algorithm, the programs, BLASTN and BLASTX, have been developed (Altschul et al. J. Mol. Biol. 215: 403-410, 1990). When nucleotide sequences are analyzed by BLASTN based on BLAST, the parameters are set, for example, as follows: score= 100; and wordlength= 12. Alternatively, when amino acid sequences are analyzed by BLASTX based on BLAST, the parameters are set, for example, as follows: score= 50; and wordlength= 3. When BLAST and the Gapped BLAST program are used for the analysis, the default parameters are used in each program. The specific techniques used in these analysis methods are already known (<http://www.ncbi.nlm.nih.gov>).

[0022] Further, primers are designed based on a part of the DNA sequence (SEQ ID NOs: 5 to 8 and 22 to 26) encoding the GPRv protein, a DNA fragment having high homology to the DNA sequence encoding the GPRv protein is isolated by the gene amplification technique (PCR) (*Current protocols in Molecular Biology*, edit. Ausubel et al. (1987) Publish. John Wiley & Sons Section 6.1-6.4), and then the protein functionally equivalent to the GPRv protein can be obtained.

[0023] The present invention also includes partial peptides of the protein of the present invention. These partial peptides include peptides binding to the ligand but not transducing signals. An affinity column prepared using such a peptide can be used suitably for ligand screening. In addition, the partial peptides of the protein of the present invention can be used for preparing antibodies. The partial peptides of the present invention can be produced, for example, by using genetic engineering techniques, known peptide synthetic methods, or methods of digesting the protein of the present invention with an appropriate peptidase. The partial peptides of the present invention typically consist of 8 or more amino acid residues, preferably 12 or more amino acid residues (for example, 15 or more amino acid residues).

[0024] The protein of the present invention can be prepared as a recombinant protein or natural protein. The recombinant protein can be prepared, for example, as follows, by introducing a DNA encoding the protein of the present invention, which has been inserted in a vector, into an appropriate host cell and purifying the protein expressed in the transformant. On the other hand, the natural protein can be prepared, for example, by using the affinity column, in which an antibody against the protein of the present invention has been immobilized, as follows (*Current Protocols in Molecular Biology*, edit. Ausubel et al. (1987) Publish. John Wiley & Sons Section 16.1-16.19). The antibody to be used in the affinity purification may be a polyclonal or monoclonal antibody. Further, the protein of the present invention can be prepared by *in vitro* translation (see, for example, "On the fidelity of mRNA translation in the nuclease-treated rabbit reticulocyte lysate system. Dasso, M.C., Jackson, R. J. (1989) *NAR* 17:3129-3144"), or the like.

[0025] The present invention also provides DNAs encoding the above-mentioned proteins of the present invention. There is no limitation on the type of DNA of the present invention, as far as it can encode the protein of the present invention; comprising cDNA, genomic DNA, chemically synthesized DNA, etc. Further, when it includes the protein of the present invention, a DNA having any nucleotide sequence based on the degeneration of genetic code is included. The DNA of the present invention can be isolated according to a standard method, such as the hybridization method using a DNA sequence encoding the GPRv protein (SEQ ID NOs: 5 to 8 and 22 to 26) or a partial sequence thereof as a probe or PCR method using primers synthesized based on these DNA sequence, as described above.

[0026] In addition, the present invention also provides a vector, in which the DNA of the present invention has been inserted. There is no limitation on the type of vector of the present invention, as far as it stably retains the inserted DNA. For example, when *E. coli* is used as a host, the preferable cloning vector is pBluescript vector (Stratagene) or the like. When the vector is used for the purpose of producing the protein of the present invention, an expression vector is especially useful. There is no limitation on the type of expression vector, as far as it directs the expression of the protein *in vitro*, in *E. coli*, in culture cells, in the living body, for example, pBEST (Promega) for *in vitro* expression; pET (Invitrogen) for in *E. coli*; pME18S-FL3 (GenBank Accession No. AB009864) for in culture cells; and, pME18S (*Mol Cell Biol.* 8:466-472(1988)) for in the living body of an organism are preferred vectors. The insertion of the DNA of the present invention into a vector can be achieved according to a standard method, for example, by ligation using restriction enzyme sites (*Current protocols in Molecular Biology*, edit. Ausubel et al. (1987) Publish. John Wiley & Sons. Section 11.4-11.11).

[0027] Also, the present invention provides a transformant containing the DNA of the present invention or the vector of the present invention. There is no limitation on the type of host cell into which the vector of the present invention is to be introduced, and various types of host cells can be used depending on the purposes. Exemplary eukaryotic cells, in which the protein is to be expressed at high levels, include COS cell and CHO cell. The vector can be introduced into the host cell, by a known method such as, for example, calcium-phosphate precipitation method, electroporation method, (*Current protocols in Molecular Biology*, edit. Ausubel et al. (1987) Publish. John Wiley & Sons. Section 9.1-9.9), a method with lipofectamine (GIBCO-BRL), microinjection, and so forth.

[0028] The present invention also provides nucleotides comprising at least 15 nucleotide residues, which is complementary to the DNA encoding the protein of the present invention (DNA comprising any one of the nucleotide sequences of SEQ ID NOs: 5 to 8 and 22 to 26 or the complementary strand thereof). The term "complementary strand" means one strand complementary to the other strand of the two of double-stranded nucleic acid consisting of A:T (U in the case of RNA) and G:C nucleotide pairs. Further, the term "complementary" means not only being a perfect complementary sequence in a region of at least consecutive 15 nucleotide residues, but also nucleotide sequences with at least 70% homology, preferably at least 80%, more preferably 90%, further preferably 95% of homology or higher. The algorithm described herein can be used for determining homology. These nucleotides can be used as probes for detecting and isolating the DNA of the present invention, and as primers for amplifying the DNA of the present invention. When used as the primer, it typically comprises 15 bp -100 bp, preferably of 15 bp -35bp of nucleotides. Alternatively, when used as the probe, it is at least 15 bp of nucleotide containing at least a part of the DNA of the present invention or the entire sequence. Preferably, such nucleotide specifically hybridize to the DNA encoding the protein of the present invention. The term "specifically hybridizing" means that a DNA hybridizes to the DNA encoding the protein of the present invention (SEQ ID NOs: 5 to 8 and 22 to 26) but not to DNAs encoding other proteins, under typical hybridization conditions, preferably under stringent conditions.

[0029] These nucleotides can be used for testing and diagnosing abnormalities of the protein of the present invention. For example, abnormal expression of the DNA encoding the protein of the present invention can be tested by Northern hybridization or RT-PCR using these nucleotides as probes or primers. The nucleotides can be used, for example, in the tests for cancers, cirrhosis, or Alzheimer's disease. In addition, the DNA encoding the protein of the present invention or the regulatory region for the expression is amplified by polymerase chain reaction (PCR) using the nucleotides as primers, and then abnormalities in the DNA sequence can be tested and diagnosed by using the methods such as RFLP analysis, SSCP, and sequencing.

[0030] Moreover, the antisense DNA for suppressing expression of the protein of present invention is included in these nucleotides. In order to cause the antisense effect, antisense DNA comprises at least 15 bp of nucleotides or more, preferably 100 bp, more preferably 500 bp or more, and usually comprises 3000 bp or less, preferably 2000 bp or less. Such antisense DNA may be applied to the gene therapy for the disease resulting from the abnormalities (abnormalities of function or expression) of the protein of present invention and so forth. This antisense DNA can be prepared, for example, based on the sequence information of DNA (for example, from SEQ ID NO: 5 to 8 and 22 to 26) encoding the protein of the present invention, by the phosphorothioate method (Stein, 1988 Physicochemical properties of phosphorothioate oligodeoxynucleotides. *Nucleic Acids Res* 16, 3209-21 (1988)), etc.

[0031] For gene therapy, the nucleotide of a present invention can be administered to a patient by *ex vivo* method, *in vivo* method, and so forth using virus vectors, such as a retrovirus vector, an adenovirus vector, and an adeno associated virus vector, and non-virus vectors, such as liposome, etc.

[0032] Further, the present invention provides the antibody bound with the protein of the present invention. There is no limitation in the form of the antibody of the present invention, and a polyclonal antibody and a monoclonal antibody, or a part thereof having antigen affinity are also included. Moreover, the antibody of all classes is included. Furthermore, the antibody of a present invention also includes special antibodies, such as a humanized antibody.

[0033] For a polyclonal antibody, the antibody of the present invention can be obtained by synthesizing oligopeptides corresponding to the amino acid sequence of the protein of the present invention according to a standard, and then immunized to rabbit (*Current protocols in Molecular Biology*, edit. Ausubel et al. (1987) Publish. John Wiley & Sons.

Section 11.12-11.13). For a monoclonal antibody, the hybridoma cell prepared by the cell fusion of the spleen cell and myeloma cell of the mouse immunized using the protein expressing in *E. coli* and then purified according to the standard method, and the antibody of the present invention can be obtained from this hybridoma cell (Current protocols in Molecular Biology, edit. Ausubel et al. (1987) Publish. John Wiley & Sons. Section 11.4-11.11).

[0034] In addition to purifying of the protein of the present invention, the antibody bound with the protein of the present invention may be also used for a test and a diagnosis of the abnormalities in expression or in structure of the protein of a present invention. Specifically, protein can be extracted from tissue, blood, or cell, and then can be used for the test and the diagnose for presence or absence of the abnormalities of expression or structure, via a detection of the protein of the present invention by Western blotting method, immunoprecipitation, ELISA, and so forth. The antibody

of the present invention may be used for a test of cancer, liver cirrhosis, or Alzheimer's disease.
[0035] Moreover, the antibody bound with the protein of the present invention may be used for the purposes of, such as treatment of the disease relevant to the protein of the present invention. The antibody of the present invention can effect as the agonist and antagonist for the protein of the present invention. When using an antibody for the purpose of treatment of a patient, an antibody derived from human or a humanized antibody is preferable because of little immunogenicity. An antibody derived from human can be prepared by immunizing the mouse of which immune system is replaced with those of human (for example, refer to "Functional transplant of megabase human immunoglobulin loci recapitulates human antibody response in mice" Mendez, M.J. et al. (1997) Nat. Genet. 15: 146-156). Moreover, a humanized antibody can be prepared by recombination with the hypervariable region of a monoclonal antibody (Methods in Enzymology 203, 99-121 (1991)).

[0036] Further, the present invention also provides a screening method for ligands binding to the protein of the present invention using the protein of the present invention. This screening method comprises the step of: (a) contacting a test sample with the protein of the present invention or a partial peptide thereof; and (b) selecting compounds binding to the protein or the partial peptide thereof.

[0037] Without limiting, the test sample include, for example, known compounds or peptides (for example, deposited in the Chemical File) whose activities as the ligands to the various G protein-coupled receptors have not yet been identified or a group of random peptides which have been prepared by phage display method (*J. Mol. Biol.* (1991) 222, 301-310). Further, culture supernatants of microorganisms, natural ingredients from plants or marine organisms, and, in addition to these, biological extracts from tissues including brain, cell extracts, expression products of gene libraries, but not limited thereto, can be screened.

[0038] The protein of the present invention to be used for the screening can be, for example, the form displayed on cell surface, the form as the cell membrane fraction of the cells, or the form immobilized in an affinity column.

[0039] Specific screening methods include many known methods such as, for example, a method of contacting a test sample with an affinity column of the protein of the present invention and purifying compounds bound to the protein of the present invention; and Western blotting method. When these methods are used, the test sample is labeled appropriately and the binding with the protein of the present invention can be detected by using the label. In addition to these methods, another method can be used; in which cell membranes expressing the protein of the present invention are prepared and immobilized on a chip, and the alterations in surface plasmon resonance, which represent the dissociation of the trimer-type GTP-binding protein during the ligand binding, are detected (*Nature Biotechnology* (99) 17: 1105).

[0040] Further, the binding activity between a test sample and the protein of the present invention can be detected for alterations as indices in cells, which is caused by the binding of the test sample to the protein of the present invention expressed on cell surface. Such alterations include, for example, alterations of intracellular Ca^{2+} level and cAMP levels, but not limited thereto. Specifically, the agonist activity to the G protein-coupled receptor can be assayed by GTP γ S binding method.

[0041] In an example where this method is used, cell membranes on which the G protein-coupled receptor has been displayed are mixed with 400 pM ^{35}S -labeled GTP γ S in a solution containing 20 mM HEPES (pH 7.4), 100 mM NaCl, 10 mM MgCl_2 , and 50 μM GDP, the mixture is incubated either in the presence or in absence of a test sample and then filtrated, and the radioactivities of the bound GTP γ S are compared.

[0042] Further, the G protein-coupled receptors share the system of transducing signals into cells via the activation of the trimer-type GTP-binding protein. The trimer-type GTP-binding proteins are categorized into three classes depending on the types of activated systems of intracellular signal transduction: namely, Gq type that increases the Ca^{2+} level; Gs type that increases the cAMP level; and Gi type that reduces the cAMP. Thus, the use of a chimeric protein consisting of α -subunit from Gq protein and α -subunit from another type of G protein, or promiscuous $\text{G}\alpha$ proteins, $\text{G}\alpha 15$ and $\text{G}\alpha 16$, allows the positive signal in the ligand screening to result in increased Ca^{2+} levels in the pathway of Gq intracellular signal transduction. The increased Ca^{2+} levels can be detected by using, as indices, altered levels of a reporter gene having TRE (TPA responsive element) or MRE (multiple responsive element) on upstream, dye indicator such as Fura-2 and Fluo-3, and fluorescent protein aequorin. Similarly, the use of a chimeric protein consisting of α -subunit from Gs protein and α -subunit from another type of G protein allows the positive signal to result in increased

cAMP levels in the pathway of Gs intracellular signal transduction, and the increased levels can be detected by using, as indices, altered levels of a reporter gene having CRE (cAMP-responsive element) on upstream (*Trends Pharmacol. Sci.* (99) 20:118).

[0043] There is no limitation on the type of host cell to be used for the expression of the protein of the present invention in this screening system, and various types of host cells can be used depending on the purposes. Such host cells include, for example, COS cell, CHO cell, HEK293 cell, etc. The vectors directing the expression of the protein of the present invention in vertebrate cells, comprising the promoter upstream of the gene encoding the protein of the present invention, RNA splice site, polyadenylation site, and transcription termination sequence and replication origin, and so forth can be preferably used. For example, pSV2dhfr (*Mol. Cell. Biol.* (1981) 1, 854-864), pEF-BOS (*Nucleic Acids Res.* (1990) 18, 5322), pCDM8 (*Nature* (1987) 329, 840-842), and pCEP4 (Invitrogen), containing the SV40 early promoter, are useful vectors for the expression of the G protein-coupled receptor. The insertion of the DNA of the present invention into a vector can be achieved according to a standard method by ligation using restriction enzyme sites (*Current protocols in Molecular Biology*, edit. Ausubel et al. (1987) Publish. John Wiley & Sons. Section 11.4-11.11). Further, the vector introduction into a host cell can be achieved by a known method, for example, such as calcium-phosphate precipitation method, electroporation method (*Current protocols in Molecular Biology*, edit. Ausubel et al. (1987) Publish. John Wiley & Sons. Section 9.1-9.9), a method with lipofectamine (GIBCO-BRL), a method with FuGENE6 reagent (Boehringer-Mannheim), microinjection method, etc.

[0044] Once the ligands are isolated by the above screening method for ligands binding to the protein of the present invention, screening of compounds inhibiting the interaction between the protein of the present invention and the ligands can be achieved. Thus, the present invention provides a screening method for compounds having the activity of inhibiting the binding of the protein of the present invention and the ligand thereof. This screening method comprises the step of: (a) contacting the ligand with the protein of the present invention or a partial peptide thereof in the presence of a test sample, and detecting the binding activity of the protein or a partial peptide thereof with the ligand; and (b) selecting compounds reducing the binding activity detected in the step (a) relative to the binding activity in the absence of the test sample.

[0045] Without limiting, the test sample include, for example, a group of compounds obtained by combinatorial chemistry technology (Tetrahedron (1995) 51, 8135-8137), a group of random peptides prepared by phage display method (*J. Mol. Biol.* (1991) 222, 301-310), and such. Further, culture supernatants of microorganisms and natural ingredients from plants or marine organisms, and in addition to these, biological extracts from tissues including brain, cell extracts, expression products of gene libraries, synthetic low-molecular-weight compounds, synthetic peptides, natural compounds, and so forth can be screened, but not limited thereto.

[0046] The protein of the present invention to be used for the screening can be, for example, the form expressed on cell surface, the form in the cell membrane fraction of the cells, or the form immobilized in an affinity column.

[0047] Specific methods that can be used for the screening include, for example, a method in which the ligand is labeled with a radioisotope or the like, and contacted with the protein of the present invention in the presence of a test sample, and then, based on the label linked to the ligand, compounds reducing the binding activity of the protein of the present invention to the ligand are detected as compared to those detected in the absence of the test sample. Further, the screening can also be achieved by using the intracellular alterations as an index by the same method as used in the above-mentioned screening to isolate ligands capable of binding to the protein of the present invention. Specifically, the screening for a compound inhibiting the binding of the protein of the present invention with the ligand can be carried out by contacting cells expressing the protein of the present invention with the ligands in the presence of a test sample, and selecting a compound decreasing the degree of alteration in the cells as compared with those detected in the absence of the test sample. The cells expressing the protein of the present invention can be prepared by the same method as used in the above-described screening of ligands binding to the protein of the present invention. The compounds isolated by the screening can be candidates for the agonist or antagonist to the protein of the present.

[0048] Further, the present invention provides a screening method for compounds inhibiting or enhancing the activity of the protein of the present invention. This screening method comprises the step of: (a) contacting the ligand to the protein with cells expressing the protein of the present invention in the presence of a test sample; (b) detecting an alteration in the cells due to the binding of the ligand to the protein of the present invention; and (c) selecting compounds suppressing or enhancing the alteration in the cells detected in the step (b) as compared with the alteration of the cells in the absence of the test sample.

[0049] Such test samples to be used, like those to be used in the above-mentioned screening method for ligands binding to the protein of the present invention, include a group of compounds obtained by combinatorial chemistry technology, a group of random peptides prepared by using phage display method, culture supernatants of microorganisms, natural ingredients from plants or marine organisms, biological tissue extracts, cell extracts, expression products of gene libraries, synthetic low-molecular-weight compounds, synthetic peptides, natural compounds, and such. Further, the compounds isolated by the above-mentioned screening of ligands binding to the protein of the present invention can be used as the test samples. The cells expressing the protein of the present invention can be prepared by the

same method as the above-described screening of ligands binding to the protein of the present invention. The alteration in the cells after contact with the test sample can be detected by using the alteration of intracellular Ca^{2+} level or cAMP level as an index, as with the above screening method. Further, the intracellular signal transduction can also be detected by using an assay system such as a reporter assay using luciferase as a reporter gene.

[0050] When the result of the detection shows that the alteration in the cells contacted with a test sample is suppressed as compared to those in the cells contacted with the ligand in the absence of the test sample, the test sample used is determined to be a compound inhibiting the activity of the protein of the present invention. Conversely, when the test sample enhances the alteration in the cells, the compound is determined to be a compound enhancing the activity of the protein of the present invention. The term "enhancing or inhibiting the activity of protein of the present invention" means that, regardless of a direct or an indirect interaction to the protein of the present invention, the interaction results in the enhancement or inhibition of the activity of protein of the present invention. Accordingly, the compounds isolated by the screening include compounds acting on the protein of the present invention or the ligand and inhibiting or enhancing the activity of the protein of the present invention by inhibiting or enhancing the binding, as well as compounds which do not inhibit nor enhance the binding itself but result in the inhibition or enhancement of the activity of the protein of the present invention. Such compounds include, for example, compounds which do not inhibit nor enhance the binding of the protein of the present invention and the ligand but inhibit or enhance the pathway of intracellular signal transduction.

[0051] When the compounds isolated by the screening method of the present invention are used as pharmaceuticals, the isolated compound not only can be directly administered itself to patients but also can be administered as pharmaceutical compositions which have been formulated by a known pharmaceutical method. For example, the compound can be formulated, in a form suitable for oral or parenteral administration, as a pharmaceutical composition obtained by combining the compound with pharmaceutically acceptable carrier (for example, excipient, binder, disintegrator, flavor, corrigent, emulsifier, diluent, solubilizer, etc.), or preparations, such as tablet, pill, powder, granule, capsule, troche, syrup, liquid drug, emulsion, suspension, injection (e.g. liquid drug and suspension), suppository, inhalant, percutaneous absorbent, eye drop, eye ointment, and so forth. In general, the administration to patients can be carried out by a method known to those skilled in the art, including intraarterial injection, intravenous injection, subcutaneous injection, etc. While the doses are different depending on the weight and age of patient, administration method, and such, those skilled in the art can choose proper administration doses if necessary. Further, when the compound is encoded by a DNA, the DNA can be inserted into a vector for gene therapy and thus can be used for gene therapy. The compound isolated by the screening method of the present invention is expected to be applied to the treatment of, for example, cancers, cirrhosis, and Alzheimer's disease.

[0052] The present invention also provides a disease diagnosing method for cancers, cirrhosis, or Alzheimer's disease, comprising the step of detecting the expression of the gene encoding the GPRv protein of the present invention.

[0053] In the Example herein, it has been found that the expression levels of the genes encoding the GPRv proteins of the present invention in affected tissues associated with cancers, cirrhosis, or Alzheimer's disease are significantly different as compared to those in normal tissues. Thus, these diseases can be diagnosed by detecting the expression of the genes encoding the GPRv proteins of the present invention in tissues of subjects. The term "gene expression" means both transcription and translation.

[0054] The diagnosis method of the present invention can be carried out, for example, as follows.

[0055] The diagnosis can be achieved by extracting RNA from an aliquot of a tissue collected by biopsy or blood sample according to a standard method, and quantifying GPRv mRNA by quantitative PCR, Northern hybridization, or dot blot hybridization, and such, as described in the Example herein. Alternatively, the diagnosis can also be achieved by quantifying the GPRv protein in a protein extract from the above tissue by a method such as Western blotting, immunoprecipitation, ELISA, and such, or by a noninvasive method where a labeled compound or antibody binding to the GPRv protein is administered to patients and detected by PET (positron emission tomography) or the like.

[0056] When the result of the diagnosis shows that the gene expression in the tissues of a subject exhibits a pattern (for example, an increased or decreased gene expression level as compared to that in the normal tissue) identical to that of the gene expression in the tissue derived from a patient affected with any one of the above diseases, the subject is determined as being affected or as being at a risk of affection with the disease.

[0057] For example, the expression of GPRv8 was detectable in the colon, and the expression level was markedly higher in colon cancers. Accordingly, when the expression of GPRv8 is detected at a high level in the colon tissue of a subject, the subject is suspected of colon cancer. Alternatively, the expression of GPRv8 was undetectable in the normal pancreas and uterus, but GPRv8 was expressed at a moderate level after canceration. Accordingly, when the expression of GPRv8 can be detected in the pancreas or uterus of a subject, the subject is suspected of pancreatic cancer or uterine cancer.

[0058] The expression of GPRv12 was undetectable in the normal ovary and testis, but was detectable after canceration. Further, the expression level decreased in the hippocampus with Alzheimer's disease. Accordingly, when the expression of GPRv12 is detected in the ovary or testis of a subject, the subject is suspected of ovary cancer or

testicular cancer. Similarly, when the expression of GPRv12 is detected in the hippocampus of a subject at a lower level than the normal level, the subject is suspected of Alzheimer's disease.

[0059] GPRv16 was expressed in the colon, but was undetectable after canceration. The expression level increased in the brain after canceration. In the liver, the expression was undetectable after cirrhosis. In the brain of patients with Alzheimer's disease, the expression level was elevated at the hippocampus. Accordingly, when the expression of GPRv16 is detected in the colon of a subject at a lower level than the normal level, the subject is suspected of colon cancer. Further, when the expression is detected in the brain at a higher level than the normal level, the subject is suspected of brain cancer. Further, the expression of GPRv16 is detected in the liver at a lower level than the normal level, the subject is suspected of cirrhosis. Further, when the expression of GPRv16 is detected in the hippocampus at a higher level than the normal level, the subject is suspected of Alzheimer's disease.

[0060] The expression of GPRv21 was undetectable in the colon and testis after canceration. Accordingly, when the expression of GPRv21 is detected in the colon or testis of a subject at a lower level than the normal level, the subject is suspected of colon cancer or testicular cancer.

[0061] The expression level of GPRv40 increased in the brain and testis after canceration, and decreased in the liver after cirrhosis. Accordingly, when the expression of GPRv40 is detected in the brain or testis at a higher level than the normal level, the subject is suspected of brain tumor or testicular cancer. Further, when the expression of GPRv40 was detected in the liver at a lower level than the normal level, the subject is suspected of cirrhosis.

[0062] The expression level of GPRv47 increased in the brain and kidney and decreased in the testis, after canceration. The expression was undetectable in the liver after cirrhosis. Accordingly, when the expression of GPRv47 is detected in the brain or kidney at a higher level than the normal level, the subject is suspected of brain tumor or kidney cancer. Further, when the expression of GPRv47 is detected in the liver at a lower level than the normal level, the subject is suspected of cirrhosis.

[0063] The expression level of GPRv51 decreased in the colon and testis after canceration. The expression level also decreased in the liver after cirrhosis as compared to the normal liver. The expression level increased in the hippocampus with Alzheimer's disease. Accordingly, when the expression of GPRv51 is detected in the colon and testis at a lower level than the normal level, the subject is suspected of colon cancer or testicular cancer. Further, when the expression of GPRv51 is detected in the liver at a lower level than the normal level, the subject is suspected of cirrhosis. Further, when the expression of GPRv51 is detected in the hippocampus at a higher level than the normal level, the subject is suspected of Alzheimer's disease.

[0064] The expression level of GPRv71 decreased in the colon and kidney, and was undetectable in the liver, after cirrhosis. In Alzheimer's disease, the expression level decreased in the frontal lobe. Accordingly, when the expression of GPRv71 is detected in the colon or kidney at a lower level than the normal level, the subject is suspected of colon cancer or kidney cancer. Further, when the expression of GPRv71 is detected in the liver at a lower level than the normal level, the subject is suspected of cirrhosis. Further, when the expression of GPRv71 is detected in the frontal lobe at a lower level than the normal level, the subject is suspected of Alzheimer's disease.

[0065] GPRv72 was expressed strongly in the colon, but the expression was undetectable after canceration. The expression level of GPRv72 increased in the hippocampus with Alzheimer's disease. Accordingly, when the expression of GPRv72 is detected in the colon at a lower level than the normal level, the subject is suspected of colon cancer. Further, when the expression of GPRv72 is detected in the hippocampus at a higher level than the normal level, the subject is suspected of Alzheimer's disease.

[0066] Furthermore, mutations in the genes encoding GPRv proteins of the present invention may result in the onset of the above-mentioned diseases. Thus, the diagnosis for the above-mentioned diseases can be carried out by detecting such mutations in the genes encoding GPRv proteins of the present invention.

[0067] Such gene diagnosis can be carried out, for example, as follows.

[0068] As a nucleic acid to be used for the diagnosis, genomic DNA or cDNA may be amplified directly or by PCR or other amplification technique. Deletions and insertions can be detected based on size differences of the amplification products as compared with that of the normal gene. Point mutations can be identified based on the differences in the melting temperature of the amplified DNA hybridized with DNA encoding GPRv. Differences between DNA sequences can be found by detecting alterations in the electrophoretic mobility of DNA fragment in a denaturant-containing or denaturant-free gel or by direct sequencing of nucleotide sequence of DNA.

[0069] When the diagnosis result shows that the gene encoding the GPRv protein from a subject has mutations as compared with the wild-type sequence, the subject diagnosed to be suspected of the above disease.

[0070] Namely, a method for diagnosing cancers, cirrhosis, or Alzheimer's disease or a method for diagnosing the susceptibility to the diseases are provided by detecting, according to the method described herein, mutations in the genes encoding the GPRv proteins or increase or decrease in the expression levels of the mRNAs or proteins.

Brief Description of the Drawings

[0071]

Figure 1 shows a result of BLAST SEARCH with the "GPRv8" amino acid sequence as the query against the entire sequence data in SWISS-PROT. The sequence showed 36% homology to HUMAN VASOPRESSIN V1B RECEPTOR.

Figure 2 shows a result of BLAST SEARCH with the "GPRv12" amino acid sequence as the query against the entire sequence data in SWISS-PROT. The sequence showed 27% homology to RAT 5-HYDROXYTRYPTAMINE 6 RECEPTOR.

Figure 3 shows a result of BLAST SEARCH with the "GPRv16" amino acid sequence as the query against the entire sequence data in SWISS-PROT. The sequence showed 28% homology to MOUSE GALANIN RECEPTOR TYPE 1.

Figure 4 shows a result of BLAST SEARCH with the "GPRv21" amino acid sequence as the query against the entire sequence data in SWISS-PROT. The sequence showed 30% homology to BOVIN NEUROPEPTIDE Y RECEPTOR TYPE 2.

Figure 5 shows a result of BLAST SEARCH with the "GPRv40" amino acid sequence as the query against the entire sequence data in SWISS-PROT. The sequence showed 34% homology to OXYTOCIN RECEPTOR (P97926).

Figure 6 shows a result of BLAST SEARCH with the "GPRv47" amino acid sequence as the query against the entire sequence data in SWISS-PROT. The sequence showed 43% homology to GPRX_ORYLA PROBABLE G PROTEIN-COUPLED RECEPTOR (Q91178).

Figure 7 shows a result of BLAST SEARCH with the "GPRv51" amino acid sequence as the query against the entire sequence data in SWISS-PROT. The sequence showed 37% homology to PROBABLE G PROTEIN-COUPLED RECEPTOR RTA (P23749).

Figure 8 shows a result of BLAST SEARCH with the "GPRv71" amino acid sequence as the query against the entire sequence data in SWISS-PROT. The sequence showed 45% homology to P2Y PURINOCEPTOR 3 (P2Y3) (Q98907).

Figure 9 shows a result of BLAST SEARCH with the "GPRv72" amino acid sequence as the query against the entire sequence data in SWISS-PROT. The sequence showed 30% homology to ALPHA-1A ADRENERGIC RECEPTOR (002824).

Figure 10 shows a hydropathy plot for GPRv8.

Figure 11 shows an alignment of GPRv8 and similar families. The mark '*' means that the amino acid is completely conserved in all the sequences at the position marked therewith. The mark ':' means that amino acids at the position marked therewith are conserved within any one of the following groups: {STA}, {NEQK}, {NHQK}, {NDBQ}, {QHRK}, {MILV}, {MILF}, {HY}, and {FYW}. The mark '.' means that amino acids at the position marked therewith are conserved within any one of the following groups: {CSA}, {ATV}, {SAG}, {STNK}, {STPA}, {SGND}, {SNDEQK}, {NDEQHK}, and {NEQHRK}.

Figure 12 is continued from Figure 11.

Figure 13 shows a hydropathy plot for GPRv12.

Figure 14 shows an amino acid sequence alignment of GPRv12 and AF208288. The mark '*' means that the amino acid is completely conserved in all the sequences at the position marked therewith. The mark ':' means that amino acids at the position marked therewith are conserved within any one of the following groups: {STA}, {NEQK}, {NHQK}, {NDBQ}, {QHRK}, {MILV}, {MILF}, {HY}, and {FYW}. The mark '.' means that amino acids at the position marked therewith are conserved within any one of the following groups: {CSA}, {ATV}, {SAG}, {STNK}, {STPA}, {SGND}, {SNDEQK}, {NDEQHK}, and {NEQHRK}.

Figure 15 shows a hydropathy plot for GPRv16.

Figure 16 shows a summary of HMMPFAM, transmembrane domain, and S-S bond of GPRv16. The mark '****' indicates a region assigned as 7tm_1 based on the result of HMMPFAM. The mark '###' represents transmembrane domain. The mark '@' indicates Cys capable of forming S-S bond.

Figure 17 shows a hydropathy plot for GPRv21.

Figure 18 shows an amino acid sequence alignment of GPRv21 and the related proteins. The mark '*' means that the amino acid is completely conserved in all the sequences at the position marked therewith. The mark ':' means that amino acids at the position marked therewith are conserved within any one of the following groups: {STA}, {NEQK}, {NHQK}, {NDBQ}, {QHRK}, {MILV}, {MILF}, {HY}, and {FYW}. The mark '.' means that amino acids at the position marked therewith are conserved within any one of the following groups: {CSA}, {ATV}, {SAG}, {STNK}, {STPA}, {SGND}, {SNDEQK}, {NDEQHK}, and {NEQHRK}.

Figure 19 is continued from Figure 18.

Figure 20 shows a hydropathy plot for GPRv40.

Figure 21 shows a summary of HMMPFAM, transmembrane domain, and S-S bond of GPRv40. The mark "****" indicates a region assigned as 7tm_1 based on the result of HMMPFAM. The mark "###" indicates transmembrane domain. The mark "@" indicates Cys capable of forming S-S bond.

Figure 22 shows a hydropathy plot for GPRv47.

Figure 23 shows an alignment of GPRv47 and the related proteins. The mark "*" means that the amino acid is completely conserved in all the sequences at the position marked therewith. The mark "." means that amino acids at the position marked therewith are conserved within any one of the following groups: {STA}, {NEQK}, {NHQK}, {NDBQ}, {QHRK}, {MILV}, {MILF}, {HY}, and {FYW}. The mark ':' means that amino acids at the position marked therewith are conserved within any one of the following groups: {CSA}, {ATV}, {SAG}, {STNK}, {STPA}, {SGND}, {SNDEQK}, {NDEQHK}, and {NEQHRK}.

Figure 24 is continued from Figure 23.

Figure 25 is continued from Figure 24.

Figure 26 shows a hydropathy plot for GPRv51.

Figure 27 shows an alignment of GPRv51 and the related proteins. The mark "*" means that the amino acid is completely conserved in all the sequences at the position marked therewith. The mark "." means that amino acid at the position marked therewith are conserved within any one of the following groups: {STA}, {NEQK}, {NHQK}, {NDBQ}, {QHRK}, {MILV}, {MILF}, {HY}, and {FYW}. The mark ':' means that amino acid at the position marked therewith are conserved within any one of the following groups: {CSA}, {ATV}, {SAG}, {STNK}, {STPA}, {SGND}, {SNDEQK}, {NDEQHK}, and {NEQHRK}.

Figure 28 shows a hydropathy plot for GPRv71.

Figure 29 shows an alignment of GPRv71 and related proteins. The mark "*" means that the amino acid is completely conserved in all the sequences at the position marked therewith. The mark "." means that amino acid at the position marked therewith are conserved within any one of the following groups: {STA}, {NEQK}, {NHQK}, {NDBQ}, {QHRK}, {MILV}, {MILF}, {HY}, and {FYW}. The mark ':' means that amino acid at the position marked therewith are conserved within any one of the following groups: {CSA}, {ATV}, {SAG}, {STNK}, {STPA}, {SGND}, {SNDEQK}, {NDEQHK}, and {NEQHRK}.

Figure 30 is continued from Figure 29.

Figure 31 shows a hydropathy plot for GPRv72.

Figure 32 shows an alignment of GPRv72 and related proteins. The mark "*" means that the amino acid is completely conserved in all the sequences at the position marked therewith. The mark "." means that amino acid at the position marked therewith are conserved within any one of the following groups: {STA}, {NEQK}, {NHQK}, {NDBQ}, {QHRK}, {MILV}, {MILF}, {HY}, and {FYW}. The mark ':' means that amino acid at the position marked therewith are conserved within any one of the following groups: {CSA}, {ATV}, {SAG}, {STNK}, {STPA}, {SGND}, {SNDEQK}, {NDEQHK}, and {NEQHRK}.

Figure 33 is continued from Figure 32.

Figure 34 is continued from Figure 33.

Best Mode for Carrying out the Invention

[0072] The present invention is specifically illustrated below with reference to Examples, but it is not to be construed as being limited thereto. Unless otherwise stated, they can be carried out by known methods (Maniatis, T. et al. (1982): "Molecular Cloning - A Laboratory Manual", Cold Spring Harbor Laboratory, NY).

[Example 1] Isolation of the genes encoding the novel G protein-coupled receptors

[0073] The full-length cDNAs encoding the novel G protein-coupled receptors of the present invention (GPRv8, GPRv12, GPRv16, GPRv21, GPRv40, GPRv47, GPRv51, GPRv71, and GPRv72) were obtained by PCR.

[0074] The amplification of the novel G protein-coupled receptor GPRv8 was carried out using a Marathon Ready cDNA (Clontech) derived from human fetus as a template, and forward primer: 5'-ATGCCAGCCAACTTCACAGAGGGCAGCT-3' (SEQ ID NO: 9) and reverse primer: 5'-CTAGATGAATTCTGGCTTGGACAGAATC-3' (SEQ ID NO: 10). PCR was carried out with Pyrobest DNA polymerase (Takara); the thermal cycling profile consisted of preheat at 94°C (2.5 minutes) and 25 cycles of 94°C (30 seconds)/60°C (30 seconds)/72°C (1 minute). The amplification resulted in about 1.1-kbp DNA fragments. The fragments were cloned into pCR2.1 plasmid (Invitrogen). The nucleotide sequence of the resultant clone was determined by dideoxy terminator method in an ABI377 DNA Sequencer (Applied Biosystems). The determined sequence is shown in SEQ ID NO: 5.

[0075] The sequence comprises an open reading frame of 1116 nucleotides (from the first nucleotide to the 1116th nucleotide in SEQ ID NO: 5). An amino acid sequence deduced from the open reading frame (371 amino acids) is

shown in SEQ ID NO: 1. Since the deduced amino acid sequence contains hydrophobic regions corresponding to seven transmembrane domains characteristic of G protein-coupled receptor, the gene is found to encode a G protein-coupled receptor.

[0076] The amplification of the novel G protein-coupled receptor GPRv12 was carried out using a Marathon Ready cDNA (Clontech) derived from human fetal brain as a template, and forward primer: 5'-ATGGGCCCCGGCGAGGCGCT-GCTGGCGG-3' (SEQ ID NO: 11) and reverse primer: 5'-TCAGTGTGTCTGCTGCAGGCAGGAATCA-3' (SEQ ID NO: 12). PCR was carried out with Pyrobest DNA polymerase (Takara) under the presence of 5% formamide; the thermal cycling profile consisted of preheat at 94°C (2.5 minutes), 5 cycles of 94°C (5 seconds)/72°C (4 minutes), 5 cycles of 94°C (5 seconds)/70°C (4 minutes), and 25 cycles of 94°C (5 seconds)/68°C (4 minutes). The amplification resulted in about 1.1-kbp DNA fragments. The fragments were cloned into pCR2.1 plasmid (Invitrogen). The nucleotide sequence of the resultant clone was determined by dideoxy terminator method in an ABI377 DNA Sequencer (Applied Biosystems). The determined sequence is shown in SEQ ID NO: 6.

[0077] The sequence comprises an open reading frame of 1092 nucleotides (from the first nucleotide to the 1092th nucleotide in SEQ ID NO: 6). An amino acid sequence deduced from the open reading frame (363 amino acids) is shown in SEQ ID NO: 2. Since the deduced amino acid sequence contains hydrophobic regions corresponding to seven transmembrane domains characteristic of G protein-coupled receptor, the gene is found to encode a G protein-coupled receptor.

[0078] The amplification of the novel G protein-coupled receptor GPRv16 was carried out using a Marathon Ready cDNA (Clontech) derived from human brain as a template, and forward primer: 5'-ATGCTGGCAGCTGCCTTTGCA-GACTCTAAC-3' (SEQ ID NO: 13) and reverse primer: 5'-CTATTTAACACCTTCCCTGTCTCTTGATC-3' (SEQ ID NO: 14). PCR was carried out with Pyrobest DNA polymerase (Takara); the thermal cycling profile consisted of preheat at 94°C (2 minutes) and 30 cycles of 94°C (30 seconds)/60°C (30 seconds)/72°C (1 minute). The amplification resulted in about 1.2-kbp DNA fragments. The fragments were cloned into pCR2.1 plasmid (Invitrogen). The nucleotide sequence of the resultant clone was determined by dideoxy terminator method in an ABI377 DNA Sequencer (Applied Biosystems). The determined sequence is shown in SEQ ID NO: 7.

[0079] The sequence comprises an open reading frame of 1260 nucleotides (from the first nucleotide to the 1260th nucleotide in SEQ ID NO: 7). An amino acid sequence deduced from the open reading frame (419 amino acids) is shown in SEQ ID NO: 3. Since the deduced amino acid sequence contains hydrophobic regions corresponding to seven transmembrane domains characteristic of G protein-coupled receptor, the gene is found to encode a G protein-coupled receptor.

[0080] The amplification of the novel G protein-coupled receptor GPRv21 was carried out using a Marathon Ready cDNA (Clontech) derived from human fetus as a template, and forward primer: 5'-ATGGAGACCACCATGGGGTTCAT-GGATG-3' (SEQ ID NO: 15) and reverse primer: 5'-TTATTTTAGTCTGATGCAGTCCACCTCTTC-3' (SEQ ID NO: 16). PCR was carried out with Pyrobest DNA polymerase (Takara) under the presence of 5% formamide; the thermal cycling profile consisted of preheat at 94°C (2.5 minutes), 5 cycles of 94°C (5 seconds)/72°C (4 minutes), 5 cycles of 94°C (5 seconds)/70°C (4 minutes), and 25 cycles of 94°C (5 seconds)/68°C (4 minutes). The amplification resulted in about 1.2-kbp DNA fragments. The fragments were cloned into pCR2.1 plasmid (Invitrogen). The nucleotide sequence of the resultant clone was determined by dideoxy terminator method in an ABI377 DNA Sequencer (Applied Biosystems). The determined sequence is shown in SEQ ID NO: 8.

[0081] The sequence comprises an open reading frame of 1182 nucleotides. An amino acid sequence deduced from the open reading frame (333 amino acids) is shown in SEQ ID NO: 4. Since the deduced amino acid sequence contains hydrophobic regions corresponding to seven transmembrane domains characteristic of G protein-coupled receptor, the gene is found to encode a G protein-coupled receptor.

[0082] The amplification of the novel G protein-coupled receptor GPRv40 was carried out using a Marathon Ready cDNA (Clontech) derived from human fetus as a template, and forward primer: 5'-ATGGAGGATCTCTTTAGCCCCT-CAATTC-3' (SEQ ID NO: 27) and reverse primer: 5'-CTAGAAGGCACTTTCGCAGGAGCAAGGC-3' (SEQ ID NO: 28). PCR was carried out with Pyrobest DNA polymerase (Takara) under the presence of 5% formamide; the thermal cycling profile consisted of preheat at 98°C (2.5 minutes), 5 cycles of 98°C (5 seconds)/72°C (4 minutes), 5 cycles of 98°C (5 seconds)/70°C (4 minutes), and 25 cycles of 98°C (5 seconds)/68°C (4 minutes). The amplification resulted in about 1.3-kbp DNA fragments. The fragments were cloned into pCR2.1 plasmid (Invitrogen). The nucleotide sequence of the resultant clone was determined by dideoxy terminator method in an ABI377 DNA Sequencer (Applied Biosystems). The determined sequence is shown in SEQ ID NO: 22.

[0083] The sequence comprises an open reading frame of 1305 nucleotides (SEQ ID NO: 22). An amino acid sequence deduced from the open reading frame (434 amino acids) is shown in SEQ ID NO: 17. Since the deduced amino acid sequence contains hydrophobic regions corresponding to seven transmembrane domains characteristic of G protein-coupled receptor, the gene is found to encode a G protein-coupled receptor.

[0084] The amplification of the novel G protein-coupled receptor GPRv47 was carried out using a Marathon Ready cDNA (Clontech) derived from human fetal brain as a template, and forward primer: 5'-ATGGAGTCCTCACCCATC-

CCCCAGTCATC-3' (SEQ ID NO: 29) and reverse primer: 5'-TCATGACTCCAGCCGGGGTGAGGCGGCAG-3' (SEQ ID NO: 30). PCR was carried out with Pyrobest DNA polymerase (Takara) under the presence of 5% formamide; the thermal cycling profile consisted of preheat at 94°C (2 minutes) and 35 cycles of 94°C (30 seconds)/50°C (30 seconds)/72°C (1.5 minutes). The amplification resulted in about 1.4-kbp DNA fragments. The fragments were cloned into pCR2.1 plasmid (Invitrogen). The nucleotide sequence of the resultant clone was determined by dideoxy terminator method in an ABI377 DNA Sequencer (Applied Biosystems). The determined sequence is shown in SEQ ID NO: 23.

[0085] The sequence comprises an open reading frame of 1356 nucleotides (SEQ ID NO: 23). An amino acid sequence deduced from the open reading frame (451 amino acids) is shown in SEQ ID NO: 18. Since the deduced amino acid sequence contains hydrophobic regions corresponding to seven transmembrane domains characteristic of G protein-coupled receptor, the gene is found to encode a G protein-coupled receptor.

[0086] The amplification of the novel G protein-coupled receptor GPRv51 was carried out using a Marathon Ready cDNA (Clontech) derived from human testis as a template, and forward primer: 5'-ATGAACCAGACTTTGAATAGCAGTGG-3' (SEQ ID NO: 31) and reverse primer: 5'-TCAAGCCCCCATCTCATTGGTGCCACG-3' (SEQ ID NO: 32). PCR was carried out with Pyrobest DNA polymerase (Takara); the thermal cycling profile consisted of preheat at 98°C (2.5 minutes) and 35 cycles of 98°C (30 seconds)/50°C (30 seconds)/68°C (4 minutes). The amplification resulted in about 1.0-kbp DNA fragments. The fragments were cloned into pCR2.1 plasmid (Invitrogen). The nucleotide sequence of the resultant clone was determined by dideoxy terminator method in an ABI377 DNA Sequencer (Applied Biosystems). The determined sequence is shown in SEQ ID NO: 24.

[0087] The sequence comprises an open reading frame of 966 nucleotides (SEQ ID NO: 24). An amino acid sequence deduced from the open reading frame (321 amino acids) is shown in SEQ ID NO: 19. Since the deduced amino acid sequence contains hydrophobic regions corresponding to seven transmembrane domains characteristic of G protein-coupled receptor, the gene is found to encode a G protein-coupled receptor.

[0088] The amplification of the novel G protein-coupled receptor GPRv71 was carried out using a Marathon Ready cDNA (Clontech) derived from human fetus as a template, and forward primer: 5'-ATGGAGAAGGTGGACATGAATACATCAC-3' (SEQ ID NO: 33) and reverse primer: 5'-TTACCCAGATCTGTTC AACCTGGGCATC-3' (SEQ ID NO: 34). PCR was carried out with Pyrobest DNA polymerase (Takara); the thermal cycling profile consisted of preheat at 94°C (2.5 minutes), 5 cycles of 98°C (5 seconds)/72°C (4 minutes), 5 cycles of 98°C (5 seconds)/70°C (4 minutes), and 25 cycles of 98°C (5 seconds)/68°C (4 minutes). The amplification resulted in about 1.0-kbp DNA fragments. The fragments were cloned into pCR2.1 plasmid (Invitrogen). The nucleotide sequence of the resultant clone was determined by dideoxy terminator method in an ABI377 DNA Sequencer (Applied Biosystems). The determined sequence is shown in SEQ ID NO: 25.

[0089] The sequence comprises an open reading frame of 1002 nucleotides (SEQ ID NO: 25). An amino acid sequence deduced from the open reading frame (333 amino acids) is shown in SEQ ID NO: 20. Since the deduced amino acid sequence contains hydrophobic regions corresponding to seven transmembrane domains characteristic of G protein-coupled receptor, the gene is found to encode a G protein-coupled receptor.

[0090] The amplification of the novel G protein-coupled receptor GPRv72 was carried out using human genome DNA (Clontech) as a template, and forward primer: 5'-ATGACGTCCACCTGCACCAACAGCACGC-3' (SEQ ID NO: 35) and reverse primer: 5'-TCAAGGAAAAGTAGCAGAATCGTAGGAAG-3' (SEQ ID NO: 36). PCR was carried out with Pyrobest DNA polymerase (Takara); the thermal cycling profile consisted of preheat at 94°C (2 minutes) and 30 cycles of 94°C (30 seconds)/55°C (30 seconds)/68°C (4 minutes). The amplification resulted in about 1.5-kbp DNA fragments. The fragments were cloned into pCR2.1 plasmid (Invitrogen). The nucleotide sequence of the resultant clone was determined by dideoxy terminator method in an ABI377 DNA Sequencer (Applied Biosystems). The determined sequence is shown in SEQ ID NO: 26.

[0091] The sequence comprises an open reading frame of 1527 nucleotides (SEQ ID NO: 26). An amino acid sequence deduced from the open reading frame (508 amino acids) is shown in SEQ ID NO: 21. Since the deduced amino acid sequence contains hydrophobic regions corresponding to seven transmembrane domains characteristic of G protein-coupled receptor, the gene is found to encode a G protein-coupled receptor.

[Example 2] BLAST SEARCH of the amino acid sequences of the novel G protein-coupled receptors against SWISS-PROT

[0092] The result of BLAST SEARCH of the amino acid sequence of "GPRv8" against SWISS-PROT is shown in Figure 1. "GPRv8" exhibited the highest homology (36%) to HUMAN VASOPRESSIN V1B RECEPTOR (P47901, 424 aa) of known G protein-coupled receptors. Thus, "GPRv8" was concluded to be a novel G protein-coupled receptor.

[0093] The result of BLAST SEARCH of the amino acid sequence of "GPRv12" against SWISS-PROT is shown in Figure 2. "GPRv12" exhibited the highest homology (27%) to RAT 5-HYDROXYTRYPTAMINE 6 RECEPTOR (P31388, 436 aa) of known G protein-coupled receptors. Thus, GPRv12 was concluded to be a novel G protein-coupled receptor.

[0094] The result of BLAST SEARCH of the amino acid sequence of "GPRv16" against SWISS-PROT is shown in

Figure 3. "GPRv16" exhibited the highest homology (28%) to MOUSE GALANIN RECEPTOR TYPE 1 (P56479, 348 aa) of known G protein-coupled receptors. Thus, "GPRv16" was concluded to be a novel G protein-coupled receptor.

[0095] The result of BLAST SEARCH of the amino acid sequence of "GPRv21" against SWISS-PROT is shown in Figure 4. "GPRv21" exhibited the highest homology (30%) to BOVIN NEUROPEPTIDE Y RECEPTOR TYPE 2 (P79113, 384 aa) of known G protein-coupled receptors. Thus, "GPRv21" was concluded to be a novel G protein-coupled receptor.

[0096] The result of BLAST SEARCH of the amino acid sequence of "GPRv40" against SWISS-PROT is shown in Figure 5. "GPRv40" was not identical to any of known G protein-coupled receptors, but exhibited the highest homology (34%) to OXYTOCIN RECEPTOR (P97926, 388 aa). Thus, "GPRv40" was concluded to be a novel G protein-coupled receptor.

[0097] The result of BLAST SEARCH of the amino acid sequence of "GPRv47" against SWISS-PROT is shown in Figure 6. "GPRv47" was not identical to any of known G protein-coupled receptors, but exhibited the highest homology (43%) to GPRX_ORYLA PROBABLE G PROTEIN-COUPLED RECEPTOR (Q91178, 428 aa). Thus, "GPRv47" was concluded to be a novel G protein-coupled receptor.

[0098] The result of BLAST SEARCH of the amino acid sequence of "GPRv51" against SWISS-PROT is shown in Figure 7. "GPRv51" was not identical to any of known G protein-coupled receptors, but exhibited the highest homology (37%) to PROBABLE G PROTEIN-COUPLED RECEPTOR RTA (P23749, 343 aa). Thus, "GPRv51" was concluded to be a novel G protein-coupled receptor.

[0099] The result of BLAST SEARCH of the amino acid sequence of "GPRv71" against SWISS-PROT is shown in Figure 8. "GPRv71" was not identical to any of known G protein-coupled receptors, but exhibited the highest homology (45%) to Chicken P2Y PURINOCEPTOR 3 (P2Y3) (Q98907, 328 aa). Thus, "GPRv71" was concluded to be a novel G protein-coupled receptor.

[0100] The result of BLAST SEARCH of the amino acid sequence of "GPRv72" against SWISS-PROT is shown in Figure 9. "GPRv72" was not identical to any of known G protein-coupled receptors, but exhibited the highest homology (30%) to ALPHA-1A ADRENERGIC RECEPTOR (002824, 466 aa). Thus, "GPRv72" was concluded to be a novel G protein-coupled receptor.

[Example 3] Analysis of tissue-specific expression

1. Reagents

1.1. Primers for quantitative polymerase chain reaction (PCR) and TaqMan probes:

[0101] Sense primers, antisense primers, and TaqMan probes were designed by using genetic analysis software "Primer Express version 1.0" from PE Biosystems. The ordinary custom-made primers and TaqMan probes were purchased from Amersham Pharmacia Biotech (Tokyo) and PE Biosystems Japan, respectively. The TaqMan probes were connected with a reporter pigment FAM at the 5' end and with a quencher Tamra at the 3' end. The nucleotide sequences of primers and TaqMan probes are shown below.

Synthetic DNA for GPRv8

[0102]

PCR primer G8.957F: CCAGGAGCGTTTCTATGCCT (SEQ ID NO: 37)
G8.1082R: TGTGATCTTTGCTCCCTGCA (SEQ ID NO: 38)

TaqMan Probe GPRv8.987T: TCAGAACCTGCCAGCATTGAATAGTGCC (SEQ ID NO: 39)

EP 1 243 648 A1

Synthetic DNA for GPRv12

[0103]

5

PCR primer G12.794F: ATCTGCTTTGCCCCGTATGT (SEQ ID NO: 40)
G12.903R: ACCGCCTTGCTGTAGGTCAG (SEQ ID NO: 41)

10

TaqMan Probe GPRv12.834T: TCGTGCCCTTCGTCACCGTGAA (SEQ ID NO: 42)

15

Synthetic DNA for GPRv16

[0104]

20

PCR primer G16.1133F: CCCAGCATCCATACCAGAAAA (SEQ ID NO: 43)
G16.1254R: CTGTGTCCCTCTCATGCCAAA (SEQ ID NO: 44)

25

TaqMan Probe GPRv16.1193T: TGAGAAGGCAGAGATTCCCATCCTTCCT (SEQ ID NO: 45)

Synthetic DNA for GPRv21

30

[0105]

PCR primer G21.989F: TCGCCATGAGCAACAGCAT (SEQ ID NO: 46)
G21.1114R: CACTGGACTTACCGCCATTGT (SEQ ID NO: 47)

35

TaqMan Probe GPRv21.1064T: AGATCATGTTGCTCCACTGGAAGGCTTCT (SEQ ID NO: 48)

40

Synthetic DNA for GPRv40

[0106]

45

PCR primer G40.16F: GGATCTCTTTAGCCCCTCAATTC (SEQ ID NO: 49)
G40.99R: AAGGTCAGGTTGAGACCCAG (SEQ ID NO: 50)

50

TaqMan Probe GPRv40.53T: AACATTTCCGTGCCCATCTTGCTGG (SEQ ID NO: 51)

55

EP 1 243 648 A1

Synthetic DNA for GPRv47

[0107]

5

PCR primer G47.1292F: GCTGTTGACTTTCGAATCCCA (SEQ ID NO: 52)
G47.1393R: ACGGAGGTAGCTGTCTGACATGA (SEQ ID NO: 53)

10

TaqMan Probe GPRv47.1336T: TGAGTTCCTGGAGCAGCAACTCACCA (SEQ
ID NO: 54)

15

Synthetic DNA for GPRv51

[0108]

20

PCR primer G51.190F: GGCTTTCGAATGCACAGGAA (SEQ ID NO: 55)
G51.276R: GGAAGCCATGCTGAAGAGGA (SEQ ID NO: 56)

25

TaqMan Probe GPRv51.214T: TTCTGCATCTATATCCTCAACCTGGCGG (SEQ
ID NO: 57)

Synthetic DNA for GPRv71

30

[0109]

35

PCR primer G71.746F: TGGCCTCTTCACCCTCTGTTT (SEQ ID NO: 58)
G71.841R: ATCAAGAGCTGGCAGTCCTGA (SEQ ID NO: 59)

40

TaqMan Probe GPRv71.775T: TCCATATCACTCGCTCCTTCTACCTCACCA (S
EQ ID NO: 60)

Synthetic DNA for GPRv72

45

[0110]

50

PCR primer G72.101F: CCAAATGCCCATCAGCCT (SEQ ID NO: 61)
G72.190R: GCACTATGTTGCCGACGAAA (SEQ ID NO: 62)

55

TaqMan Probe GPRv72.132T: CATCCGCTCAACCGTGCTGGTTATCT (SEQ I
D NO: 63)

1.2. CDNA derived from patients

[0111] As cDNAs which had been derived from tumor and normal tissues from a single patient, Matched cDNA Pairs from Clontech were used. The tissues are lung, stomach, colon, ovary, prostate, uterus, and kidney.

[0112] Some cDNAs derived from following tissues were purchased from BioChain Institute: brain, pancreas, and testis from patients with tumor and normal adults; liver from cirrhosis patients and normal adults; kidney from lupus disease patients; and the hippocampus and frontal lobe from Alzheimer's disease (AD) patients and normal adults.

1.3. Reagents for quantitative PCR:

[0113] TaqMan Universal PCR Master Mix (PE Biosystems) was used in this assay. TaqMan β -actin Control Reagents (PE Biosystems) was used for measuring the internal standard.

2. Quantitative PCR:

1) Dilution of template cDNA

[0114] The cDNAs from BioChain were diluted 50 fold with water, and the cDNAs from Clontech were diluted 5 fold with water, for use.

2) Preparation of Master Mix

[0115] A reaction solution with the following composition was prepared.

	Reaction volume	Preparation volume
2x Master Mix	12.5 μ l	1380 μ l
Sense primer (50 μ M)	0.5 μ l	55.2 μ l
Antisense primer (50 μ M)	0.5 μ l	55.2 μ l
TaqMan Probe (5 μ M)	1 μ l	110.4 μ l
Template cDNA	2.5 μ l	
Purified water	8 μ l	883.2 μ l
Total volume	25 μ l	2484 μ l

3) Preparation of PCR solution

[0116] 6 μ l template cDNA solution was added to 54 μ l Master Mix solution. Then, 25- μ l aliquots of the mixture were added in duplicate to the sample wells of a PCR plate to be placed in a device for quantitative PCR. A 25- μ l aliquot of the above-mentioned Master Mix was added to each of two wells for non-template control. The standard curve was produced using eight 10-fold serial dilutions of cDNA which had been subcloned into pCEP4 vector, where the dilution started from 100 pg/ μ l. A 25- μ l aliquot of each mixture obtained by combining 54 μ l of Master Mix prepared in Section 2) and 6 μ l of each standard solution prepared above was added into a standard well. Namely, the largest amount of the plasmid DNA was 250 pg and the smallest was 25 ag (a: atto, 10^{-18}) in the standard wells. After 8-cap strips were placed to the top of the wells, the bubbles were removed by light centrifugation.

4) PCR

[0117] The plate was placed in the device for quantitative PCR (GeneAmp 5700 Sequence Detection System: PE Biosystems), and then the reaction was carried out according to the following cycling program.

- (1) 50°C, 2 minutes: 1 cycle
- (2) 95°C, 10 minutes: 1 cycle
- (3)

95°C, 15 seconds } : 50 cycles
60°C, 1 minutes }

5) Quantitative analysis

[0118] The quantification was carried out according to the operation manual of GeneAmp 5700, and the result was outputted.

3. Results and conclusions:

[0119] The GPCR expression profiles obtained with the cDNAs from the organs from normal human and those from patients with disease were represented as ratios relative to the expression level of the actin gene as an internal standard. The experiment was carried out in duplicate, and the average values are shown in Table 1.

Table 1

		relative copy number								
		GPRv8	GPRv12	GPRv16	GPRv21	GPRv40	GPRv47	GPRv51	GPRv71	GPRv72
Brain	Normal ¹⁾	0	0	1	0	6	9	0	0	0
	Tumor ¹⁾	5	2	11	0	23	76	2	5	0
Lung	Normal	0	0	1	0	11	0	1	1	0
	Tumor	1	0	1	0	11	2	1	1	1
Stomach	Normal	6	0	0	0	28	0	1	1	0
	Tumor	3	0	2	0	1	0	3	0	1
Pancreas	Normal ¹⁾	0	0	0	0	4	0	0	0	0
	Tumor ¹⁾	45	2	0	0	23	2	3	4	1
Colon	Normal	141	0	61	11	119	50	111	44	113
	Tumor	2768	0	0	0	110	21	6	2	0
Ovary	Normal	0	0	1	0	2	1	2	1	1
	Tumor	0	4	0	0	21	1	3	3	0
Uterus	Normal	0	0	3	0	7	0	3	3	1
	Tumor	19	0	0	0	9	1	21	0	1
Prostate	Normal	0	0	0	0	18	1	3	1	0
	Tumor	6	0	0	0	9	0	8	3	0
Testis	Normal ¹⁾	18	0	10	5	3	22	20	2	1
	Tumor	8	3	13	0	21	3	3	2	0
Kidney	Normal	9	0	0	0	29	0	27	3	5
	Tumor	9	0	0	0	28	10	15	0	0
Liver	Lupus ¹⁾	25	0	1	0	1	0	3	1	0
	Normal ¹⁾	0	0	10	0	27	11	13	5	1
Hippocampus	Cirrhosis ¹⁾	1	0	0	0	4	0	2	0	0
	Normal ¹⁾	6	12	4	0	40	113	2	5	2
Frontal lobe	AD ¹⁾	16	1	50	3	111	63	55	12	27
	Normal/AD ¹⁾	2	1	1	0	9	29	2	2	0

[0120] When a 3-fold or more alternation in the expression level was reproducible, the difference is assessed as being significant. The cDNAs derived from the organs marked with ¹⁾ were purchased from BioChain; and the cDNAs derived from the organs without the mark were purchased from Clontech. The disease-dependent differences in the expression levels of the respective genes are summarized below.

[0121] The expression of GPRv8 was undetectable in the normal pancreas and uterus, but GPRv8 was expressed at a moderate level after canceration. GPRv8 was strongly expressed in the colon, and was more strongly expressed in colon cancer.

[0122] The expression level of GPRv12 was generally low. The expression was undetectable in the normal ovary and testis, but was found after canceration. The expression level decreased in the hippocampus with Alzheimer's disease.

[0123] GPRv16 was expressed in the colon, but was undetectable after canceration. The expression level increased in the brain after canceration. In the liver, the expression was undetectable after cirrhosis. In the brain of Alzheimer's disease patients, the expression level was elevated in the hippocampus.

[0124] The expression level of GPRv21 was low, and was undetectable in the colon and testis after canceration.

[0125] The expression level of GPRv40 increased in the brain and testis after canceration, and decreased in the

liver after cirrhosis.

[0126] The expression level of GPRv47 increased in the brain and kidney and decreased in the testis after canceration. The expression was undetectable in the liver after cirrhosis.

[0127] GPRv51 was strongly expressed in the colon, but the expression level decreased after canceration. The expression level decreased in the testis after canceration. The expression level also decreased in the liver after cirrhosis as compared to the normal liver. The expression level was low in the brain, but increased in the hippocampus with Alzheimer's disease.

[0128] The expression level of GPRv71 decreased in the colon and kidney after canceration, and the expression thereof was undetectable in the liver after cirrhosis. In the patient with Alzheimer's disease, the expression level decreased in the frontal lobe.

[0129] GPRv72 was expressed strongly in the colon, but the expression thereof was undetectable after canceration. The expression level was low in the brain, but increased in the hippocampus with Alzheimer's disease.

[Example 4] Analysis of GPRv8 with bioinformatics

1. Homology search of GPRv8

[0130] The amino acid sequence of GPRv8 was analyzed by searching known sequences (the known sequence databases are produced in EMBL (Release 64, <http://www.ebi.ac.uk/>), GENBANK (Release 120.0, <http://www.ncbi.nlm.nih.gov/>), and PIR (Release 66.00, <http://www-nbrf.georgetown.edu/pir/>)) with an analysis program (BLAST 2.0) (Altschul, Stephen F. et al. (1997) *Nucleic Acids Res.* 25:3389-3402.). The result showed that GPRv8 had homology to the sequences shown in Table 2. Thus, GPRv8 was revealed to be a novel clone having homology to GPCR. The amino acid sequence of GPRv8 was analyzed by searching known sequences with an analysis program (BLAST 2.0); the result (data with the E-value lower than e^{-39}) is shown in Table 2.

Table 2

Hit (ID)	E-value	Identities %	Description
AE003754	2e-68	43	gene: "CG6111"-Drosophila melanogaster
AF147743	7e-43	33	vasotocin VT1 receptor-Gallus gallus
AF184966	2e-42	33	arginine vasotocin receptor-Platichthys flesus
X93313	4e-42	36	mesotocin receptor-giant toad
X76321	8e-42	32	vasotocin receptor-white sucker
X87783	4e-41	33	isotocin receptor-white sucker
X64878	3e-40	32	oxytocin receptor- H.sapiens
U82440	7e-40	32	oxytocin receptor-Macaca mulatta

2. Prediction of transmembrane domain

[0131] The amino acid sequence of GPRv8 was analyzed according to the method of Kyte-Doolittle (J. Kyte and R. F. Doolittle, (1982), *J. Mol. Biol.*, 157,105-132.), for obtaining a hydropathy plot and used to predict the transmembrane domain. The result showed that GPRv8 had seven transmembrane domains (TM1-TM7) (Figure 10).

3. HMMPfam search

[0132] Using the amino acid sequence of GPRv8 as the query, PFAM search based on the hidden Markov model (HMMPFAM (Sonnhammer EL, et al., *Nucleic Acids Res* 1998 Jan 1; 26 (1) :320-322)) was carried out. The search was carried out with the hidden Markov model of HMMER version 2.1 (<http://hmmer.wustl.edu/>) and the PFAM database of Pfam Version 5.5 (<http://www.sanger.ac.uk/Software/Pfam/index.shtml>).

[0133] The result indicated that GPRv8 comprises tm7_1 (Rhodopsin family). The result of HMMPfam search is shown in Table 3.

Table 3

Hit	Score	Exp ct	Q from	Q to	Description
7tm_1	164.2	5.1e-51	66	330	7 transmembrane receptor (rhodopsin family)
Hit: name of the domain deduced by the search. Score: the higher the value, the higher the reliability. Expe: as the value approaches 0, the reliability becomes higher. Q from: the start position of the deduced domain. Q to: the termination position of the deduced domain. Description: explanation of the deduced domain.					

4. Amino acid sequence alignment

[0134] The amino acid sequences of GPRv8 and proteins shown in Table 2 were aligned together by using Clustalw 1.7 (Figures 11 and 12). The result showed that GPRv8 comprise seven transmembrane domains (### ###) and Cys (Cys marked with "@") participating in specific S-S bonding of GPCR.

[Example 5] Analysis of GPRv12 with bioinformatics

1. Homology search of GPRv12

[0135] The amino acid sequence of GPRv12 was analyzed by searching known sequences (the known sequence databases are produced in EMBL (Release 64, <http://www.ebi.ac.uk/>), GENBANK (Release 120.0, <http://www.ncbi.nlm.nih.gov/>), and PIR (Release 66.00, <http://www-nbrf.georgetown.edu/pir/>)) with an analysis program (BLAST 2.0) (Altschul, Stephen F. et al. (1997) *Nucleic Acids Res.* 25:3389-3402.). The result showed that GPRv12 had homology to the sequences shown in Table 4. Thus, GPRv12 was revealed to be a novel clone having homology to GPCR. The amino acid sequence of GPRv12 was analyzed by searching known sequences with an analysis program (BLAST 2.0); the result (data with the E-value lower than e-15) is shown in Table 4.

Table 4

Hit (ID)	E-value	Identities %	Description
AF208288	8e-88	50	orphan G protein-coupled receptor GPR26-Rattus norvegicus
L03202	2e-17	24	5-hydroxytryptamine receptor-rat
L41146	5e-17	23	5-HT6 serotonin receptor-Rattus norvegicus
S62043	2e-16	25	serotonin receptor 6-rat
L41147	2e-16	24	5-HT6 serotonin receptor-Homo sapiens
AF134158	4e-16	23	serotonin 6 receptor-Mus musculus
L14856	4e-16	26	somatostatin receptor 4-Human
Y14627	5e-16	21	Dopamine receptor-Cyprinus carpio
L07833	6e-16	26	somatostatin receptor 4-Homo sapiens
AF069547	8e-16	21	putative odorant receptor LOR4 Lampetra fluviatilis

2. Prediction of transmembrane domain

[0136] The amino acid sequence of GPRv12 was analyzed according to the method of Kyte-Doolittle (J. Kyte and R. F. Doolittle, (1982), *J. Mol. Biol.*, 157,105-132.), for obtaining a hydropathy plot and used to predict the transmembrane domain. The result showed that GPRv12 had seven transmembrane domains (TM1-TM7) (Figure 13).

3. HMMPfam search

[0137] Using the amino acid sequence of GPRv12 as the query, PFAM search based on the hidden Markov model (HMMPFAM (Sonnhammer EL, et al., *Nucleic Acids Res* 1998 Jan 1; 26 (1):320-322)) was carried out. The search was carried out with the hidden Markov model of HMMER version 2.1 (<http://hmmer.wustl.edu/>) and the PFAM database of Pfam Version 5.5 (<http://www.sanger.ac.uk/Software/Pfam/index.shtml>).

[0138] The result indicated that GPRv12 comprises tm7_1 (Rhodopsin family). The result of HMMPfam search is shown in Table 5.

Table 5

Hit	Score	Expect	Q from	Q to	Description
7tm_1	74.7	7.7e-23	22	294	7 transmembrane receptor (rhodopsin family)
Hit: name of the domain deduced by the search. Score: the higher the value, the higher the reliability. Expect: as the value approaches 0, the reliability becomes higher. Q from: the start position of the deduced domain. Q to: the termination position of the deduced domain. Description: explanation of the deduced domain.					

4. Amino acid sequence alignment

[0139] The amino acid sequences of GPRv12 and orphan G protein-coupled receptor GPR26- *Rattus norvegicus* (AF208288) were aligned together by using Clustalw 1.7 (Figure 14). The result showed that GPRv12 comprise seven transmembrane domains (### ###) and Cys (Cys marked with "@") participating in specific S-S bonding of GPCR.

[Example 6] Analysis of GPRv16 with bioinformatics

1. Homology search of GPRv16

[0140] The amino acid sequence of GPRv16 was analyzed by searching known sequences (the known sequence databases are produced in EMBL (Release 64, <http://www.ebi.ac.uk/>), GENBANK (Release 120.0, <http://www.ncbi.nlm.nih.gov/>), and PIR (Release 66.00, <http://www-nbrf.georgetown.edu/pir/>) with an analysis program (BLAST 2.0) (Altschul, Stephen F. et al. (1997) *Nucleic Acids Res.* 25:3389-3402.). The result showed that GPRv16 had homology to the sequences shown in Table 6. Thus, GPRv16 was revealed to be a novel clone having homology to GPCR. The amino acid sequence of GPRv16 was analyzed by searching known sequences with an analysis program (BLAST 2.0); the result (data with the E-value lower than e-18) is shown in Table 6.

Table 6

Hit (ID)	E-value	Identities %	Description
AF042784	4e-20	23	GALANIN RECEPTOR TYPE 2-Mus musculus
U30290	4e-20	27	galanin receptor GALR1-Rattus norvegicus
U90657	6e-20	27	GALANIN RECEPTOR TYPE 1-mouse
AF042782	7e-20	25	galanin receptor type 2-Homo sapiens
U94322	1e-19	24	galanin receptor type2-Rattus norvegicus
AF077375	6e-19	23	galanin receptor type2-Mus musculus

2. Prediction of transmembrane domain

[0141] The amino acid sequence of GPRv16 was analyzed according to the method of Kyte-Doolittle (J. Kyte and R. F. Doolittle, (1982), *J. Mol. Biol.*, 157,105-132.), for obtaining a hydropathy plot and used to predict the transmembrane domain. The result showed that GPRv16 had seven transmembrane domains (TM1-TM7) (Figure 15).

3. HMMPfam search

[0142] Using the amino acid sequence of GPRv16 as the query, PFAM search based on the hidden Markov model (HMMPFAM (Sonnhammer EL, et al., *Nucleic Acids Res* 1998 Jan 1; 26 (1):320-322)) was carried out. The search was carried out with the hidden Markov model of HMMER version 2.1 (<http://hmmer.wustl.edu/>) and the PFAM database of Pfam Version 5.5 (<http://www.sanger.ac.uk/Software/Pfam/index.shtml>).

[0143] The result indicated that GPRv16 comprises tm7_1 (Rhodopsin family). The result of HMMPfam search is shown in Table 7.

Table 7

Hit	Score	Expect	Q from	Q to	Description
7tm_1	23.8	8.3e-7	155	306	7 transmembrane receptor (rhodopsin family)
7tm_1	13.3	0.0017	53	133	7 transmembrane receptor (rhodopsin family)
Hit: name of the domain deduced by the search. Score: the higher the value, the higher the reliability. Expect: as the value approaches 0, the reliability becomes higher. Q from: the start position of the deduced domain. Q to: the termination position of the deduced domain. Description: explanation of the deduced domain.					

4. Amino acid sequence alignment

[0144] The result of sections 3 and 4 are indicated in Figure 16. The result showed that GPRv16 comprise Cys (@) participating in specific S-S bonding of GPCR.

[Example 7] Analysis of GPRv21 with bioinformatics

1. Homology search of GPRv21

[0145] The amino acid sequence of GPRv21 was analyzed by searching known sequences (the known sequence databases are produced in EMBL (Release 64, <http://www.ebi.ac.uk/>), GENBANK (Release 120.0, <http://www.ncbi.nlm.nih.gov/>), and PIR (Release 66.00, <http://www-nbrf.georgetown.edu/pir/>)) with an analysis program (BLAST 2.0) (Altschul, Stephen F. et al. (1997) *Nucleic Acids Res.* 25:3389-3402.). The result showed that GPRv21 had homology to the sequences shown in Table 8. Thus, GPRv21 was revealed to be a novel clone having homology to GPCR. The amino acid sequence of GPRv21 was analyzed by searching known sequences with an analysis program (BLAST 2.0); the result (data with the E-value lower than e-35) is shown in Table 8.

Table 8

Hit (ID)	E-value	Identities %	Description
AL121755	0.0	89	G-protein coupled receptor-Human
AF236082	0.0	83	G-protein coupled receptor GPR73-Mus musculus
M81490	9e-37	34	neuropeptide receptor-D. melanogaster
U50144	3e-36	30	type 2 neuropeptide Y receptor-Bos taurus
U42766	6e-36	29	neuropeptide y2 receptor-Human
AF037444	8e-36	28	cardioexcitatory receptor-Lymnaea stagnalis
D86238	8e-36	28	neuropeptideY-Y2 receptor-Mus musculus
U42389	8e-36	29	neuropeptid y/peptid YY receptor type 2-human
U76254	8e-36	29	neuropeptide Y receptor type 2-Human

2. Prediction of transmembrane domain

[0146] The amino acid sequence of GPRv21 was analyzed according to the method of Kyte-Doolittle (J. Kyte and R. F. Doolittle, (1982); *J. Mol. Biol.*, 157,105-132.), for obtaining a hydropathy plot and used to predict the transmembrane domain. The result showed that GPRv21 had seven transmembrane domains (TM1-TM7) (Figure 17).

3. HMMPfam search

[0147] Using the amino acid sequence of GPRv21 as the query, PFAM search based on the hidden Markov model (HMMPFAM (Sonnhammer EL, et al., *Nucleic Acids Res* 1998 Jan 1; 26 (1):320-322)) was carried out. The search was carried out with the hidden Markov model of HMMER version 2.1 (<http://hmmer.wustl.edu/>) and the PFAM database of Pfam Version 5.5 (<http://www.sanger.ac.uk/Software/Pfam/index.shtml>).

[0148] The result indicated that GPRv21 comprises tm7_1 (Rhodopsin family). The result of HMMPfam search is shown in Table 9.

Table 9

Hit	Score	Expect	Q from	Q to	Description
7tm_1	188.1	1.6e-58	79	338	7 transmembrane receptor (rhodopsin family)
Hit: name of the domain deduced by the search. Score: the higher the value, the higher the reliability. Expect: as the value approaches 0, the reliability becomes higher. Q from: the start position of the deduced domain. Q to: the termination position of the deduced domain. Description: explanation of the deduced domain.					

4. Amino acid sequence alignment

[0149] The amino acid sequences of GPRv21 and proteins shown in Table 8 were aligned together by using Clustalw 1.7 (Figures 18 and 19). The result showed that GPRv21 comprise seven transmembrane domains (#####) and Cys (Cys marked with "@") participating in specific S-S bonding of GPCR.

[Example 8] Analysis of GPRv40 with bioinformatics

1. Homology search of GPRv40

[0150] The amino acid sequence of GPRv40 was analyzed by searching known sequences (the known sequence databases are produced in EMBL (Release 64, <http://www.ebi.ac.uk/>), GENBANK (Release 120.0, <http://www.ncbi.nlm.nih.gov/>), and PIR (Release 66.00, <http://www-nbrf.georgetown.edu/pir/>)) with an analysis program (BLAST 2.0) (Altschul, Stephen F. et al. (1997) *Nucleic Acids Res.* 25:3389-3402.). The result showed that GPRv40 had homology to the sequences shown in Table 10. Thus, GPRv40 was revealed to be a novel clone having homology to GPCR. The amino acid sequence of GPRv40 was analyzed by searching known sequences with an analysis program (BLAST 2.0); the result (data with the E-value lower than e-11) is shown in Table 10.

Table 10

Hit (ID)	E-value	Identities %	Description
D86599	1e-13	23	oxytocin receptor- Mus sp.
U15280	4e-13	23	oxytocin 23 receptor-Rattus norvegicus
X76321	1e-12	22	vasotocin receptor-white sucker
X64878	2e-12	21	oxytocin receptor-H.sapiens
X87783	2e-12	21	isotocin receptor-C.commersoni
D45400	3e-12	23	vasopressin receptor V1b-rat
L37112	3e-12	24	vasopressin receptor subtype 1b-Hom sapi ns

EP 1 243 648 A1

Tabl 10 (continued)

Hit (ID)	E-value	Identities %	Description
U27322	6e-12	23	arginine-vasopressin V1b receptor-Rattus norvegicus
U82440	6e-12	21	oxytocin receptor-Macaca mulatta

2. Prediction of transmembrane domain

[0151] The amino acid sequence of GPRv40 was analyzed according to the method of Kyte-Doolittle (J. Kyte and R. F. Doolittle, (1982), *J. Mol. Biol.*, 157,105-132.), for obtaining a hydropathy plot and used to predict the transmembrane domain. The result showed that GPRv40 had seven transmembrane domains (TM1-TM7) (Figure 20).

3. HMMPfam search

[0152] Using the amino acid sequence of GPRv40 as the query, PFAM search based on the hidden Markov model (HMMPFAM (Sonnhammer EL, et al., *Nucleic Acids Res* 1998 Jan 1; 26 (1):320-322)) was carried out. The search was carried out with the hidden Markov model of HMMER version 2.1 (<http://hmmerr.wustl.edu/>) and the PFAM database of Pfam Version 5.5 (<http://www.sanger.ac.uk/Software/Pfam/index.shtml>).

[0153] The result indicated that GPRv40 comprises tm7_1 (Rhodopsin family). The result of HMMPfam search is shown in Table 11.

Table 11

Hit	Score	Expect	Q from	Q to	Description
7tm_1	26.5	1.1e-07	228	352	7 transmembrane receptor (rhodopsin family)
7tm_1	18.1	5e-05	59	181	7 transmembrane receptor (rhodopsin family)
Hit: name of the domain deduced by the search. Score: the higher the value, the higher the reliability. Expect: as the value approaches 0, the reliability becomes higher. Q from: the start position of the deduced domain. Q to: the termination position of the deduced domain. Description: explanation of the deduced domain.					

4. Amino acid sequence alignment

[0154] The result of section 3 and 4 are indicated in Figure 21. The result showed that GPRv40 comprise Cys (@) participating in specific S-S bonding of GPCR.

[Example 9] Analysis of GPRv47 with bioinformatics

1. Homology search of GPRv47

[0155] The amino acid sequence of GPRv47 was analyzed by searching known sequences (the known sequence databases are produced in EMBL (Release 64, <http://www.ebi.ac.uk/>), GENBANK (Release 120.0, <http://www.ncbi.nlm.nih.gov/>), and PIR (Release 66.00, <http://www-nbrf.georgetown.edu/pir/>)) with an analysis program (BLAST 2.0) (Altschul, Stephen F. et al. (1997) *Nucleic Acids Res.* 25:3389-3402.). The result showed that GPRv47 had homology to the sequences shown in Table 12. Thus, GPRv47 was revealed to be a novel clone having homology to GPCR. The amino acid sequence of GPRv47 was analyzed by searching known sequences with an analysis program (BLAST 2.0); the result (data with the E-value lower than e-11) is shown in Table 12.

Table 12

Hit (ID)	E-value	Identities %	Description
D43633	1e-85	41	G protein-coupled 7-transmembrane receptor-Medaka fish

Table 12 (continued)

Hit (ID)	E-value	Identities %	Description
X98133	2e-28	27	histamine H2 receptor-H.sapiens
M32701	3e-28	28	histamine H2 receptor-Canine histamine
L41147	6e-28	31	5-HT6 serotonin receptor-Homo sapiens
U25440	8e-28	26	histamine H2 receptor-Cavia porcellus
D49783	1e-27	28	histamine H2 receptor- Human
U64032	2e-27	27	alpha 1d adrenoceptor-Oryctolagus cuniculus
S73473	3e-27	28	beta 3-adrenergic receptor-rats
M74716	4e-27	28	beta-adrenergic receptor- Rat
S57565	6e-27	27	histamine H2-receptor- rats

2. Prediction of transmembrane domain

[0156] The amino acid sequence of GPRv47 was analyzed according to the method of Kyte-Doolittle (J. Kyte and R. F. Doolittle, (1982), *J. Mol. Biol.*, 157,105-132.), for obtaining a hydropathy plot and used to predict the transmembrane domain. The result showed that GPRv47 had seven transmembrane domains (TM1-TM7) (Figure 22).

3. HMMPfam search

[0157] Using the amino acid sequence of GPRv47 as the query, PFAM search based on the hidden Markov model (HMMPFAM (Sonnhammer EL, et al., *Nucleic Acids Res* 1998 Jan 1; 26 (1):320-322)) was carried out. The search was carried out with the hidden Markov model of HMMER version 2.1 (<http://hmmer.wustl.edu/>) and the PFAM database of Pfam Version 5.5 (<http://www.sanger.ac.uk/Software/Pfam/index.shtml>).

[0158] The result indicated that GPRv47 comprises tm7_1 (Rhodopsin family). The result of HMMPfam search is shown in Table 13.

Table 13

Hit	Score	Expect	Q from	Q to	Description
7tm_1	137.9	9.6e-43	59	341	7 transmembrane receptor (rhodopsin family)
Hit: name of the domain deduced by the search. Score: the higher the value, the higher the reliability. Expect: as the value approaches 0, the reliability becomes higher. Q from: the start position of the deduced domain. Q to: the termination position of the deduced domain. Description: explanation of the deduced domain.					

4. Amino acid sequence alignment

[0159] The amino acid sequences of GPRv47 and proteins shown in Table 2 were aligned together by using Clustalw 1.7 (Figures 23 to 25). The result showed that GPRv47 comprise seven transmembrane domains (### ###) and Cys (Cys marked with "@") participating in specific S-S bonding of GPCR.

[Example 10] Analysis of GPRv51 with bioinformatics

1. Homology search of GPRv51

[0160] The amino acid sequence of GPRv51 was analyzed by searching known sequences (the known sequence databases are produced in EMBL (Release 64, <http://www.ebi.ac.uk/>), GENBANK (Release 120.0, <http://www.ncbi.nlm.nih.gov/>), and PIR (Release 66.00, <http://www-nbrf.georgetown.edu/pir/>)) with an analysis program (BLAST 2.0) (Altschul, Stephen F. et al. (1997) *Nucleic Acids Res.* 25:3389-3402.). The result showed that GPRv51 had homology

to the sequences shown in Table 14. Thus, GPRv51 was revealed to be a novel clone having homology to GPCR. The amino acid sequence of GPRv51 was analyzed by searching known sequences with an analysis program (BLAST 2.0); the result (data with the E-value lower than $e-18$) is shown in Table 14.

Table 14

Hit (ID)	E-value	Identities %	Description
M35297	4e-43	36	G-protein coupled receptor-Rat
J03823	1e-42	34	Rat mas oncogene, complete cds.
M13150	3e-40	34	mas proto-oncogene- Human
X67735	1e-39	35	Mas proto-oncogene-M.musculus mas
AL035542	1e-35	36	MAS-related Gprotein-coupled receptor MRG-Human

2. Prediction of transmembrane domain

[0161] The amino acid sequence of GPRv51 was analyzed according to the method of Kyte-Doolittle (J. Kyte and R. F. Doolittle, (1982), *J. Mol. Biol.*, 157,105-132.), for obtaining a hydropathy plot and used to predict the transmembrane domain. The result showed that GPRv51 had seven transmembrane domains (TM1-TM7) (Figure 26).

3. HMMPfam search

[0162] Using the amino acid sequence of GPRv51 as the query, PFAM search based on the hidden Markov model (HMMPFAM (Sonnhammer EL, et al., *Nucleic Acids Res* 1998 Jan 1; 26 (1):320-322)) was carried out. The search was carried out with the hidden Markov model of HMMER version 2.1 (<http://hmmerr.wustl.edu/>) and the PFAM database of Pfam Version 5.5 (<http://www.sanger.ac.uk/Software/Pfam/index.shtml>).

[0163] The result indicated that GPRv51 comprises tm7_1 (Rhodopsin family). The result of HMMPfam search is shown in Table 15.

Table 15

Hit	Score	Expect	Q from	Q to	Description
7tm_1	32.6	1.4e-09	44	78	7 transmembrane receptor (rhodopsin family)
7tm_1	30.1	8.7e-09	104	276	7 transmembrane receptor (rhodopsin family)
Hit: name of the domain deduced by the search. Score: the higher the value, the higher the reliability. Expect: as the value approaches 0, the reliability becomes higher. Q from: the start position of the deduced domain. Q to: the termination position of the deduced domain. Description: explanation of the deduced domain.					

4. Amino acid sequence alignment

[0164] The amino acid sequences of GPRv51 and G-protein coupled receptor- Rat (M35297) were aligned together by using Clustalw 1.7 (Figure 27). The result showed that GPRv51 comprise seven transmembrane domains (### ###).

[Example 11] Analysis of GPRv71 with bioinformatics

1. Homology search of GPRv71

[0165] The amino acid sequence of GPRv71 was analyzed by searching known sequences (the known sequences databases are produced in EMBL (Release 64, <http://www.ebi.ac.uk/>), GENBANK (Release 120.0, <http://www.ncbi.nlm.nih.gov/>), and PIR (Release 66.00, <http://www-nbrf.georgetown.edu/pir/>)) with an analysis program (BLAST 2.0) (Altschul, Stephen F. et al. (1997) *Nucleic Acids Res.* 25:3389-3402.). The result showed that GPRv71 had homology to the sequences shown in Table 16. Thus, GPRv71 was revealed to be a novel clone having homology to GPCR. The

EP 1 243 648 A1

amino acid sequence of GPRv71 was analyzed by searching known sequences with an analysis program (BLAST 2.0); the result (data with the E-value lower than e^{-35}) is shown in Table 16.

Table 16

Hit (ID)	E-value	Identities %	Description
AF069555	9e-44	44	G protein-coupled receptor p2y3-Meleagris gallopavo
X98283	9e-44	45	P2Y PURINOCEPTOR 3-G.domesticus
AF031897	6e-41	40	P2Y nucleotide receptor-Meleagris gallopavo
X99953	1e-39	41	P2Y PURINOCEPTOR 8- X.laevis
D63665	2e-37	41	novel G protein-coupled P2 receptor-Rat
Y14705	1e-36	40	P2Y4 receptor gene-Rattus norvegicus
AJ277752	2e-36	41	P2Y4 receptor- Mus musculus

2. Prediction of transmembrane domain

[0166] The amino acid sequence of GPRv71 was analyzed according to the method of Kyte-Doolittle (J. Kyte and R. F. Doolittle, (1982), *J. Mol. Biol.*, 157,105-132.), for obtaining a hydropathy plot and used to predict the transmembrane domain. The result showed that GPRv71 had seven transmembrane domains (TM1-TM7) (Figure 28).

3. HMMPfam search

[0167] Using the amino acid sequence of GPRv71 as the query, PFAM search based on the hidden Markov model (HMMPFAM (Sonnhammer EL, et al., *Nucleic Acids Res* 1998 Jan 1; 26 (1) : 320-322)) was carried out. The search was carried out with the hidden Markov model of HMMER version 2.1 (<http://hmmerr.wustl.edu/>) and the PFAM database of Pfam Version 5.5 (<http://www.sanger.ac.uk/Software/Pfam/index.shtml>).

[0168] The result indicated that GPRv71 comprises tm7_1 (Rhodopsin family). The result of HMMPfam search is shown in Table 17.

Table 17

Hit	Score	Expect	Q from	Q to	Description
7tm_1	90.6	7.6e-28	40	161	7 transmembrane receptor (rhodopsin family)
Hit: name of the domain deduced by the search. Score: the higher the value, the higher the reliability. Expect: as the value approaches 0, the reliability becomes higher. Q from: the start position of the deduced domain. Q to: the termination position of the deduced domain. Description: explanation of the deduced domain.					

4. Amino acid sequence alignment

[0169] The amino acid sequences of GPRv71 and proteins shown in Table 2 were aligned together by using Clustalw 1.7 (Figures 29 and 30). The result showed that GPRv71 comprise seven transmembrane domains (### ###).

[Example 12] Analysis of GPRv72 with bioinformatics

1. Homology search of GPRv72

[0170] The amino acid sequence of GPRv72 was analyzed by searching known sequences (the known sequence databases are produced in EMBL (Release 64, <http://www.ebi.ac.uk/>), GENBANK (Release 120.0, <http://www.ncbi.nlm.nih.gov/>), and PIR (Release 66.00, <http://www-nbrf.georgetown.edu/pir/>)) with an analysis program (BLAST 2.0) (Altschul, Stephen F. et al. (1997) *Nucleic Acids Res.* 25:3389-3402.). The result showed that GPRv72 had homology to the sequences shown in Table 18. Thus, GPRv72 was revealed to be a novel clone having homology to GPCR. Th

EP 1 243 648 A1

amino acid sequence of GPRv72 was analyzed by searching known sequences with an analysis program (BLAST 2.0); the result (data with the E-value lower than e^{-24}) is shown in Table 18.

Table 18

Hit (ID)	E-value	Identities %	Description
AF091890	4e-29	32	G-protein coupled receptor RE2-Homo sapiens
U81982	3e-25	30	alpha 1a-adrenoceptor-Oryctolagus cuniculus
S71323	6e-25	32	alpha-1A adrenergic receptor-Japanese medaka
D63859	6e-25	32	alpha1A-adrenoceptor-Oryzias latipes
U07126	8e-25	29	alpha1c adrenergic receptor-Rattus norvegicus
U03866	8e-25	30	adrenergic alpha-1c receptor protein-Human
AF013261	8e-25	30	alpha 1A adrenergic receptor isoform 4-Homo sapiens
L31774	8e-25	30	alpha-1C-adrenergic receptor-Human
D32202	8e-25	30	alpha 1C adrenergic receptor isoform 2-Human
D32201	8e-25	30	alpha 1C adrenergic receptor isoform 3-Human
D25235	8e-25	30	alpha1C adrenergic receptor

2. Prediction of transmembrane domain

[0171] The amino acid sequence of GPRv72 was analyzed according to the method of Kyte-Doolittle (J. Kyte and R. F. Doolittle, (1982), *J. Mol. Biol.*, 157,105-132.), for obtaining a hydropathy plot and used to predict the transmembrane domain. The result showed that GPRv72 had seven transmembrane domains (TM1-TM7) (Figure 31).

3. HMMPfam search

[0172] Using the amino acid sequence of GPRv72 as the query, PFAM search based on the hidden Markov model (HMMPFAM (Sonhammer EL, et al., *Nucleic Acids Res* 1998 Jan 1; 26 (1) :320-322)) was carried out. The search was carried out with the hidden Markov model of HMMER version 2.1 (<http://hmmer.wustl.edu/>) and the PFAM database of Pfam Version 5.5 (<http://www.sanger.ac.uk/Software/Pfam/index.shtml>).

[0173] The result indicated that GPRv72 comprises tm7_1 (Rhodopsin family). The result of HMMPfam search is shown in Table 19.

Table 19

Hit	Score	Expect	Q from	Q to	Description
7tm_1	196.1	4.7e-61	48	454	7 transmembrane receptor (rhodopsin family)
Hit: name of the domain deduced by the search. Score: the higher the value, the higher the reliability. Expect: as the value approaches 0, the reliability becomes higher. Q from: the start position of the deduced domain. Q to: the termination position of the deduced domain. Description: explanation of the deduced domain.					

4. Amino acid sequence alignment

[0174] The amino acid sequences of GPRv72 and proteins shown in Table 18 were aligned together by using Clustalw 1.7 (Figures 32 to 34). The result showed that GPRv72 comprise seven transmembrane domains (### ###) and Cys (Cys marked with "@") participating in specific S-S bonding of GPCR.

Industrial Applicability

[0175] The present invention provided novel G protein-coupled receptors (GPRv8, GPRv12, GPRv16, GPRv21, GPRv40, GPRv47, GPRv51, GPRv71, and GPRv72), the genes encoding the proteins, vectors containing the genes, host cells containing the vectors, and a method for producing the proteins. Further, the present invention provided a screening method for compounds modifying the activities of the proteins. The proteins and genes of the present invention, and compounds modifying the activity of the proteins, are expected to be used for the development of new preventives and therapeutics for the diseases, with which the G protein-coupled receptors of the present invention are associated.

SEQUENCE LISTING

5 <110> HELIX RESEARCH INSTITUTE

<120> NOVEL GUANOSINE TRIPHOSPHATE-BINDING PROTEIN-COUPLED RECEPTORS AND GENES
10 THEREOF, AND PRODUCTION AND USES THEREOF

<130> H1-113DF1PCT

15 <140>
<141>

20 <150> JP 1999-375152
<151> 1999-12-28

25 <150> JP 2000-101339
<151> 2000-03-31

30 <160> 63

<170> PatentIn Ver. 2.1

35 <210> 1
<211> 371
40 <212> PRT
<213> Homo sapiens

45 <400> 1
Met Pro Ala Asn Phe Thr Glu Gly Ser Phe Asp Ser Ser Gly Thr Gly
1 5 10 15
50 Gln Thr Leu Asp Ser Ser Pro Val Ala Cys Thr Glu Thr Val Thr Phe
20 25 30
55 Thr Glu Val Val Glu Gly Lys Glu Trp Gly Ser Phe Tyr Tyr Ser Ph

EP 1 243 648 A1

	35	40	45
5	Lys Thr Glu Gln Leu Ile Thr Leu Trp Val Leu Phe Val Phe Thr Ile		
	50	55	60
10	Val Gly Asn Ser Val Val Leu Phe Ser Thr Trp Arg Arg Lys Lys Lys		
	65	70	75 80
15	Ser Arg Met Thr Phe Phe Val Thr Gln Leu Ala Ile Thr Asp Ser Phe		
	85	90	95
20	Thr Gly Leu Val Asn Ile Leu Thr Asp Ile Asn Trp Arg Phe Thr Gly		
	100	105	110
25	Asp Phe Thr Ala Pro Asp Leu Val Cys Arg Val Val Arg Tyr Leu Gln		
	115	120	125
30	Val Val Leu Leu Tyr Ala Ser Thr Tyr Val Leu Val Ser Leu Ser Ile		
	130	135	140
35	Asp Arg Tyr His Ala Ile Val Tyr Pro Met Lys Phe Leu Gln Gly Glu		
	145	150	155 160
40	Lys Gln Ala Arg Val Leu Ile Val Ile Ala Trp Ser Leu Ser Phe Leu		
	165	170	175
45	Phe Ser Ile Pro Thr Leu Ile Ile Phe Gly Lys Arg Thr Leu Ser Asn		
	180	185	190
50	Gly Glu Val Gln Cys Trp Ala Leu Trp Pro Asp Asp Ser Tyr Trp Thr		
	195	200	205
55	Pro Tyr Met Thr Ile Val Ala Phe Leu Val Tyr Phe Ile Pro Leu Thr		
	210	215	220
55	Ile Ile Ser Ile Met Tyr Gly Il Val Il Arg Thr Il Trp Ile Lys		

EP 1 243 648 A1

	225	230	235	240
5	Ser Lys Thr Tyr Glu Thr Val Ile Ser Asn Cys Ser Asp Gly Lys Leu			
	245	250	255	
10	Cys Ser Ser Tyr Asn Arg Gly Leu Ile Ser Lys Ala Lys Ile Lys Ala			
	260	265	270	
15	Ile Lys Tyr Ser Ile Ile Ile Ile Leu Ala Phe Ile Cys Cys Trp Ser			
	275	280	285	
20	Pro Tyr Phe Leu Phe Asp Ile Leu Asp Asn Phe Asn Leu Leu Pro Asp			
	290	295	300	
25	Thr Gln Glu Arg Phe Tyr Ala Ser Val Ile Ile Gln Asn Leu Pro Ala			
	305	310	315	320
30	Leu Asn Ser Ala Ile Asn Pro Leu Ile Tyr Cys Val Phe Ser Ser Ser			
	325	330	335	
35	Ile Ser Phe Pro Cys Arg Glu Gln Arg Ser Gln Asp Ser Arg Met Thr			
	340	345	350	
40	Phe Arg Glu Arg Thr Glu Arg His Glu Met Gln Ile Leu Ser Lys Pro			
	355	360	365	
45	Glu Phe Ile			
	370			
50	<210> 2			
	<211> 363			
	<212> PRT			
	<213> Homo sapiens			
55	<400> 2			

EP 1 243 648 A1

Met Gly Pro Gly Glu Ala Leu Leu Ala Gly Leu Leu Val Met Val Leu
1 5 10 15

Ala Val Ala Leu Leu Ser Asn Ala Leu Val Leu Leu Cys Cys Ala Tyr
20 25 30

Ser Ala Glu Leu Arg Thr Arg Ala Ser Gly Val Leu Leu Val Asn Leu
35 40 45

Ser Leu Gly His Leu Leu Leu Ala Ala Leu Asp Met Pro Phe Thr Leu
50 55 60

Leu Gly Val Met Arg Gly Arg Thr Pro Ser Ala Pro Gly Ala Cys Gln
65 70 75 80

Val Ile Gly Phe Leu Asp Thr Phe Leu Ala Ser Asn Ala Ala Leu Ser
85 90 95

Val Ala Ala Leu Ser Ala Asp Gln Trp Leu Ala Val Gly Phe Pro Leu
100 105 110

Arg Tyr Ala Gly Arg Leu Arg Pro Arg Tyr Ala Gly Leu Leu Leu Gly
115 120 125

Cys Ala Trp Gly Gln Ser Leu Ala Phe Ser Gly Ala Ala Leu Gly Cys
130 135 140

Ser Trp Leu Gly Tyr Ser Ser Ala Phe Ala Ser Cys Ser Leu Arg Leu
145 150 155 160

Pro Pro Glu Pro Glu Arg Pro Arg Phe Ala Ala Phe Thr Ala Thr Leu
165 170 175

His Ala Val Gly Phe Val Leu Pro Leu Ala Val Leu Cys Leu Thr Ser
180 185 190

EP 1 243 648 A1

Leu Gln Val His Arg Val Ala Arg Arg His Cys Gln Arg Met Asp Thr
195 200 205

Val Thr Met Lys Ala Leu Ala Leu Leu Ala Asp Leu His Pro Ser Val
210 215 220

Arg Gln Arg Cys Leu Ile Gln Gln Lys Arg Arg Arg His Arg Ala Thr
225 230 235 240

Arg Lys Ile Gly Ile Ala Ile Ala Thr Phe Leu Ile Cys Phe Ala Pro
245 250 255

Tyr Val Met Thr Arg Leu Ala Glu Leu Val Pro Phe Val Thr Val Asn
260 265 270

Ala Gln Trp Gly Ile Leu Ser Lys Cys Leu Thr Tyr Ser Lys Ala Val
275 280 285

Ala Asp Pro Phe Thr Tyr Ser Leu Leu Arg Arg Pro Phe Arg Gln Val
290 295 300

Leu Ala Gly Met Val His Arg Leu Leu Lys Arg Thr Pro Arg Pro Ala
305 310 315 320

Ser Thr His Asp Ser Ser Leu Asp Val Ala Gly Met Val His Gln Leu
325 330 335

Leu Lys Arg Thr Pro Arg Pro Ala Ser Thr His Asn Gly Ser Val Asp
340 345 350

Thr Glu Asn Asp Ser Cys Leu Gln Gln Thr His
355 360

<210> 3

<211> 419

EP 1 243 648 A1

<212> PRT

<213> Homo sapiens

<400> 3

Met Leu Ala Ala Ala Phe Ala Asp Ser Asn Ser Ser Ser Met Asn Val

1 5 10 15

Ser Phe Ala His Leu His Phe Ala Gly Gly Tyr Leu Pro Ser Asp Ser

20 25 30

Gln Asp Trp Arg Thr Ile Ile Pro Ala Leu Leu Val Ala Val Cys Leu

35 40 45

Val Gly Phe Val Gly Asn Leu Cys Val Ile Gly Ile Leu Leu His Asn

50 55 60

Ala Trp Lys Gly Lys Pro Ser Met Ile His Ser Leu Ile Leu Asn Leu

65 70 75 80

Ser Leu Ala Asp Leu Ser Leu Leu Leu Phe Ser Ala Pro Ile Arg Ala

85 90 95

Thr Ala Tyr Ser Lys Ser Val Trp Asp Leu Gly Trp Phe Val Cys Lys

100 105 110

Ser Ser Asp Trp Phe Ile His Thr Cys Met Ala Ala Lys Ser Leu Thr

115 120 125

Ile Val Val Val Ala Lys Val Cys Phe Met Tyr Ala Ser Asp Pro Ala

130 135 140

Lys Gln Val Ser Ile His Asn Tyr Thr Ile Trp Ser Val Leu Val Ala

145 150 155 160

Ile Trp Thr Val Ala Ser Leu Leu Pro Leu Pro Glu Trp Phe Phe Ser

165 170 175

EP 1 243 648 A1

Thr Ile Arg His His Glu Gly Val Glu Met Cys Leu Val Asp Val Pro
 180 185 190
 5
 Ala Val Ala Glu Glu Phe Met Ser Met Phe Gly Lys Leu Tyr Pro Leu
 195 200 205
 10
 Leu Ala Phe Gly Leu Pro Leu Phe Phe Ala Ser Phe Tyr Phe Trp Arg
 210 215 220
 15
 Ala Tyr Asp Gln Cys Lys Lys Arg Gly Thr Lys Thr Gln Asn Leu Arg
 225 230 235 240
 20
 Asn Gln Ile Arg Ser Lys Gln Val Thr Val Met Leu Leu Ser Ile Ala
 245 250 255
 25
 Ile Ile Ser Ala Val Leu Trp Leu Pro Glu Trp Val Ala Trp Leu Trp
 260 265 270
 30
 Val Trp His Leu Lys Ala Ala Gly Pro Ala Pro Pro Gln Gly Phe Ile
 275 280 285
 35
 Ala Leu Ser Gln Val Leu Met Phe Ser Ile Ser Ser Ala Asn Pro Leu
 290 295 300
 40
 Ile Phe Leu Val Met Ser Glu Glu Phe Arg Glu Gly Leu Lys Gly Val
 305 310 315 320
 45
 Trp Lys Trp Met Ile Thr Lys Lys Pro Pro Thr Val Ser Glu Ser Gln
 325 330 335
 50
 Glu Thr Pro Ala Gly Asn Ser Glu Gly Leu Pro Asp Lys Val Pro Ser
 340 345 350
 55
 Pro Glu Ser Pro Ala Ser Ile Pro Glu Lys Glu Lys Pro Ser Ser Pro
 355 360 365

EP 1 243 648 A1

Ser Ser Gly Lys Gly Lys Thr Glu Lys Ala Glu Il Pro Ile Leu Pro
370 375 380

Asp Val Glu Gln Phe Trp His Glu Arg Asp Thr Val Pro Ser Val Gln
385 390 395 400

Asp Asn Asp Pro Ile Pro Trp Glu His Glu Asp Gln Glu Thr Gly Glu
405 410 415

Gly Val Lys

<210> 4

<211> 393

<212> PRT

<213> Homo sapiens

<400> 4

Met Glu Thr Thr Met Gly Phe Met Asp Asp Asn Ala Thr Asn Thr Ser
1 5 10 15

Thr Ser Phe Leu Ser Val Leu Asn Pro His Gly Ala His Ala Thr Ser
20 25 30

Phe Pro Phe Asn Phe Ser Tyr Ser Asp Tyr Asp Met Pro Leu Asp Glu
35 40 45

Asp Glu Asp Val Thr Asn Ser Arg Thr Phe Phe Ala Ala Lys Ile Val
50 55 60

Ile Gly Met Ala Leu Val Gly Ile Met Leu Val Cys Gly Ile Gly Asn
65 70 75 80

Phe Il Phe Ile Ala Ala Leu Val Arg Tyr Lys Lys Leu Arg Asn Leu

EP 1 243 648 A1

	85	90	95
5	Thr Asn Leu Leu Ile Ala Asn Leu Ala Ile Ser Asp Phe Leu Val Ala		
	100	105	110
10	Ile Val Cys Cys Pro Phe Glu Met Asp Tyr Tyr Val Val Arg Gln Leu		
	115	120	125
15	Ser Trp Glu His Gly His Val Leu Cys Thr Ser Val Asn Tyr Leu Arg		
	130	135	140
20	Thr Val Ser Leu Tyr Val Ser Thr Asn Ala Leu Leu Ala Ile Ala Ile		
	145	150	155 160
25	Asp Arg Tyr Leu Ala Ile Val His Pro Leu Arg Pro Arg Met Lys Cys		
	165	170	175
30	Gln Thr Ala Thr Gly Leu Ile Ala Leu Val Trp Thr Val Ser Ile Leu		
	180	185	190
35	Ile Ala Ile Pro Ser Ala Tyr Phe Thr Thr Glu Thr Val Leu Val Ile		
	195	200	205
40	Val Lys Ser Gln Glu Lys Ile Phe Cys Gly Gln Ile Trp Pro Val Asp		
	210	215	220
45	Gln Gln Leu Tyr Tyr Lys Ser Tyr Phe Leu Phe Ile Phe Gly Ile Glu		
	225	230	235 240
50	Phe Val Gly Pro Val Val Thr Met Thr Leu Cys Tyr Ala Arg Ile Ser		
	245	250	255
55	Arg Glu Leu Trp Phe Lys Ala Val Pro Gly Phe Gln Thr Glu Gln Ile		
	260	265	270
60	Arg Lys Arg Leu Arg Cys Arg Arg Lys Thr Val Leu Val Leu Met Cys		

EP 1 243 648 A1

275

280

285

5 Ile Leu Thr Ala Tyr Val Leu Cys Trp Ala Pro Phe Tyr Gly Phe Thr
290 295 300

10 Ile Val Arg Asp Phe Phe Pro Thr Val Phe Val Lys Glu Lys His Tyr
305 310 315 320

15 Leu Thr Ala Phe Tyr Ile Val Glu Cys Ile Ala Met Ser Asn Ser Met
325 330 335

20 Ile Asn Thr Leu Cys Phe Val Thr Val Lys Asn Asp Thr Val Lys Tyr
340 345 350

25 Phe Lys Lys Ile Met Leu Leu His Trp Lys Ala Ser Tyr Asn Gly Gly
355 360 365

30 Lys Ser Ser Ala Asp Leu Asp Leu Lys Thr Ile Gly Met Pro Ala Thr
370 375 380

35 Glu Glu Val Asp Cys Ile Arg Leu Lys
385 390

<210> 5

<211> 1116

<212> DNA

<213> Homo sapiens

<400> 5

atgccagcca acttcacaga gggcagcttc gattccagtg ggaccgggca gacgctggat 60
tcttccccag tggcttgac tgaacagtg acttttactg aagtgggtga aggaaaggaa 120
tggggttcct tctactactc tttaagact gagcaattga taactctgtg ggtcctcttt 180
gtttttacca ttgttgaaa ctccgttggtg cttttttcca catggaggag aaagaagaag 240
tcaagaatga ccttctttgt gactcagctg gccatcacag attctttcac aggactggc 300
aacatcttga cagatattaa ttggcgattc actggagact tcacggcacc tgacctggtt 360

EP 1 243 648 A1

tgccgagtgg tccgctatTT gcaggTtTg ctgctctacg cctctaccta cgtcctggTg 420
 tccctcagca tagacagata ccatgccatc gtctacccca tgaagttcct tcaaggagaa 480
 5 aagcaagcca gggTcctcat tTgTatcgcc Tggagcctgt cttttctgtt ctccattccc 540
 accctgatca tattTgggaa gaggacactg tccaacggTg aagtgcagtg ctgggccctg 600
 Tggcctgacg actcctactg gaccccatac atgaccatcg Tggccttcct ggtgtacttc 660
 10 atccctctga caatcatcag catcatgtat ggcaTtTga tccgaactat ttggattaaa 720
 agcaaaacct acgaaacagt gatttccaac Tgtcagatg ggaaactTg cagcagctat 780
 aaccgaggac tcatctcaaa ggcaaaaatc aaggctatca agtatagcat catcatcatt 840
 ctTgccttca tctgtgtTg gagtccatac ttctgtTtTg acattTtTga caatttcaac 900
 15 ctcttccag acaccagga gcgtTtctat gcctctTga tcatcagaa cctgccagca 960
 ttgaatagtT ccatcaaccc cctcatctac Tgtgtcttca gcagctccat ctctttcccc 1020
 Tgcagggagc aaagatcaca ggattccaga atgacgtTcc gggagagaaT tgagaggcat 1080
 20 gagatgcaga ttctgtccaa gccagaattc atctag 1116

<210> 6

<211> 1092

<212> DNA

<213> Homo sapiens

<400> 6

atgggccccg gcgaggcgct gctggcggtT ctctggtga Tggtactggc cgtggcgctg 60
 35 ctatccaacg cactggTgct gctTtTtTgc gcctacagcg ctgagctccg cactcgagcc 120
 TcaggcgTcc tctTggtgaa tctgtctctg ggccacctgc Tgctggcggc gctggacatg 180
 cccttcacgc TgtcggTgt gatgcgcggg cggacaccgt cggcgccccg cgcattgcaa 240
 40 gtcattggct tctTggacac ctTcctggcg tccaacgcgg cgctgagcgt ggcgcgctg 300
 agcgagacc agTggctggc agTgggcttc ccaTgcgt acgccggacg cctgcgaccg 360
 cgctatgccg gcctgtgct gggtgtTgcc Tggggacagt cgctggcctt ctcaggcgct 420
 45 gcactTggct gctcTggct Tggctacagc agcgctTcg cgtcctgttc gctgcgcctg 480
 ccgccccagc ctgagcgTcc gcgtTcgca gccttcaccg ccacgtcca Tgccgtgggc 540
 ttctgtctgc cgctggcggt gctctgcctc acctcgctcc aggtgcaccg ggtggcacgc 600
 agacactgcc agcgcatgga caccgtcacc atgaaggcgc Tcgcgctgct cgccgacctg 660
 50 caccacagtT Tgcggcagcg ctgcctcatc cagcagaagc ggcgccgcca ccgcgccacc 720
 aggaagattg gcattgtat Tgcgacctc ctcatctgct ttgccccgta Tgtcatgacc 780
 aggtTggcg agctcgTgcc ctTcgtcacc gtgaacgccc agTggggcat cctcagcaag 840
 55 Tgcctgacct acagcaaggc gTggcgcgac ccgttcacgt actctctgct ccgccggccg 900

ttccgcccaag tcctggccgg catggtgcac cggtgtgta agagaacccc gcgccagca 960
 tccacccatg acagctctct ggatgtggcc ggcatggtgc accagctgct gaagagaacc 1020
 ccgcgccag cgtccacca caacggctct gtggacacag agaatgattc ctgcctgcag 1080
 cagacacact ga 1092

<210> 7

<211> 1260

<212> DNA

<213> Homo sapiens

<400> 7

atgctggcag ctgccttgc agactctaac tccagcagca tgaatgtgtc ctttgctcac 60
 ctccactttg ccggagggtta cctgccctct gattcccagg actggagaac catcatcccg 120
 gctctcttgg tggctgtctg cctggtgggc ttcgtgggaa acctgtgtgt gattggcatc 180
 ctcccttcaca atgcttggaaggaaaggcca tccatgatcc actccctgat tctgaatctc 240
 agcctggctg atctctccct cctgctgttt tctgcaccta tccgagctac ggcgtactcc 300
 aaaagtgttt gggatctagg ctggtttgtc tgcaagtcct ctgactggtt tatccacaca 360
 tgcattggcag ccaagagcct gacaatcggt gtggtggcca aagtatgctt catgtatgca 420
 agtgacccag ccaagcaagt gattatccac aactacacca tctggtcagt gctggtggcc 480
 atctggactg tggctagcct gttacccctg ccggaatggt tctttagcac catcaggcat 540
 catgaagggtg tggaaatgtg cctcgtggat gtaccagctg tggctgaaga gtttatgtcg 600
 atgttttgga agctctaccc actcctggca ttggccttc cattattttt tgccagcttt 660
 tatttctgga gagcttatga ccaatgtaaa aaacgaggaa ctaagactca aaatcttaga 720
 aaccagatac gctcaaagca agtcacagtg atgctgtgta gcattgccat catctctgct 780
 gtcttgtggc tcccgaatg ggtagcttgg ctgtgggtat ggcatctgaa ggctgcaggc 840
 ccggcccccac cacaagggtt catagccctg tctcaagtct tgatgttttc catctcttca 900
 gcaaatcctc tcatttttct tgtgatgtcg gaagagttca gggaaggctt gaaagggtga 960
 tggaaatgga tgataaccaa aaaacctcca actgtctcag agtctcagga aacaccagct 1020
 ggcaactcag aggtctctcc tgacaagggt ccatctccag aatccccagc atccatacca 1080
 gaaaaagaga aaccagctc tccctcctct ggcaaggga aaactgagaa ggcagagatt 1140
 cccatccttc ctgacgtaga gcagttttgg catgagaggg acacagtccc ttctgtacag 1200
 gacaatgacc ctatccctg ggaacatgaa gatcaagaga cagggaagg tgtaaatag 1260

<210> 8

<211> 1182

<212> DNA

<213> Homo sapiens

<400> 8

```

atggagacca ccatgggggtt catggatgac aatgccacca acacttccac cagcttcctt 60
tctgtgctca accctcatgg agcccatgcc acttccttcc cattcaactt cagctacagc 120
gactatgata tgcctttgga tgaagatgag gatgtgacca attccaggac gttctttgct 180
gccaaagattg tcattgggat ggccctgggtg ggcatcatgc tggctctcgg cattggaaac 240
ttcatcttta tcgctgccct ggtccgctac aagaaactgc gcaacctcac caacctgctc 300
atcgccaacc tggccatctc tgacttcctg gtggccattg tctgctgccc ctttgagatg 360
gactactatg tggtgcgcca gctctcctgg gacgacggcc acgtcctgtg cacctctgtc 420
aactacctgc gcactgtctc tctctatgtc tccaccaatg cctgctggc catcgccatt 480
gacaggtatc tggctattgt ccatccgtg agaccacgga tgaagtcca aacagccact 540
ggcctgattg ccttgggtgtg gacggtgtcc atcctgatcg ccatcccttc cgcctacttc 600
accaccgaga cggtcctcgt cattgtcaag agccaggaaa agatcttctg cggccagatc 660
tggcctgtgg accagcagct ctactacaag tctacttcc tctttatctt tggcatagaa 720
ttcgtgggcc ccggtggcac catgaccctg tgctatgcca ggatctcccg ggagctctgg 780
ttcaaggcgg tccctggatt ccagacagag cagatccgca agaggctgcg ctgccgcagg 840
aagacggtcc tgggtgctcat gtgcatctc accgcctacg tgctatgctg ggcgcccttc 900
tacggcttca ccatcgtgcg cgacttcttc cccaccgtgt ttgtgaagga gaagcactac 960
ctcactgcct tctacatcgt cgagtgcac gccatgagca acagcatgat caacactctg 1020
tgcttcgtga ccgtcaagaa cgacaccgtc aagtacttca aaaagatcat gttgctccac 1080
tggaaggctt cttacaatgg cggtaagtcc agtgacagacc tggacctcaa gacaattggg 1140
atgcctgcca ccgaagaggt ggactgcac agactaaaat aa 1182

```

<210> 9

<211> 28

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: an artificially
synthesized primer sequence

<400> 9

atgccagcca acttcacaga gggcagct

28

5

<210> 10

<211> 28

<212> DNA

<213> Artificial Sequence

10

15

<220>

<223> Description of Artificial Sequence:an artificially
synthesized primer sequence

20

<400> 10

ctagatgaat tctggcttgg acagaatc

28

25

<210> 11

<211> 28

<212> DNA

<213> Artificial Sequence

30

35

<220>

<223> Description of Artificial Sequence:an artificially
synthesized primer sequence

40

<400> 11

atgggccccg gcgaggcgct gctggcgg

28

45

<210> 12

<211> 28

<212> DNA

<213> Artificial Sequence

50

55

<220>

<223> Description of Artificial Sequence:an artificially
synthesized primer sequence

5

<400> 12

tcagtgtgtc tgctgcaggc aggaatca

28

10

<210> 13

<211> 30

15

<212> DNA

<213> Artificial Sequence

20

<220>

<223> Description of Artificial Sequence:an artificially
synthesized primer sequence

25

<400> 13

atgctggcag ctgcctttgc agactctaac

30

30

<210> 14

<211> 30

35

<212> DNA

<213> Artificial Sequence

40

<220>

<223> Description of Artificial Sequence:an artificially
synthesized primer sequence

45

<400> 14

ctatttaaca ccttcccctg tctcttgatc

30

50

<210> 15

<211> 28

55

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:an artificially synthesized primer sequence

<400> 15

atggagacca ccatgggggtt catggatg

28

<210> 16

<211> 30

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:an artificially synthesized primer sequence

<400> 16

ttattttagt ctgatgcagt ccacctcttc

30

<210> 17

<211> 434

<212> PRT

<213> Homo sapiens

<400> 17

Met Glu Asp Leu Phe Ser Pro Ser Ile Leu Pro Pro Ala Pro Asn Ile

1

5

10

15

Ser Val Pro Ile Leu Leu Gly Trp Gly Leu Asn Leu Thr Leu Gly Gln

20

25

30

Gly Ala Pr Ala Ser Gly Pro Pro Ser Arg Arg Val Arg Leu Val Phe

EP 1 243 648 A1

	35	40	45
5	Leu Gly Val Ile Leu Val Val Ala Val Ala Gly Asn Thr Thr Val Leu		
	50	55	60
10	Cys Arg Leu Cys Gly Gly Gly Gly Pro Trp Ala Gly Pro Lys Arg Arg		
	65	70	75 80
15	Lys Met Asp Phe Leu Leu Val Gln Leu Ala Leu Ala Asp Leu Tyr Ala		
	85	90	95
20	Cys Gly Gly Thr Ala Leu Ser Gln Leu Ala Trp Glu Leu Leu Gly Glu		
	100	105	110
25	Pro Arg Ala Ala Thr Gly Asp Leu Ala Cys Arg Phe Leu Gln Leu Leu		
	115	120	125
30	Gln Ala Ser Gly Arg Gly Ala Ser Ala His Leu Val Val Leu Ile Ala		
	130	135	140
35	Leu Glu Arg Arg Arg Ala Val Arg Leu Pro His Gly Arg Pro Leu Pro		
	145	150	155 160
40	Ala Arg Ala Leu Ala Ala Leu Gly Trp Leu Leu Ala Leu Leu Leu Ala		
	165	170	175
45	Leu Pro Pro Ala Phe Val Val Arg Gly Asp Ser Pro Ser Pro Leu Pro		
	180	185	190
50	Pro Pro Pro Pro Pro Thr Ser Leu Gln Pro Gly Ala Pro Pro Ala Ala		
	195	200	205
55	Arg Ala Trp Pro Gly Gln Arg Arg Cys His Gly Ile Phe Ala Pro Leu		
	210	215	220
60	Pr Arg Trp His Leu Gln Val Tyr Ala Phe Tyr Glu Ala Val Ala Gly		

EP 1 243 648 A1

	225	230	235	240
5	Phe Val Ala Pro Val Thr Val Leu Gly Val Ala Cys Gly His Leu Leu			
	245	250	255	
10	Ser Val Trp Trp Arg His Arg Pro Gln Ala Pro Ala Ala Ala Pro			
	260	265	270	
15	Trp Ser Ala Ser Pro Gly Arg Ala Pro Ala Pro Ser Ala Leu Pro Arg			
	275	280	285	
20	Ala Lys Val Gln Ser Leu Lys Met Ser Leu Leu Leu Ala Leu Leu Phe			
	290	295	300	
25	Val Gly Cys Glu Leu Pro Tyr Phe Ala Ala Arg Leu Ala Ala Ala Trp			
	305	310	315	320
30	Ser Ser Gly Pro Ala Gly Asp Trp Glu Gly Glu Gly Leu Ser Ala Ala			
	325	330	335	
35	Leu Arg Val Val Ala Met Ala Asn Ser Ala Leu Asn Pro Phe Val Tyr			
	340	345	350	
40	Leu Phe Phe Gln Ala Gly Asp Cys Arg Leu Arg Arg Gln Leu Arg Lys			
	355	360	365	
45	Arg Leu Gly Ser Leu Cys Cys Ala Pro Gln Gly Gly Ala Glu Asp Glu			
	370	375	380	
50	Glu Gly Pro Arg Gly His Gln Ala Leu Tyr Arg Gln Arg Trp Pro His			
	385	390	395	400
55	Pro His Tyr His His Ala Arg Arg Glu Pro Leu Asp Glu Gly Gly Leu			
	405	410	415	
60	Arg Pro Pro Pro Pro Arg Pr Arg Pr Leu Pro Cys Ser Cys Glu Ser			

EP 1 243 648 A1

420

425

430

5 Ala Phe

10

<210> 18
 <211> 451
 <212> PRT
 <213> Homo sapiens

15

<400> 18

20 Met Glu Ser Ser Pro Ile Pro Gln Ser Ser Gly Asn Ser Ser Thr Leu
 1 5 10 15

25 Gly Arg Val Pro Gln Thr Pro Gly Pro Ser Thr Ala Ser Gly Val Pro
 20 25 30

30 Glu Val Gly Leu Arg Asp Val Ala Ser Glu Ser Val Ala Leu Phe Phe
 35 40 45

35 Met Leu Leu Leu Asp Leu Thr Ala Val Ala Gly Asn Ala Ala Val Met
 50 55 60

40 Ala Val Ile Ala Lys Thr Pro Ala Leu Arg Lys Phe Val Phe Val Phe
 65 70 75 80

45 His Leu Cys Leu Val Asp Leu Leu Ala Ala Leu Thr Leu Met Pro Leu
 85 90 95

50 Ala Met Leu Ser Ser Ser Ala Leu Phe Asp His Ala Leu Phe Gly Glu
 100 105 110

55 Val Ala Cys Arg Leu Tyr Leu Phe Leu Ser Val Cys Phe Val Ser Leu
 115 120 125

EP 1 243 648 A1

Ala Ile Leu Ser Val Ser Ala Ile Asn Val Glu Arg Tyr Tyr Tyr Val
130 135 140

Val His Pro Met Arg Tyr Glu Val Arg Met Thr Leu Gly Leu Val Ala
145 150 155 160

Ser Val Leu Val Gly Val Trp Val Lys Ala Leu Ala Met Ala Ser Val
165 170 175

Pro Val Leu Gly Arg Val Ser Trp Glu Glu Gly Ala Pro Ser Val Pro
180 185 190

Pro Gly Cys Ser Leu Gln Trp Ser His Ser Ala Tyr Cys Gln Leu Phe
195 200 205

Val Val Val Phe Ala Val Leu Tyr Phe Leu Leu Pro Leu Leu Leu Ile
210 215 220

Leu Val Val Tyr Cys Ser Met Phe Arg Val Ala Arg Val Ala Ala Met
225 230 235 240

Gln His Gly Pro Leu Pro Thr Trp Met Glu Thr Pro Arg Gln Arg Ser
245 250 255

Glu Ser Leu Ser Ser Arg Ser Thr Met Val Thr Ser Ser Gly Ala Pro
260 265 270

Gln Thr Thr Pro His Arg Thr Phe Gly Gly Gly Lys Ala Ala Val Val
275 280 285

Leu Leu Ala Val Gly Gly Gln Phe Leu Leu Cys Trp Leu Pro Tyr Phe
290 295 300

Ser Phe His Leu Tyr Val Ala Leu Ser Ala Gln Pro Ile Ser Thr Gly
305 310 315 320

EP 1 243 648 A1

Gln Val Glu Ser Val Val Thr Trp Ile Gly Tyr Phe Cys Phe Thr Ser
325 330 335

Asn Pro Phe Phe Tyr Gly Cys Leu Asn Arg Gln Ile Arg Gly Glu Leu
340 345 350

Ser Lys Gln Phe Val Cys Phe Phe Lys Pro Ala Pro Glu Glu Glu Leu
355 360 365

Arg Leu Pro Ser Arg Glu Gly Ser Ile Glu Glu Asn Phe Leu Gln Phe
370 375 380

Leu Gln Gly Thr Gly Cys Pro Ser Glu Ser Trp Val Ser Arg Pro Leu
385 390 395 400

Pro Ser Pro Lys Gln Glu Pro Pro Ala Val Asp Phe Arg Ile Pro Gly
405 410 415

Gln Ile Ala Glu Glu Thr Ser Glu Phe Leu Glu Gln Gln Leu Thr Ser
420 425 430

Asp Ile Ile Met Ser Asp Ser Tyr Leu Arg Pro Ala Ala Ser Pro Arg
435 440 445

Leu Glu Ser
450

<210> 19
<211> 321
<212> PRT
<213> Homo sapiens

<400> 19
Met Asn Gln Thr Leu Asn Ser Ser Gly Thr Val Glu Ser Ala Leu Asn
1 5 10 15

EP 1 243 648 A1

5	Tyr Ser Arg Gly Ser Thr Val His Thr Ala Tyr Leu Val Leu Ser Ser	20	25	30
10	Leu Ala Met Phe Thr Cys Leu Cys Gly Met Ala Gly Asn Ser Met Val	35	40	45
15	Ile Trp Leu Leu Gly Phe Arg Met His Arg Asn Pro Phe Cys Ile Tyr	50	55	60
20	Ile Leu Asn Leu Ala Ala Ala Asp Leu Leu Phe Leu Phe Ser Met Ala	65	70	75
25	Ser Thr Leu Ser Leu Glu Thr Gln Pro Leu Val Asn Thr Thr Asp Lys	85	90	95
30	Val His Glu Leu Met Lys Arg Leu Met Tyr Phe Ala Tyr Thr Val Gly	100	105	110
35	Leu Ser Leu Leu Thr Ala Ile Ser Thr Gln Arg Cys Leu Ser Val Leu	115	120	125
40	Phe Pro Ile Trp Phe Lys Cys His Arg Pro Arg His Leu Ser Ala Trp	130	135	140
45	Val Cys Gly Leu Leu Trp Thr Leu Cys Leu Leu Met Asn Gly Leu Thr	145	150	155
50	Ser Ser Phe Cys Ser Lys Phe Leu Lys Phe Asn Glu Asp Arg Cys Phe	165	170	175
55	Arg Val Asp Met Val Gln Ala Ala Leu Ile Met Gly Val Leu Thr Pro	180	185	190
	Val Met Thr Leu Ser Ser Leu Thr Leu Phe Val Trp Val Arg Arg Ser	195	200	205

EP 1 243 648 A1

Ser Gln Gln Trp Arg Arg Gln Pro Thr Arg Leu Phe Val Val Val Leu
210 215 220

Ala Ser Val Leu Val Phe Leu Ile Cys Ser Leu Pro Leu Ser Ile Tyr
225 230 235 240

Trp Phe Val Leu Tyr Trp Leu Ser Leu Pro Pro Glu Met Gln Val Leu
245 250 255

Cys Phe Ser Leu Ser Arg Leu Ser Ser Ser Val Ser Ser Ser Ala Asn
260 265 270

Pro Val Ile Tyr Phe Leu Val Gly Ser Arg Arg Ser His Arg Leu Pro
275 280 285

Thr Arg Ser Leu Gly Thr Val Leu Gln Gln Ala Leu Arg Glu Glu Pro
290 295 300

Glu Leu Glu Gly Gly Glu Thr Pro Thr Val Gly Thr Asn Glu Met Gly
305 310 315 320

Ala

<210> 20

<211> 333

<212> PRT

<213> Homo sapiens

<400> 20

Met Glu Lys Val Asp Met Asn Thr Ser Gln Glu Gln Gly Leu Cys Gln
1 5 10 15

Phe Ser Glu Lys Tyr Lys Gln Val Tyr Leu Ser Leu Ala Tyr Ser Il

EP 1 243 648 A1

	20	25	30
5	Ile Phe Ile Leu Gly Leu Pro Leu Asn Gly Thr Val Leu Trp His Phe		
	35	40	45
10	Trp Gly Gln Thr Lys Arg Trp Ser Cys Ala Thr Thr Tyr Leu Val Asn		
	50	55	60
15	Leu Met Val Ala Asp Leu Leu Tyr Val Leu Leu Pro Phe Leu Ile Ile		
	65	70	75 80
20	Thr Tyr Ser Leu Asp Asp Arg Trp Pro Phe Gly Glu Leu Leu Cys Lys		
	85	90	95
25	Leu Val His Phe Leu Phe Tyr Ile Asn Leu Tyr Gly Ser Ile Leu Leu		
	100	105	110
30	Leu Thr Cys Ile Ser Val His Gln Phe Leu Gly Val Cys His Pro Leu		
	115	120	125
35	Cys Ser Leu Pro Tyr Arg Thr Arg Arg His Ala Trp Leu Gly Thr Ser		
	130	135	140
40	Thr Thr Trp Ala Leu Val Val Leu Gln Leu Leu Pro Thr Leu Ala Phe		
	145	150	155 160
45	Ser His Thr Asp Tyr Ile Asn Gly Gln Met Ile Trp Tyr Asp Met Thr		
	165	170	175
50	Ser Gln Glu Asn Phe Asp Arg Leu Phe Ala Tyr Gly Ile Val Leu Thr		
	180	185	190
55	Leu Ser Gly Phe Leu Ser Leu Leu Gly His Phe Gly Val Leu Phe Thr		
	195	200	205
55	Asp Gly Gln Glu Pro Asp Gln Ala Arg Gly Glu Pro His Glu Asp Arg		

EP 1 243 648 A1

	210	215	220
5	Gln His Ser Pro Ser Gln Val His Pro Asp His Pro Thr Gly Val Trp		
	225	230	235 240
10	Pro Leu His Pro Leu Phe Cys Ala Leu Pro Tyr His Ser Leu Leu Leu		
	245	250	255
15	Pro His His Leu Leu Ser Ala Phe Ser Gly Leu Pro Ala Leu Asp Gly		
	260	265	270
20	Ser Gln Cys Gly Leu Gln Asp Met Glu Ala Ser Gly Glu Cys Glu Gln		
	275	280	285
25	Leu Pro Gln Pro Ser Pro Val Leu Ser Phe Lys Gly Gly Lys Asn Arg		
	290	295	300
30	Val Arg Leu Leu Gln Lys Leu Arg Gln Asn Lys Leu Gly Glu His Pro		
	305	310	315 320
35	Ala Gly Arg Lys Arg Cys Pro Gly Leu Asn Arg Ser Gly		
	325	330	
40	<210> 21		
	<211> 508		
	<212> PRT		
	<213> Homo sapiens		
45	<400> 21		
50	Met Thr Ser Thr Cys Thr Asn Ser Thr Arg Glu Ser Asn Ser Ser His		
	1	5	10 15
55	Thr Cys Met Pro Leu Ser Lys Met Pro Ile Ser Leu Ala His Gly Ile		
	20	25	30

EP 1 243 648 A1

Ile Arg Ser Thr Val Leu Val Ile Phe Leu Ala Ala Ser Phe Val Gly
35 40 45

Asn Ile Val Leu Ala Leu Val Leu Gln Arg Lys Pro Gln Leu Leu Gln
50 55 60

Val Thr Asn Arg Phe Ile Phe Asn Leu Leu Val Thr Asp Leu Leu Gln
65 70 75 80

Ile Ser Leu Val Ala Pro Trp Val Val Ala Thr Ser Val Pro Leu Phe
85 90 95

Trp Pro Leu Asn Ser His Phe Cys Thr Ala Leu Val Ser Leu Thr His
100 105 110

Leu Phe Ala Phe Ala Ser Val Asn Thr Ile Val Val Val Ser Val Asp
115 120 125

Arg Tyr Leu Ser Ile Ile His Pro Leu Ser Tyr Pro Ser Lys Met Thr
130 135 140

Gln Arg Arg Gly Tyr Leu Leu Leu Tyr Gly Thr Trp Ile Val Ala Ile
145 150 155 160

Leu Gln Ser Thr Pro Pro Leu Tyr Gly Trp Gly Gln Ala Ala Phe Asp.
165 170 175

Glu Arg Asn Ala Leu Cys Ser Met Ile Trp Gly Ala Ser Pro Ser Tyr
180 185 190

Thr Ile Leu Ser Val Val Ser Phe Ile Val Ile Pro Leu Ile Val Met
195 200 205

Ile Ala Cys Tyr Ser Val Val Phe Cys Ala Ala Arg Arg Gln His Ala
210 215 220

EP 1 243 648 A1

Leu Leu Tyr Asn Val Lys Arg His Ser Leu Glu Val Arg Val Lys Asp
225 230 235 240

Cys Val Glu Asn Glu Asp Glu Glu Gly Ala Glu Lys Lys Glu Glu Phe
245 250 255

Gln Asp Glu Ser Glu Phe Arg Arg Gln His Glu Gly Glu Val Lys Ala
260 265 270

Lys Glu Gly Arg Met Glu Ala Lys Asp Gly Ser Leu Lys Ala Lys Glu
275 280 285

Gly Ser Thr Gly Thr Ser Glu Ser Ser Val Glu Ala Arg Gly Ser Glu
290 295 300

Glu Val Arg Glu Ser Ser Thr Val Ala Ser Asp Gly Ser Met Glu Gly
305 310 315 320

Lys Glu Gly Ser Thr Lys Val Glu Glu Asn Ser Met Lys Ala Asp Lys
325 330 335

Gly Arg Thr Glu Val Asn Gln Cys Ser Ile Asp Leu Gly Glu Asp Asp
340 345 350

Met Glu Phe Gly Glu Asp Asp Ile Asn Phe Ser Glu Asp Asp Val Glu
355 360 365

Ala Val Asn Ile Pro Glu Ser Leu Pro Pro Ser Arg Arg Asn Ser Asn
370 375 380

Ser Asn Pro Pro Leu Pro Arg Cys Tyr Gln Cys Lys Ala Ala Lys Val
385 390 395 400

Ile Phe Ile Ile Ile Phe Ser Tyr Val Leu Ser Leu Gly Pro Tyr Cys
405 410 415

EP 1 243 648 A1

Phe Leu Ala Val Leu Ala Val Trp Val Asp Val Glu Thr Gln Val Pr
420 425 430

Gln Trp Val Ile Thr Ile Ile Ile Trp Leu Phe Phe Leu Gln Cys Cys
435 440 445

Ile His Pro Tyr Val Tyr Gly Tyr Met His Lys Thr Ile Lys Lys Glu
450 455 460

Ile Gln Asp Met Leu Lys Lys Phe Phe Cys Lys Glu Lys Pro Pro Lys
465 470 475 480

Glu Asp Ser His Pro Asp Leu Pro Gly Thr Glu Gly Gly Thr Glu Gly
485 490 495

Lys Ile Val Pro Ser Tyr Asp Ser Ala Thr Phe Pro
500 505

<210> 22

<211> 1305

<212> DNA

<213> Homo sapiens

<400> 22

atggaggatc tctttagccc ctcaattctg ccgccggcgc ccaacatttc cgtgcccatc 60
ttgctgggct ggggtctcaa cctgaccttg gggcaaggag cccctgcctc tgggccgcc 120
agccgccgcg tccgcctggt gttcctgggg gtcctcctgg tggcggcggt ggcaggcaac 180
accacagtgc tgtgccgcct gtgccggcgc gccggggcct gggcggggcc caagcgtgc 240
aagatggact tcctgctggt gcagctggcc ctggcggacc tgtacgcgtg cggggggcacg 300
gcgctgtcac agctggcctg ggaactgctg ggcgagcccc gcgcggccac gggggacctg 360
gcgtgccgt tcctgcagct gctgcaggca tccggggcgg gcgcctcggc ccacctcgtg 420
gtgctcatcg cctcgcagcg ccggcgcgcg gtgcgtcttc cgcacggcgc gccgctgcc 480
gcgcgtgcc tgcgcgcct gggctggctg ctggcactgc tgctggcgct gccccggcc 540
ttcgtggtgc gcggggactc cccctgcgcg ctgccgccgc cgcgcgcgc aacgtccctg 600
cagccaggcg cgcgcccgcc cgcgcgcgc tggccggggc agcgtcgctg ccacgggatc 660

EP 1 243 648 A1

ttcgcgcccc tgcgcgctg gcacctgcag gtctacgctg tctacgagge cgtcgcgggc 720
 ttcgtcgcgc ctgttacggt cctggggcgtc gcttgcggcc acctactctc cgtctggtgg 780
 5 cggcacccggc cgcaggcccc cgcggctgca gcgccctggt cggcgagccc aggtcgagcc 840
 cctgcgcccc gcgcgctgcc ccgcgccaag gtgcagagcc tgaagatgag cctgctgctg 900
 gcgctgctgt tcgtgggctg cgagctgccc tactttgccg cccggctggc ggccgcgtgg 960
 10 tcgtccgggc ccgcgggaga ctgggaggga gagggcctgt cggcggcgct gcgcgtggtg 1020
 gcgatggcca acagcgtct caatcccttc gtctacctct tcttcaggc gggcgactgc 1080
 cggctccggc gacagctgcg gaagcggctg ggctctctgt gctgcgcgcc gcaggggaggc 1140
 15 gcggaggagc aggaggggcc ccggggccac caggcgctct accgccaacg ctggccccac 1200
 cctcattatc accatgctcg gcgggaaccg ctggacgagg gcggcttgcg cccacccccct 1260
 ccgcgccccca gacctctgcc ttgctcctgc gaaagtgcct tctag 1305

<210> 23

<211> 1356

<212> DNA

<213> Homo sapiens

<400> 23

atggagtccct caccatcccc ccagtcacaa gggaactctt ccactttggg gagggtccct 60
 caaaccaccag gtccctctac tgccagtggg gtcccggagg tggggctacg ggatgttgct 120
 35 tcggaatctg tggccctctt ctcatgctc ctgctggact tgactgctgt ggctggcaat 180
 gccgtgtga tggccgtgat cgccaagacg cctgccctcc gaaaatttgt cttcgtcttc 240
 cacctctgcc tggtggaact gctggctgcc ctgacctca tggccctggc catgctctcc 300
 agctctgccc tctttgacca cgccctcttt ggggagggtg cctgccgcct ctacttgttt 360
 40 ctgagcgtgt gctttgtcag cctggccatc ctctcggtgt cagccatcaa tgtggagcgc 420
 tactattacg tagtccacce catgcgtac gaggtgcgca tgacgtggg gctggtggcc 480
 tctgtgctgg tgggtgtgtg ggtgaaggcc ttggccatgg cttctgtgcc agtgttggga 540
 45 agggctctcct gggaggaagg agctcccagt gtccccccag gctgttact ccagtggagc 600
 cacagtgcct actgccagct tttgtggtg gtctttgtg tcccttactt tctgttgccc 660
 ctgctcctca tacttggtgt ctactgcagc atgttccgag tggcccgcgt ggctgccatg 720
 cagcacgggc cgtgcccac gtggatggag acaccccggc aacgctccga atctctcagc 780
 50 agccgtcca cgtggtcac cagctcgggg gccccccaga ccacccaca ccggacgttt 840
 gggggaggga aagcagcagt ggttctcctg gctgtggggg gacagttcct gctctgttgg 900
 ttgccctact tctctttcca cctctatgtt gccctgagtg ctcagcccat ttcaactggg 960
 55 cagggtggaga gtgtggtcac ctggattggc tacttttgc tcaacttcaa ccctttcttc 1020

EP 1 243 648 A1

tatggatgtc tcaaccggca gatccgggg gagctcagca agcagtttgt ctgtttcttc 1080
aagccagctc cagaggagga gctgaggctg cctagccggg agggctccat tgaggagaac 1140
5 ttcctgcagt tccttcaggg gactggctgt ccttctgagt cctgggtttc ccgacccta 1200
cccagcccca agcaggagcc acctgctgtt gactttcgaa tcccaggcca gatagctgag 1260
gagacctctg agttectgga gcagcaactc accagcgaca tcatcatgtc agacagctac 1320
10 ctccgtcctg ccgcctcacc ccggctggag tcatga 1356

<210> 24

<211> 966

<212> DNA

<213> Homo sapiens

<400> 24

atgaaccaga ctttgaatag cagtgggacc gtggagtcag ccctaaacta ttccagaggg 60
25 agcacagtgc acacggccta cctgggtgctg agctccctgg ccatgttcac ctgcctgtgc 120
gggatggcag gcaacagcat ggtgatctgg ctgctgggct ttcgaatgca caggaacccc 180
ttctgcatct atatcctcaa cctggcggca gccgacctcc tcttctctt cagcatggct 240
30 tccacgtcga gcctggaaac ccagccctg gtcaatacca ctgacaaggc ccacgagctg 300
atgaagagac tgatgtactt tgccacaca gtgggcctga gcctgctgac ggccatcagc 360
accagcgtgt gtctctctgt cctcttccct atctggttca agtgtcaccg gccagggcac 420
ctgtcagcct ggggtgtgtg cctgctgtgg acactctgtc tctgatgaa cgggttgacc 480
35 tcttcttctt gcagcaagtt cttgaaattc aatgaagatc ggtgcttcag ggtggacatg 540
gtccaggccg ccctcatcat gggggtctta accccagtga tgactctgtc cagcctgacc 600
ctctttgtct ggggtcggag gagctcccag cagtggcggc ggcagccac acggctgttc 660
40 gtggtggtcc tggectctgt cctgggtgtc ctcatctgtt cctgcctct gagcatctac 720
tggtttgtgc tctactggtt gagcctgccg cccgagatgc aggtcctgtg cttcagcttg 780
tcacgcctct cctcgtccgt aagcagcagc gccaaacccg tcatctactt cctgggtggc 840
45 agccggagga gccacaggct gcccaaccag tccctgggga ctgtgtcca acaggcgtt 900
cgcgaggagc ccgagctgga aggtggggag acgcccaccg tgggcaccaa tgagatgggg 960
gcttga 966

<210> 25

<211> 1002

<212> DNA

<213> Homo sapiens

<400> 25

atggagaagg tggacatgaa tacatcacag gaacaaggtc tctgccagtt ctcagagaag 60
 tacaagcaag tctacctctc cctggcctac agtatcatct ttatcctagg gctgccacta 120
 aatggcactg tcttgtggca cttctggggc caaaccaagc gctggagctg tgccaccacc 180
 tatctggtga acctgatggt ggccgacctg ctttatgtgc tattgccctt cctcatcate 240
 acctactcac tagatgacag gtggcccttc ggggagctgc tctgcaagct ggtgcacttc 300
 ctgttctata tcaaccttta cggcagcate ctgtgtga cctgcatctc tgtgcaccag 360
 ttctagggtg tgtgccaccc actgtgttcg ctgccctacc ggaccgcag gcatgcctgg 420
 ctgggcacca gcaccacctg ggccctggtg gtccctccagc tgctgccac actggccttc 480
 tcccacacgg actacatcaa tggccagatg atctggtatg acatgaccag ccaagagaat 540
 tttgatcggc tttttgccta cggcatagtt ctgacattgt ctggctttct ttccctcctt 600
 ggtcattttg gtgtgctatt cactgatggt caggagcctg atcaagccag aggagaacct 660
 catgaggaca ggcaacacag cccgagccag gtccatccgg accatcctac tgggtgtgtg 720
 cctcttcacc ctctgttttg tgcccttcca tatcactcgc tcctctacc tcaccatctg 780
 ctttctgctt tctcaggact gccagctctt gatggcagcc agtgtggcct acaagatatg 840
 gaggcctctg gtgagtgtga gcagctgcct caaccagtc ctgtacttcc ttcaagggg 900
 ggcaaaaata gagtcaggt cctccagaaa ctgaggcaga acaagttggg tgagcatcca 960
 gctgggagga agagatgccc agggttgaac agatctgggt aa 1002

<210> 26

<211> 1527

<212> DNA

<213> Homo sapiens

<400> 26

atgacgtcca cctgcaccaa cagcacgcgc gagagtaaca gcagccacac gtgcatgccc 60
 ctctccaaaa tgcccatcag cctggcccaac ggcatcatcc gctcaaccgt gctggttatc 120
 ttctcgcgc cctctttcgt cggcaacata gtgctggcgc tagtgttgca gcgcaagccg 180
 cagctgctgc aggtgaccaa ccgttttctc tttaacctcc tcgtaccga cctgtctcag 240
 atttcgctcg tggccccctg ggtggtggcc acctctgtgc ctctctctg gccctcaac 300
 agccacttct gcacggccct ggtagcctc acccactgt tcgccttcgc cagcgtcaac 360
 accattgtct tgggtgcagt ggatcgctac ttgtccatca tccacctct ctcctaccg 420
 tccaagatga ccagcgcgc cggttacctg ctctctatg gcacctggat tgtggccatc 480

EP 1 243 648 A1

ctgcagagca ctctccact ctacggctgg ggccaggetg cctttgatga gcgcaatget 540
 ctctgctcca tgatctgggg ggccagcccc agctacacta ttctcagcgt ggtgtccttc 600
 atcgtcattc cactgattgt catgattgcc tgctactccg tgggtgtctg tgcagcccgg 660
 aggcagcatg ctctgctgta caatgtcaag agacacagct tggaagtgcg agtcaaggac 720
 tgtgtggaga atgaggatga agaggagca gagaagaagg aggagttcca ggatgagagt 780
 gagtttcgcc gccagcatga aggtgaggtc aaggccaagg agggcagaat ggaagccaag 840
 gacggcagcc tgaaggccaa ggaaggaagc acggggacca gtgagagtag tntagaggcc 900
 aggggcagcg aggaggtcag agagagcagc acggtggcca gcgacggcag catggagggt 960
 aaggaaggca gcaccaaagt tgaggagaac agcatgaagg cagacaaggg tcgcacagag 1020
 gtcaaccagt gcagcattga cttgggtgaa gatgacatgg agtttggtga agacgacatc 1080
 aatttcagtg aggatgacgt cgaggcagtg aacatcccgg agagcctccc acccagtcgt 1140
 cgtaacagca acagcaaccc tcctctgccc agtgctacc agtgcaaagc tgctaaagtg 1200
 atcttcatca tcattttctc ctatgtgcta tccctggggc cctactgctt tttagcagtc 1260
 ctggccgtgt ggggtggatgt cgaaaccacg gtaccccagt ggggtgatcac cataatcatc 1320
 tggcttttct tcctgcagtg ctgcatccac cctatgtct atggctacat gcacaagacc 1380
 attaagaagg aaatccagga catgctgaag aagttcttct gcaaggaaaa gccccgaaa 1440
 gaagatagcc acccagacct gcccggaaca gaggggtggga ctgaaggcaa gattgtccct 1500
 tcctacgatt ctgctacttt tccttga 1527

<210> 27

<211> 28

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:an artificially
 synthesized primer sequence

<400> 27

atggaggatc tctttagccc ctcaattc

28

<210> 28

<211> 28

<212> DNA

<213> Artificial Sequence

5

<220>

<223> Description of Artificial Sequence:an artificially
synthesized primer sequence

10

<400> 28

ctagaaggca ctttcgcagg agcaaggc

28

15

<210> 29

<211> 29

<212> DNA

<213> Artificial Sequence

25

<220>

<223> Description of Artificial Sequence:an artificially
synthesized primer sequence

30

<400> 29

atggagtcct cacccatccc ccagtcac

29

35

<210> 30

<211> 29

<212> DNA

<213> Artificial Sequence

45

<220>

<223> Description of Artificial Sequence:an artificially
synthesized primer sequence

50

<400> 30

tcatgactcc agccgggggtg aggcggcag

29

55

<210> 31

<211> 26

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:an artificially synthesized primer sequence

<400> 31

atgaaccaga ctttgaatag cagtgg

26

<210> 32

<211> 28

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:an artificially synthesized primer sequence

<400> 32

tcaagccccc atctcattgg tgcccacg

28

<210> 33

<211> 28

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:an artificially synthesized primer sequence

<400> 33

atggagaagg tggacatgaa tacatcac

28

5

<210> 34

<211> 29

10

<212> DNA

<213> Artificial Sequence

15

<220>

<223> Description of Artificial Sequence:an artificially
synthesized primer sequence

20

<400> 34

ttacccagat ctgttcaacc ctgggcac

29

25

<210> 35

<211> 28

30

<212> DNA

<213> Artificial Sequence

35

<220>

<223> Description of Artificial Sequence:an artificially
synthesized primer sequence

40

<400> 35

atgacgtcca cctgcaccaa cagcacgc

28

45

<210> 36

<211> 29

50

<212> DNA

<213> Artificial Sequence

55

<220>

<223> Description of Artificial Sequence:an artificially

synthesized primer sequence

5	<p><400> 36</p> <p>tcaaggaaaa gtagcagaat cgtaggaag</p>	29
10	<p><210> 37</p> <p><211> 20</p>	
15	<p><212> DNA</p> <p><213> Artificial Sequence</p>	
20	<p><220></p> <p><223> Description of Artificial Sequence:an artificially synthesized primer sequence</p>	
25	<p><400> 37</p> <p>ccaggagcgt ttctatgcct</p>	20
30	<p><210> 38</p> <p><211> 20</p>	
35	<p><212> DNA</p> <p><213> Artificial Sequence</p>	
40	<p><220></p> <p><223> Description of Artificial Sequence:an artificially synthesized primer sequence</p>	
45	<p><400> 38</p> <p>tgtgatcttt gctccctgca</p>	20
50	<p><210> 39</p> <p><211> 28</p>	
55	<p><212> DNA</p> <p><213> Artificial Sequence</p>	

<220>

<223> Description of Artificial Sequence:an artificially
synthesized TaqMan probe sequence

<220>

<221> misc_binding

<222> (1)

<223> Label FAM (6-carboxy-fluorescein)

<220>

<221> misc_binding

<222> (28)

<223> Label TAMRA
(6-carboxy-N,N,N',N'-tetramethylrhodamine)

<400> 39

tcagaacctg ccagcattga atagtgcc

28

<210> 40

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:an artificially
synthesized primer sequence

<400> 40

atctgctttg ccccgatatgt

20

<210> 41

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:an artificially synthesized primer sequence

<400> 41

accgccttgc tgtaggtcag

20

<210> 42

<211> 22

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:an artificially synthesized TaqMan probe sequence

<220>

<221> misc_binding

<222> (1)

<223> Label FAM (6-carboxy-fluorescein)

<220>

<221> misc_binding

<222> (22)

<223> Label TAMRA

(6-carboxy-N,N,N',N'-tetramethylrhodamine)

<400> 42

tcgtgccctt cgtcaccgtg aa

22

<210> 43

<211> 21

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:an artificially
synthesized primer sequence

<400> 43

cccagcatcc ataccagaaa a

21

<210> 44

<211> 21

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:an artificially
synthesized primer sequence

<400> 44

ctgtgtccct ctcagccaa a

21

<210> 45

<211> 28

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:an artificially
synthesized TaqMan probe sequence

<220>

<221> misc_binding

<222> (1)

<223> Label FAM (6-carb xy-fluorescein)

<220>

<221> misc_binding

<222> (28)

<223> Label TAMRA

(6-carboxy-N, N, N', N'-tetramethylrhodamine)

<400> 45

tgagaaggca gagattccca tccttct

28

<210> 46

<211> 19

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:an artificially
synthesized primer sequence

<400> 46

tcgccatgag caacagcat

19

<210> 47

<211> 21

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:an artificially
synthesized primer sequence

<400> 47

cactggactt accgccattg t

21

<210> 48

<211> 29

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:an artificially
synthesized TaqMan probe sequence

<220>

<221> misc_binding

<222> (1)

<223> Label FAM (6-carboxy-fluorescein)

<220>

<221> misc_binding

<222> (29)

<223> Label TAMRA
(6-carboxy-N,N,N',N'-tetramethylrhodamine)

<400> 48

agatcatgtt gctccactgg aaggttct

29

<210> 49

<211> 23

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:an artificially
synthesized primer sequence

<400> 49

ggatctcttt agccctcaa ttc

23

5

<210> 50

<211> 21

10

<212> DNA

<213> Artificial Sequence

15

<220>

<223> Description of Artificial Sequence:an artificially
synthesized primer sequence

20

<400> 50

aaggtcaggt tgagaccca g

21

25

<210> 51

<211> 25

30

<212> DNA

<213> Artificial Sequence

35

<220>

<223> Description of Artificial Sequence:an artificially
synthesized TaqMan probe sequence

40

<220>

<221> misc_binding

<222> (1)

45

<223> Label FAM (6-carboxy-fluorescein)

<220>

50

<221> misc_binding

<222> (25)

<223> Label TAMRA

(6-carboxy-N,N,N',N'-tetramethylrhodamine)

55

EP 1 243 648 A1

<400> 51

aacatttccg tgcccatctt gctgg

25

<210> 52

<211> 21

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:an artificially
synthesized primer sequence

<400> 52

gctgttgact ttcgaatccc a

21

<210> 53

<211> 23

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:an artificially
synthesized primer sequence

<400> 53

acggaggtag ctgtctgaca tga

23

<210> 54

<211> 26

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:an artificially
synthesized TaqMan probe sequence

<220>

<221> misc_binding

<222> (1)

<223> Label FAM (6-carboxy-fluorescein)

<220>

<221> misc_binding

<222> (26)

<223> Label TAMRA

(6-carboxy-N,N,N',N'-tetramethylrhodamine)

<400> 54

tgagttcctg gagcagcaac tcacca

26

<210> 55

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:an artificially
synthesized primer sequence

<400> 55

ggctttcgaa tgcacaggaa

20

<210> 56

<211> 20

<212> DNA

<213> Artificial Sequenc

<220>

<223> Description of Artificial Sequence:an artificially
synthesized primer sequence

<400> 56

ggaagccatg ctgaagagga

20

<210> 57

<211> 28

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:an artificially
synthesized TaqMan probe sequence

<220>

<221> misc_binding

<222> (1)

<223> Label FAM (6-carboxy-fluorescein)

<220>

<221> misc_binding

<222> (28)

<223> Label TAMRA

(6-carboxy-N,N,N',N'-tetramethylrhodamine)

<400> 57

ttctgcatct atatcctcaa cctggcgg

28

<210> 58

<211> 21

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:an artificially
synthesized primer sequence

<400> 58

tggcctcttc accctctgtt t

21

<210> 59

<211> 21

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:an artificially
synthesized primer sequence

<400> 59

atcaagagct ggcagtcctg a

21

<210> 60

<211> 30

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:an artificially
synthesized TaqMan probe sequence

<220>

<221> misc_binding

<222> (1)

<223> Label FAM (6-carboxy-fluorescein)

<220>

<221> misc_binding

<222> (30)

<223> Label TAMRA

(6-carboxy-N,N,N',N'-tetramethylrhodamine)

<400> 60

tccatatcac tcgtccttc tacctcacca

30

<210> 61

<211> 19

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:an artificially
synthesized primer sequence

<400> 61

ccaaaatgcc catcagcct

19

<210> 62

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:an artificially
synthesized primer sequence

<400> 62

gcactatggt gccgacgaaa

20

<210> 63

<211> 26

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: an artificially
synthesized TaqMan probe sequence

<220>

<221> misc_binding

<222> (1)

<223> Label FAM (6-carboxy-fluorescein)

<220>

<221> misc_binding

<222> (26)

<223> Label TAMRA

(6-carboxy-N,N,N',N'-tetramethylrhodamine)

<400> 63

catccgctca accgtgctgg ttatct

26

Claims

1. A DNA that encodes a guanosine triphosphate-binding protein-coupled receptor, wherein said DNA is selected from the group consisting of the following (a) to (d):

(a) a DNA encoding a protein comprising the amino acid sequence of any one of SEQ ID NOs: 1 to 4 and 17 to 21;

(b) a DNA comprising a coding region of the nucleotide sequence of any one of SEQ ID NOs: 5 to 8 and 22 to 26;

(c) a DNA encoding a protein comprising the amino acid sequence of any one of SEQ ID NOs: 1 to 4 and 17 to 21 in which one or more amino acids are substituted, deleted, added, and/or inserted; and

(d) a DNA hybridizing under stringent conditions to the DNA comprising the nucleotide sequence of any one of SEQ ID NOs: 5 to 8 and 22 to 26.

2. A DNA encoding a partial peptide of a protein comprising the amino acid sequence of any one of SEQ ID NOs: 1 to 4 and 17 to 21.

3. A vector comprising the DNA of any one of claims 1 and 2.

4. A transformant carrying the DNA of any one of claims 1 and 2 or the vector of claim 3.

EP 1 243 648 A1

5. A protein or a peptide encoded by the DNA of any one of claims 1 and 2.
6. A method for producing the protein or the peptide of claim 5, said method comprising the steps of culturing the transformant of claim 4 and recovering an expressed protein or peptide from the transformant or culture supernatant thereof.
7. A method of screening for ligands that bind to the protein of claim 5, said method comprising the steps of:
- (a) contacting a test sample with the protein or the peptide of claim 5; and
 - (b) selecting compounds that binds to said protein or said peptide.
8. A method of screening for compounds that have activity of inhibiting the binding between the protein of claim 5 and a ligand thereof, said method comprising the steps of:
- (a) contacting the protein of claim 5 or a partial peptide thereof with the ligand in the presence of a test sample and detecting a binding activity of said protein or said partial peptide with said ligand; and
 - (b) selecting compounds that reduces the binding activity detected in step (a) as compared with a binding activity detected in the absence of the test sample;
9. A method of screening for compounds that inhibit or enhance activity of the protein of claim 5, said method comprising the steps of:
- (a) contacting a ligand of said protein with cells expressing said protein in the presence of a test sample;
 - (b) detecting an alteration in the cells that results from binding of said ligand to said protein; and
 - (c) selecting compounds that suppress or enhance the alteration detected in step (b) as compared with an alteration detected in the cells in the absence of the test sample.
10. The method of claims 8 or 9, wherein the alteration in cells is a change in cAMP concentration or calcium concentration.
11. An antibody binding to the protein of claim 5.
12. A compound isolated by the method of any one of claim 7 to 10.
13. A pharmaceutical composition comprising the compound of claim 12 as an active ingredient.
14. The pharmaceutical composition of claim 13, wherein said pharmaceutical composition is formulated for the treatment of a disease selected from the group consisting of cancer, cirrhosis, and Alzheimer's disease.
15. A polynucleotide comprising at least 15 nucleotides, wherein said polynucleotide is complementary to the DNA comprising the nucleotide sequence of any one of SEQ ID NOs: 5 to 8 and 22 to 26 or a complementary strand thereof.
16. A method for diagnosing a disease selected from the group consisting of cancer, cirrhosis, and Alzheimer's disease, said method comprising the steps of detecting expression of the DNA of claim 1 in tissues related to the disease derived from a subject, or mutation in the DNA of claim 1 in the subject.
17. An agent for diagnosing a disease selected from the group consisting of cancer, cirrhosis, and Alzheimer's disease, said agent comprising the antibody of claim 11 or the nucleotide of claim 15.

Figure 1

```

>sp|P47901|V1BR_HUMAN VASOPRESSIN V1B RECEPTOR (AVPR V1B) (VASOPRESSIN V3
  RECEPTOR) (AVPR V3) (ANTIDIURETIC HORMONE RECEPTOR 1B).
  Length = 424

Score = 316 (111.2 bits), Expect = 3.7e-41, Sum P(2) = 3.7e-41
Identities = 70/194 (36%), Positives = 115/194 (59%)

Query:   56 LWLVFVFTIVGNSVVLFFSTWRR-KKKSRTMFFVTQLAITDSFTGLVNILTDINWRFTGDF 114
          L + V  GN VL + + +K+SRM FV LA+TD  L +L + W T F
Sbjct:   41 LATVLVLATGGNLAVLLTLGQLGRKRSRMHLFVLHLALTDLAVALFQVLPQLLDITYRF 100

Query:   115 TAPDLVCRVVRYLQVVLLYASTYVLVSLSDRYHAIVYPMKFLOGEKQARVLIVIA-WSL 173
          PDL+CR V+YLQV+ ++ASTY+L++++DRY A+ +P++ LQ  Q+ L++ A W L
Sbjct:   101 QGPDLICRAVKYLQVLSMFASTYMLLAMTLDRYLAVCHPLRSLOQPGQSTYLLIAAPWLL 160

Query:   174 SFLFSIPTLIIFGKRTL--SNGEVQCWALWPDDSY-WTP--YMTIVAFLVYFIPLTIISI 228
          + +FS+P + IF R +  +G + CWA  D + W P Y+T  ++ +P+T+++
Sbjct:   161 AAIFSLPQVFIFSLREVIQGSGLDCWA---DFGFPWGPWAYLTWTTLAIFVLPVTMLTA 217

Query:   229 MYGIVIRTIW--IKSKT 243
          Y ++  I  +K KT
Sbjct:   218 CYSLICHEICKNLKVKT 234

Score = 131 (46.1 bits), Expect = 3.7e-41, Sum P(2) = 3.7e-41
Identities = 33/80 (41%), Positives = 47/80 (58%)

Query:   258 SSYNRGLISKAKIKAIKYSIIILAFICCWSPYF---LFDILDNFNLLPDTQERFYASVI 314
          SS N  IS+AKI+ +K + +I+LA+I CW+P+F  ++ + D N PD  A I
Sbjct:   267 SSINT--ISRAKIRTVKMTFVIVLAYIACWAPFFSVQMWVWDK-NA-POEDSTNVAFTI 322

Query:   315 IQNLPALNSAINPLIYCVFSSSI 337
          L LNS NP IY F+S +
Sbjct:   323 SMLLGHLNSCCNPWIYMGFNHSL 345

```


Figure 2

```

>sp|P31388|5H6_RAT 5-HYDROXYTRYPTAMINE 6 RECEPTOR (5-HT-6) (SEROTONIN RECEPTOR)
(ST-B17).
Length = 436

Score = 224 (78.9 bits), Expect = 6.7e-17, P = 6.7e-17
Identities = 84/309 (27%), Positives = 144/309 (46%)

Query:    3 PGEA--LLAGLLVMVLAVALLSNALVLLCCAYSaelRTRASGVLLVNLSLGHLLLAALDM 60
          PG + + A L V+++ A ++ L++L C A LR S LV+L L++ + M
Sbjct:   23 PGGSGWVAAALCVVIVLTAAANSLIVLICTQPA-LRN-TSNFFLVSLFTSDLMVGLVVM 80

Query:   61 PFTLLGVMRGRTSPAGACQVIGFLDTFLASNAALSVAALSADQWLAVGFPLRYAGRRLR- 119
          P +L + GR A G C + D S + L++ +S D++L + PLRY R+
Sbjct:   81 PPAMLNALYGRWVLARGLCLLWTAFDVMCCSASILNLC LISLD RYLLILSPLRYKLRMTA 140

Query:  120 PRYAGLLLGCWQSLAFSGAALGCSWLGYSSAFASCSLRLPPEPERPRFAA---FTATL 176
          PR L+LG AW SLA AL S+L + P P + R A F
Sbjct:  141 PRALALILG-AW---SLA---ALA-SFLPLLLGWHELKARTPAPGQCRLLASLPFVLVA 192

Query:  177 HAVGFVLPLAVLCLTSLQVHRVARRHCQRM DTVT-----MKALALLADLHPSVR----- 225
          V F LP +C T ++ AR+ ++ ++T ++ L + P +
Sbjct:  193 SGVTFFLPSGAICFTYCRILLAARKQAVQVASLTGTAGQALETQLQVPRTPRPGMESADS 252

Query:  226 QRCLIQKRRRHRATRKIGIAIATFLICFAPYVMTRLAELVPFVTVNAQWGILSKCLTYS 285
          +R + R+ +A+ +GI + F + + P+ + +A+ V + +L+ L Y
Sbjct:  253 RRLATKHSRKALKASLTGILLGMFFVTWLPFFVANIAQAVCDCISPGLFDVLT-WLGYC 311

Query:  286 KAVADPFTYSLLRRPFRQVL 305
          + +P Y L R F++ L
Sbjct:  312 NSTMNP I IYPLFMRDFKRAL 331

```

Figure 3

```

>sp|P56479|GALR_MOUSE GALANIN RECEPTOR TYPE 1 (GAL1-R) (GALR1).
      Length = 348

Score = 269 (94.7 bits), Expect = 7.9e-24, P = 7.9e-24
Identities = 82/289 (28%), Positives = 136/289 (47%)

Query:   49 VGFVGNLCVIGILLHNAWKGP-SMIHSLILNLSLADLSLLLFSAPIRATAYSKSVWDLG 107
          +G +GN VI +L +   GKP S +   ILNLS+ADL+ LLF P +AT Y+   W LG
Sbjct:   46 MGVLGNSLVITVLARSK-PGKPRSTTNLFILNLSIADLAYLLFCIPQATVYALPTWVLG 104

Query:   108 WFCVCKSSDWFIIHTCMAAKSLTIVVVA--KVCIFYASDPKQVSIHNYTIWSVLVAIWTVA 165
          F+CK  +F   M   T+ ++ +   + S + ++   + V   IW ++
Sbjct:   105 AFICKFIHYFFTVMVLSIFTLAAMSVDYVAIVHSRRSSSLRVSRNALLGVGF-IWALS 163

Query:   166 SLLPLPEWFFSTIRHHEGVE-MCLVDVPAVAEEFMSMFGKLYPL--LAFG--LPLFFASF 220
          + P +   + H + + C   P           + K Y +   FG LPL   F
Sbjct:   164 IAMASPVAYHQRLFHRDSNQTFCWEQWPN-----KLHKKAYVVCTFVFGYLLPLLLICF 217

Query:   221 YFWRAYDQCKKRGTKTQNLNRNQIRSKQVTVMLLSIAIISAVLWLPWVWVWHLKAAG 280
          + + +   K+ K + +++   K+   +L + ++ + WLP V LW   A
Sbjct:   218 CYAKVLNHLHKK-LKNMSKKSEASKKTAQTVLVVVVVVFGISWLPHHVHLWAEF--GAF 274

Query:   281 PAPPQGFI--ALSQVLMFSSISSANPLIFLVMSEEFREGLKGVWKWMITKKPPTVSESQE 337
          P P F   + L +S SS NP+I+ +SE FR+ K V+K + + P SE++E
Sbjct:   275 PLTPASFFFRITAHCLAYSNSSVNPPIIYAFLSENFRKAYKQVFKCHVCDESPR-SETKE 332

```

Figure 4

```

>sp:NY2R_BOVIN-NEUROPEPTIDE Y RECEPTOR TYPE 2 (NPY2-R).
    Length = 384

Score = 153 bits (383), Expect = 5e-37
Identities = 93/308 (30%), Positives = 164/308 (53%), Gaps = 7/308 (2%)

Query: 47 DEDEDVTNSRTFFAAKIVIGMALVGIMLVCGIGNFIFIAALVRYKKLRNLTNLLIANLAI 106
          D + ++ +S      ++V+ +A  I+L+  IGN + I  ++++K +R +TN  IANLA+
Sbjct: 38 DSEPELIDSTKLIIEVQVVLILAYCSIILLGVIGNSLVIHVVIKFKSMRTVTNFFIANLAV 97

Query: 107 SDFLVAIVCCPFEMDYVVRQLSWEHGHVLCSTVNYLRTVSLYVSTNALLAIAIDRYLAI 166
          +D LV +C PF + Y ++ +  W+ G VLC  V Y + +++ VST  L  IA+DR+  I
Sbjct: 98 ADLLVNTLCLPFTLTITLMGE--WKMG PVLCHLPYQAQGLAVQVSTITLTIVIALDRHRCI 155

Query: 167 VHPLRPRMKCQTATGLIALVWTVSILIAIPSAFYTTETVLVIVKSQEKIFCGQIWPVDQQ 226
          V+ L ++  Q +  +I L W VS L+A P A F  +++ I+  E + C + WP +++
Sbjct: 156 VYHLESKISKQISFLIIGLAWGVSALLASPLAIFREYSLIEIIPDFEIVACTEKWPGECK 215

Query: 227 -LYYKSYFLFIFGIEFVGPVVTMTLCYARISRELWFKAVPGFQTEQIRKRLRCRRKTVLV 285
          +Y  Y L  I +V P+ ++  Y RI  +L  PG  +  +R  R+KT  +
Sbjct: 216 GIYGTIYSLSSLLILYVPLGIISFSYTRIWSKLNHVSPGAHDHYHQR---RQKTTKM 272

Query: 286 LMCILTAYVLCWAPFYGFTIVRDFPFTVFVKEKHYLTAFYIVECIAMSNMINTLCFVTV 345
          L+C++  ++ W P + F +  D  V + K Y  F +  IAM ++ N L +  +
Sbjct: 273 LVCVVVFAVSWLPLHAFQLAVDIDSHV-LDLKEYKLIFTVFHIIAMCSTFANPLLYGWM 331

Query: 346 KNDTVKYF 353
          ++  K F
Sbjct: 332 NSNYRKAF 339

```

Figure 5

```

>sp|P97926|OXYR_MOUSE OXYTOCIN RECEPTOR (OT-R).
      Length = 388

Score = 164 (57.7 bits), Expect = 8.9e-22, Sum P(2) = 8.9e-22
Identities = 57/166 (34%), Positives = 84/166 (50%)

Query:   24 WGLNLTGQGAP-----ASGPPSR-----RVRLVFLGVILVVAVAGNTTVLCRLCGGG 71
          W + L LG G P           +GPP R      RV + L +IL +A++GN VL L
Sbjct:   9 WSIELDLGSGVPPGAEGNLTAGPPRRNEALARVEVAVLCLILFLALSGNACVLLAL---- 64

Query:   72 GPWAGPKRRKMDFLLVQLALADLYACGGTALSQLAWEELLGEPRAATGDLACRFLQLLQAS 131
          K ++ F + L++ADL          L QL W++   R   DL CR ++ LQ
Sbjct:   65 -RTTRHKHSRLFFFMKHLSDIADLVAVFQVLPQLLWDITF--RFYGPDLLCRLVKYLQV 121

Query:   132 GRGASAHVVLIALERRRAVRLPHGRPLPARA--LAALG-WLLALLLALPPAFV 182
          G AS +L++L++L+R A+ P. R L R LA L WL L+ ++P +
Sbjct:   122 GMFASTYLLLLMSLDRCLAICQPL-RSLRRRTDRLAVLATWLGCLVASVPQVHI 174

Score = 155 (54.6 bits), Expect = 8.9e-22, Sum P(2) = 8.9e-22
Identities = 49/161 (30%), Positives = 85/161 (52%)

Query:   217 CHGIFAPLPRWHLQVYAFYEAVAGFVAPVTVLGVACGHLLS--VWW--RHRPOAPAAAAP 272
          C +F + W + Y + +A ++ PV VL AC L+S +W R + A AAAA
Sbjct:   187 CWAVF--IQPWGPKAYVTWITLAVYIVPVIVLA-ACYGLISFKIWQNLRLKTAATAAAAAAE 243

Query:   273 WSASPG-----RAPAPSALPRAKVQSLKMSLLLALLFVGCELPYFAARLAAAWS-SG 323
          S + G           R + + +AK++++KM+ ++ L F+ C P+F ++ + W +
Sbjct:   244 GSDAAGGAGRAALARVSSVKLISKAKIRTVKMTFIIVLAFIVCWTPFFVQMWVWDVNA 303

Query:   324 PAGDWEGEGLSAAALRVVAMANSALNPFVYLFFQAGDCRLRRQLRKRLGSLCCA 376
          P E A+ ++A NS NP++Y+ F L +L +R LCC+
Sbjct:   304 PK--EASAFIIAM-LLASLNSCCNPWIYMLFTG--HLFHELVQRF--LCCS 347

```

Figure 6

```

>sp|Q91178|GPRX_ORYLA PROBABLE G PROTEIN-COUPLED RECEPTOR (FRAGMENT).
      Length = 428

Score = 823 (289.7 bits), Expect = 9.8e-83, P = 9.8e-83
Identities = 182/422 (43%), Positives = 266/422 (63%)

Query:   2 ESSPIQSSGNSSTLGRVPQTPGPSTASGVPEVGL---RDVASESVALFFMLLLDLTAV 57
      ++SP+ S + S      P P+   P+VG+   +   +   LF M+ L+L A+
Sbjct:   5 KTSPMITS DHSISNFSTGLFGPHPTVP---PDVGVVTSSQSOMKDLFGLFCMVTNLIAL 61

Query:  58 AGNAAMVAIAKTPALRKVFVVFHLCVLDLLAALTLMPLAMLSSSALFDHALFGEVACRL 117
      N VM IA+ P L+KF FV HLC VD+L A+ LMPL ++SSS F   +F + C++
Sbjct:  62 LANTGMVAIARAPHLKKFAFVCHLCAVDVLCAILLMPLGISSSPFFGTVVFTILECQV 121

Query:  118 YLFLSVCVSLAILSVSAINVERYYYVHMPRYEVRMTLGLVASVLVGWVKALAMASVP 177
      Y+FL+V + L+IL+++AI+VERY+Y+VHPMRYEV+MT+ LV V++ +W K+L +A V
Sbjct:  122 YIFLNFLIWL SILTITAI SVERYFYIVHPMRYEVKMTINLVIGVMLLIWFKSLLLALVT 181

Query:  178 VLGRVSWEEGAPSVPPGCSLQWSHSA YCQLFVVVFAVLYFLLPLLLILVVCMSFVARV 237
      + G + + +      CSL SHS   +F V+F V+ FL P+++I VY +++VAR
Sbjct:  182 LFGWPPYGHQSSIAASHCSLHASHSRLRGVFAVLCVICFLAPVVVIFSVYSAVYKVAR 241

Query:  238 AAMQHGP-LPTWME-TP-RQRSESLSSRSTMTSSGAPQT-TPHRTFGGKAAVLLAVG 293
      AA+Q P +PTW + +P + RS+S++S++T++T+ PQ +P R F GKAA+ L +
Sbjct:  242 AALQQVPAVPTWADASPAKDRSDSINSQTITITRTLPQRLSPERAFSGGKAALTAFIV 301

Query:  294 GQFLLCWLPYFSFHLYVALSAQPISTGQVESVVTWIGYFCFTSNPFFYGCLNRQIRGELS 353
      GQFL+CWLP+F FHL ++L+   S G +E V W+ Y F NP FYG LNRQIR EL
Sbjct:  302 GQFLVCWLPFFIFHLQMSLTGSMKSPGDLEEAVNWLAYSSFAVNPSFYGLLNQRIRDELV 361

Query:  354 K-QFVCFKPAPEEELRLPSREGSIEENFLQFLQGTGCPSESWSRPLPSPKQ-EPPAVD 411
      K + C +P   E+ S EGS +ENFLOF+Q T SE+ S   +P+ E A
Sbjct:  362 KFRRCVTPV---EIGPSSLEGSFQENFLQFIQRTSSSSSETHPSFANSNPRNMENQA-- 416

Query:  412 FRIPGQIAEE 421
      +IPGQI EE
Sbjct:  417 HKIPGQIPEE 426

```

Figure 7

```

>sp|P23749|RTA_RAT PROBABLE G PROTEIN-COUPLED RECEPTOR RTA.
      Length = 343

Score = 461 (162.3 bits), Expect = 2.3e-44, P = 2.3e-44
Identities = 121/323 (37%), Positives = 178/323 (55%)

Query:   2 NQTLNSSGTVESALNYSRGS-TVHT-AYL----VLSSLAMFTCLCGMAGNSMVIWLLGFR 55
          NQ      G E+  YSRG T+  A L   V + + +  CLCG+ GN +V+W  GF
Sbjct:  13 NQNKMCPCGMSEALELYSRGFLTIEQIATLPPPAVTNYIFLLLCLCGLVGNGLVLWFFGFS 72

Query:   56 MHRNPFCIYILNLAAADLLFLFSMASTLSLETQPLVNT-TDKVHELMKRLMYFAYTVGLS 114
          + R PF IY L+LA+AD ++LFS A   L   + +  D V + + +   + G+S
Sbjct:  73 IKRTPFSIYFLHLASADGIYLFASKAVIALLNMGTFLGSPDYVRRVSRIVGLCTFFAGVS 132

Query:   115 LLTAISTQRCLSVLFPIWFKCHRPRHLSAWVCGLLWTLCLLMNGLTSSFCCKFL--KFNE 172
          LL AIS +RC+SV+FP+W+  RP+ LSA VC LLW L  L+  + + FC  FL  + +
Sbjct:  133 LLPAISIERCVSVIFPMWYWRRRPKRLSAGVCALLWLLSFLVTSIHNYFCM-FLGHEASG 191

Query:   173 DRCFRVDMVQAALIMGVLTVPMTLSSSLTLFVWVRRSSQWRRQPTRLFVVVLASVLVFLI 232
          C +D+   L+  +  P+M L  L L + V   +++ R++ +L  VVLA V VFL+
Sbjct:  192 TACLNMDISLGILLFFLCPLMVLPCALILHVECRARR-RQRSAKLNHVLAIVSVFLV 250

Query:   233 CSLPLSIYWFVLYWL-SLPPEMQVLCFSLRLSSSVSSSANPVIYFLVGSRRSHRLPTRS 291
          S+ L I WF L+W+ +P           ++ L  ++SSA P++YFL G  +S RL
Sbjct:  251 SSIYLGIDWF-LFWVFQIPAPFPEY---VTDLCICINSSAKPIVYFLAGRDKSQRL-WEP 305

Query:   292 LGTVLQQALRE--EPELEGGETPTVGTNEM 319
          L V Q+ALR+ EP      TP  T EM
Sbjct:  306 LRVVFQALRDGAEPGDAASSTPNTVTMEM 335

```

Figure 8

```

>sp|Q98907|P2Y3_CHICK P2Y PURINOCEPTOR 3 (P2Y3) (NUCLEOSIDE DIPHOSPHATE
  RECEPTOR).
  Length = 328

Score = 452 (159.1 bits), Expect = 2.0e-43, P = 2.0e-43
Identities = 85/185 (45%), Positives = 116/185 (62%)

Query:   15 CQFSEKYKQVYLSLAYSIIIFILGLPLNGTVLWHFWGQTKRWSCATTYLVNLMVADLLYVL 74
          C F E++KQV L L YS++F+LGLPLN V+ W K + T Y++NL +ADLLYV
Sbjct:   13 CTFHEEFKQVLLPLVYSVVFLLGLPLNAVVIGQIWLARKALTRTTIYMLNLMADLLYVC 72

Query:   75 -LPFLIITYSLDDRWPFGELLCKLVHFLFYINLYGSILLTLCISVHQFLGVCHPLCSLPY 133
          LP LI Y+ D WPG+ CK V F FY NL+GSIL LTCISV +++G+CHPL S
Sbjct:   73 SLPLLIYNYTQKDYWPGDFTCKFVRQFYTNLHGSILFI.TCISVQRYMGICHPLASWHK 132

Query:   134 RT-RRHAWLGTSTTWALVVLQLLPTLAFSHTDYINGQMIWYDMSQENFDRLFAYGIVLT 192
          + ++ WL + W +V+ Q LPT F+ T ++ YD++ + F YGI LT
Sbjct:   133 KKGKKLTLVCAAWFIVIAQCLPTFVFASTGTQRNRTVCYDLSPDRSTSYFPYGITLT 192

Query:   193 LSGFL 197
          ++GFL
Sbjct:   193 ITGFL 197

```

Figure 9

```

>sp|002824|A1AA_RABIT ALPHA-1A ADRENERGIC RECEPTOR (ALPHA 1A-ADRENOCEPTOR)
      (ALPHA-1C ADRENERGIC RECEPTOR).
      Length = 466

Score = 295 (103.8 bits), Expect = 1.0e-31, Sum P(2) = 1.0e-31
Identities = 66/215 (30%), Positives = 113/215 (52%)

Query:   8 STRESNSSHTCMPLSKMPISLAHGIIRSTVLVIFLAASFVGNIVLALVLQRKPQLLQVTN 67
          S S+SS+ P + P++++ I+ +L + +GNI++ L + L VT+
Sbjct:   5 SGNASDSSNCTHPPA--PVNISKAILLGVLGGLILFGVLGNILVILSVACHRHLHSVTH 62

Query:  68 RFIFNLLVTDLLQISLVAPWVWATSVPLFWPLNSHFCTALVSLTHLFAFASVNTIVVVS 127
          +I NL V DLL S V P+ + +W FC ++ L AS+ ++ V+S+
Sbjct:  63 YYIVNLAVADLLLTSTVLPFSAIFEILGYWAFGRVFCNIWAAVDVLCCTASIISLCVISI 122

Query:  128 DRYLSIIHPLSYPSKMTQRRGYLLLYGTWIVAILQSTPPLYGWQAADFERNALCSMIWG 187
          DRY+ + +PL YP+ +TQRRG L W +++ S --PL+GW Q A-D+ +C +
Sbjct:  123 DRYIGVSYPLRYPTIVTQRRGLRALLCVWAFSLVISVGPLFGWRQPAPDDET-ICQI--N 179

Query:  188 ASPSYTILSVVSFIVIPLIVMIACYSVVFCAARRQ 222
          P Y + S + +PL +++A Y V+ A+R+
Sbjct:  180 EEPGYVLFSAIGSFYVPLTIILAMYCRVYVAKRE 214


Score = 106 (37.3 bits), Expect = 1.0e-31, Sum P(2) = 1.0e-31
Identities = 23/75 (30%), Positives = 41/75 (54%)

Query:  396 KAAKVIFIIIFSIVLSLGPYCFVLAVLWVDVETQVPQWVITIIWLFFLOCCIHPPYVYG 455
          KAAK + I++ +VL -P+ -+ -+ + + + P+ V I+ WL +L CI+P +Y
Sbjct:  269 KAAKTLGIVVGCFLVLCWLPFFLVMPIGSFPP-DFKPPETVFKIVFWLGYLNSCINPIIYP 327

Query:  456 YMHKTIKKEIQDMLK 470
          + KK Q++LK
Sbjct:  328 CSSQEFKKAFQNVLK 342

```


Figure 10



BNSDOCID: <EP__1243648A1 | >

Figur 12

		##### TM6
X64878	FKIWQNLRLKTA#####EPEGAAAGDGRVALARVSSVKLI	SKAKIRTVKMTFIIIVLAF
U82440	FKIWQNLRLKTA#####EPEGAAAGDGRVALARVSSVKLI	SKAKIRTVKMTFIIIVLAF
X93313	YKIWQNLRLKTYCESNRLST-----	SRATLSRVSSVRLISKAKIRTVKMTFIIIVLAY
X87783	FKIWQNFKRKTKKQDCITLTAA-----	SKANALARVSSVKLVSKAKITTVKMTFVIVLAY
AF184966	HTIWKNIKYKKRKTIPGAAS-----	KNGLIGKNSVSSVTISRAKLRTVKMTFVIVLAY
X76321	HSIWKNIKCK---TMRGTRNT-----	KDGMIGKYSVSSVTISRAKLRTVKMTLVIVLAY
AF147743	KI IKRNIYVKKQNEYQVTNQ-----	KQVLPSSASSVNCISKAMIKTVKMTIVTVVAY
GPRv8	RTIWIKSKTYETVISNCSOG-----	KLCSSYNRGLISKAKIKAIKYSIIILAF
AE003754	KTIWAKGSIFVPTERAGFGA-----	APARRASSRGIIPRAKVTVKMTLTIIVFVF
	* :	..* : : * : : ..
	#####	##### TM7 #####
X64878	IVCWTPFFVQWWSVWDANAPK---EASAFIIVMLLASLNSCCNPWIMLFTGHLFHEL	V
U82440	IVCWTPFFVQWWSVWDANAPK---EASAFIIVMLLASLNSCCNPWIMLFTGHLFHEL	V
X93313	IVCWTPFFVQWWSVWDPNPPK---EASLFIIVMLLASLNSCCNPWIMLFTGHLFHDLL	
X87783	IVCWTPFFVQWWSAWDPEAPR---EAMPFIISMLLASLNSCCNPWIMFFAGHLFHDLK	
AF184966	IICWAPFFTVQWWSVWDENFQYADSENTAVTISALLASLNSCCNPWIMIFSGHLLQDFM	
X76321	IVCWAPFFIVQWWSVWDENFSWDDSENAAVTISALLASLNSCCNPWIMLFSGHLLYDFL	
AF147743	VLCWSPFFIAQLWSVWFPSGIT---EGSAFTIIMLLGNLNSCTNPWIMYFCGHIPIY---	
GPRv8	ICCWSPYFLFDILDNFNLLPDT-QERFYASVIQNLPALNSAINPLIYCVFSSSISFP---	
AE003754	IICWSPYIIFDLLQVFGQIPHIS-QTNIAIATFIQSLAPLNSAANPLIYCLFSSQVFRTLS	
	: ** * : : : :	: * ** . ** * * : . :
X64878	QR---FLCCSASYLKGRRLG---ETSASKKSN---	SSSFVLSHRSSSQRSQSQS
U82440	QR---FLCCSASYLKGRRLG---ETSTSKKSN---	SSSFVLSHRSSSQRSQSQS
X93313	QS---FLCCSARYLKTQQQS-DLSASRKS---	SSTFVLSRKSQSQSITQPS
X87783	QS---LLCCSTLYLKSSQCRCDQEHDSRKS---	CSTYVIKSTSS-QRSITQSS
AF184966	NC---FANCRANADFKED---SDSSIRRTT---	LLTKMTN-RSPTGSTGNWRD
X76321	RC---FPCCCKPRNMLQED---SDSSIRRTT---	LLTKLAAGRMTNDGFGSWRD
AF147743	---CTNKQLENTSAQ---EDSVVTGS---	IHLVD-RDPEENSTCA---
GPRv8	---CREQRSQDSRNT---FRERTER---	HEWQILS-KP-EF---
AE003754	RFPPFKWFTCCCKSYRNNSQQNRCHTVGRRHLNSCDSMRTLTTSLTVSRRSTNKTNARVV	
	*	:
X64878	TA-----	
U82440	TA-----	
X93313	TA-----	
X87783	IT-----	
AF184966	LONSPK---TSIQME-----	
X76321	PCNSRKSSQSIGLDCFCXSSQCLEHDCSRKSSQCIPLDCSRKSSQCIPLDCSRKSSQCMS	
AF147743	-----	
GPRv8	-----	
AE003754	ICERPTKVVTVPANSERRGVSLKNTDIL-----	
X64878	---	
U82440	---	
X93313	---	
X87783	---	
AF184966	---	
X76321	KES	
AF147743	---	
GPRv8	---	
AE003754	---	

Figure 13




Figure 14

GPRv12_ORF AF208288	<p>##### TM1 ##### ##### TM2 ##</p> <p>MGPGEALLAGLLVMVLAVALLSNALVLLCCAYSaelRTRASGVLLVNLslGHLlLLAALDM</p> <p>MNSWDAGLAGLLVGTIGVSLlSNGLVLLCLLHSADlRRQAPALFTLNLTCGNLLCTVVNM</p> <p>*.. :* ##### ..*:####.#### :##:* :*... :## :*## :...*</p>
GPRv12_ORF AF208288	<p>##### @##### TM3 #####</p> <p>PFTLLGVMRGRTPSAPGACQYIGFLDTFLASNAALSVAALSADQWLAVGFPLRYAGRLRP</p> <p>PLTLAGVVAQRQPAGDRLCRLAAFLDTFLAANSMLsMAALSIDRWVAVVFPLSYRAKMRL</p> <p>*:## ## : * :. *:: .#####*: ##:#### *:##* ## * :...*</p>
GPRv12_ORF AF208288	<p>##### TM4 ##### @ #####</p> <p>RYAGLLlGCAWGQSLAFSGAALGCSWLGYSSAFASCSLRLPPEPERPRFAAFTATLHAVG</p> <p>RDAAFMVAYTWLHALTFATALALSWLGFHQLYASCTLCsRRPDERLRFVFTSAFHALS</p> <p>* *.::.. :* :*:*.::*. #### : . :###* ** ##.##::##..</p>
GPRv12_ORF AF208288	<p>TM5 ##### ##</p> <p>FVLPLAVLCLTSLQVHRVARRHCQRMDTVTMKALALLADLHPSYRQRCLlQQKRRRHRAT</p> <p>FLLSFIVLCFTYlKVLKVARFHCKRIDVITMQTLVLLVDIHPSYRERCLEEQRRRQRAT</p> <p>*:*. : ###* *: * ## **:*.::*:*. ##. *:#####:## :#####:##</p>
GPRv12_ORF AF208288	<p>##### TM6 ##### ##### TM7 #####</p> <p>RKIGIAIATFLlCFAPYVMTRLAELVPFVTVNAQNGlLSKCLTYSKAVADPFTYSLLRRP</p> <p>KKISTFIGTFLVCFAPYVITRLVELFSTAPIDSHNGVLSKCLAYSKAASDPFVYSLLRHQ</p> <p>:##. *.###:#####:##.##.:##:#####:###.###.#####:</p>
GPRv12_ORF AF208288	<p>FRQVLAGMVHRLlKRTPRPASTHDSSLDVAGMVHQLLKRTPRPASTHNGSVDTENDSCLQ</p> <p>YRRSCKELLNRlFNRR----SIHSVGLTGDSHSQNILPVSE-----</p> <p>:* : :*:*: * *. * . :*: :</p>
GPRv12_ORF AF208288	<p>QTH</p> <p>---</p>

Figure 15




Figure 16

```

*****
##### TM1 #####
1 MLAAAFADSN SSSMNVSAH LHFAGGYLPS DSQDWTIIP ALLVAVCLVG FVGNLCVIGI 60

*****
##### TM2 #####
61 LLHNAWKGP SMHSLILNL SLADLSLLLF SAPIRATAYS KSVNDLGWV CKSSDWFHT 120

*****
##### TM3 ##### ##### TM4 #####
121 CMAAKSLTIV VVAKVCFNYA SDPAKQVSIH NYTIWSVLVA IWTVASLLPL PEWFFSTIRH 180

*****
##### TM5 #####
181 HEGVEMCLVD VPAVAEEFMS MFGKLYPLLA FGLPLFFASF YFWRAYDQCK KRGTKTQNL 240

*****
##### TM6 ##### ##### TM7 #####
241 NQIRSKQVTV MLLSIAIISA VLWLPEWVAM LNVWHLKAAG PAPPQGFIAL SQVLNFSISS 300

*****
#####
301 ANPLIFLYMS EEFREGLKGV WKWMITKKPP TVSESQETPA GNSEGLPDKV PSPESPASIP 360

361 EKEKPSSPSS GKCKTEKAEI PILPDVEQFW HERDTVPSVQ DNDPIPWEHE DQETGEGVK 419

```

Figure 17




Figure 18

GPRv21	-----METTNGFMDDNATNTSTSFSLVLPNGAHA-TSFPFN
AL121755	-----
AF236082	-----NETTVGALGENTTDTFTDFFSALDGHEAQT-GSLPFT
U42766	-----MGP I GAEADENQTVEENKVEQYGP-----
U76254	-----MGP I GAEADENQTVEENKVEQYGP-----
U42389	-----MGP I GAEADENQTVEENKVEQYGP-----
U50144	-----MKMGPLGAEADENQTVEENKVDQFGPG-----
D86238	-----MYLKMGPVGAEDEN-QTVEVKVEPYGPG-----
M81490	WYYIAHQQPMLRNEDDNYQEGYFIRPDPA SLIYNTTALPADDEGSNYGYGSTT-TLSGLQ
AF037444	--MSMANSENSTSLFGIKRHADYTGPHSASHDVIDPSNTSVYYDHASNYESVLSTTSTLM
<div> <div> GPRv21 AL121755 AF236082 U42766 U76254 U42389 U50144 D86238 M81490 AF037444 </div> <div> FSYSDYDMPL-----DEDEDVTNSR-----TFFAAKIVIGMALVGMVLCGIGNFIF --YGDYDLP-----DEDEDMTKTR-----TFFAAKIVIGIALAGIMVLCGIGNFVF FSYGDYDMPL-----DEEEDVTNSR-----TFFAAKIVIGMALVGMVLCGIGNFIF QTTPRGELVP-----DPEPELIDST-----KLIEVQVVLILAYCSII LLGVIGNSLV QTTPRGELVP-----DPEPELIDST-----KLIEVQVVLILAYCSII LLGVIGNSLV QTTPRGELVP-----DPEPELIDST-----KLIEVQVVLILAYCSII LLGVIGNSLV HTTLPGLAP-----DSEPELIDST-----KLIEVQVVLILAYCSII LLGVIGNSLV HTTLPGLPP-----DPEPELIDST-----KLIEVQVVLILAYCSII LLGVIGNSLV FETYNI TVMMNFSCDDYDLLSEDM-----SSAYFKIIVYMLYIPIFIFALIGNGTV LKLTDLVTPFNASEPDPEPNGSDTDGGHAAISEQPMYAKVIIVLWVYLIILVAVGGNLLF </div> </div>	
<div> <div> GPRv21 AL121755 AF236082 U42766 U76254 U42389 U50144 D86238 M81490 AF037444 </div> <div> IAALVRYKKLRNLNLLIANLAISDFLVAIVCCPFEMDYVVRQLSWEHGHVLCSTVNYL IAALTRYKKLRNLNLLIANLAISDFLVAIICPPFEMDYVVRQLSWEHGHVLCASVNYL ITALARYKKLRNLNLLIANLAISDFLVAIVCCPFEMDYVVRQLSWEHGHVLCASVNYL IHVVIKFKSMRTVTNFFIANLAVADLLVNTLCPLFTLTYYTLMG--EWKMGPVLCVLPYA IHVVIKFKSMRTVTNFFIANLAVADLLVNTLCPLFTLTYYTLMG--EWKMGPVLCVLPYA IHVVIKFKSMRTVTNFFIANLAVADLLVNTLCPLFTLTYYTLMG--EWKMGPVLCVLPYA IHVVIKFKSMRTVTNFFIANLAVADLLVNTLCPLFTLTYYTLMG--EWKMGPVLCVLPYA IHVVIKFKSMRTVTNFFIANLAVADLLVNTLCPLFTLTYYTLMG--EWKMGPVLCVLPYA CYIVYSTPRMRTVTNYFIASLAIGDILMSFFCEPSSFISLFILN-YWPFGLALCHFVNYS SYVIVMYPKMRSVTNLFLNLAISDIVKAVICNPFAFIANLILL-YWPGEFMCQVVTYI </div> </div>	
<div> <div> GPRv21 AL121755 AF236082 U42766 U76254 U42389 U50144 D86238 M81490 AF037444 </div> <div> RTVSLYVSTNALLAIAIDRYLAIVHPLRPRMKCQTATGLIALVWTVSILIAIPSAFTTE RTVSLYVSTNALLAIAIDRYLAIVHPLRPRMKCQTASFLIALVWTVSILIAIPSAFATE RTVSLYVSTNALLAIAIDRYLAIVHPLRPRMKCQTAAGLIFLVWSVILIAIPAAFTTE QGLAVQVSTITLTVIALDRHRCIVYHLESKISKRISFLIIGLAWGISALLASPLAIFREY QGLAVQVSTITLTVIALDRHRCIVYHLESKISKRISFLIIGLAWGISALLASPLAIFREY QGLAVQVSTITLTVIALDRHRCIVYHLESKISKRISFLIIGLAWGISALLASPLAIFREY QGLAVQVSTITLTVIALDRHRCIVYHLESKISKRISFLIIGLAWGISALLASPLAIFREY QGLAVQVSTITLTVIALDRHRCIVYHLESKISKRISFLIIGLAWGISALLASPLAIFREY QAVSVLVSAITLVAISIDRYLAIMWPLKPRITKRYATFIAGVWFIALATALPIPIVSGL QVVAVFLSAITLVAMSVDRYVAIKPWRPRLSKRAFAITMATIWLISLAPLPTAITSRV </div> </div>	

Figure 19

	⑧	***** TM5 *****
GPRv21	TVLVIVKSQ--EKIFCGQINPVDQQ--LYYKSYFLIFGIEFVGPVVTMTLCYARISRELW	
AL121755	TVLFIVKSQ--EKIFCGQINPVDQQ--LYYKSYFLIFGVEFVGPVVTMTLCYARISRELW	
AF236082	TVLVIVERQ--EKIFCGQINPVDQQ--FYYSYFLLVFGLEFVGPVVAMTLCYARVSRELW	
U42766	SLIEIIPDF--EIVACTEKWPGEESYIGTVYSLSSLLILYVPLGIISFSYTRIWSKLK	
U76254	SLIEIIPDF--EIVACTEKWPGEESYIGTVYSLSSLLILYVPLGIISFSYTRIWSKLK	
U42389	SLIEIIPDF--EIVPCTEKWPAEESYIGTVYSLSSLLILYVPLGIISFSYTRIWSKLK	
U50144	SLIEIIPDF--EIVACTEKWPGEESYIGTVYSLSSLLILYVPLGIISFSYTRIWSKLK	
D86238	SLIEIIPDF--EIVACTEKWPGEESYIGTVYSLSTLLILYVPLGIISFSYTRIWSKLK	
M81490	DIPNSPWHTKCEKYICREMWPSRSQ--EYYYTSLFALQFVPLGVLIIFYARITIRVW	
AF037444	TKQSNSTGL-----CLEHFENDHN--RYIYSIVIMMLQYFVPLAVITVTNTHIGYIVW	
	* : : : * : : : . * : : . : :	
	***** TM6 *****	
GPRv21	FKAVPG-FQTEQIRKRLRCRRKTVLVLMCILTAYVLCWAPFYGFTIVRDFPPTVFVKEKH	
AL121755	FKAVPG-FQTEQIRKRLRCRRKTVLVLMCILTAYVLCWAPFYGFTIVRDFPPTVFVKEKH	
AF236082	FKAVPG-FQTEQIRRTVRCRRRTVLGLVCVLSAYVLCWAPFYGFTIVRDFPPTVFVKEKH	
U42766	NHVSPG-AANDHYHQR---RQKTTKNLVCVVVFAVSWLPLHAFQLAVD-IDSQVLDLKE	
U76254	SHVSPG-AANDHYHQR---RQKTTKNLVCVVVFAVSWLPLHAFQLAVD-IDSQVLDLKE	
U42389	NHVSPG-AANDHYHQR---RQKTTKNLVCVVVFAVSWLPLHAFQLAVD-IDSQVLDLKE	
U50144	NHVSPG-AANDHYHQR---RQKTTKNLVCVVVFAVSWLPLHAFQLAVD-IDSHVLDLKE	
D86238	NHVSPG-AANDHYHQR---RHKMTKNLVCVVVFAVSWLPLHAFQLAVD-IDSHVLDLKE	
M81490	AKRPPGEAETNRDQRMARSKRMVKNMLTVVIVFTCCNLPFNILQLLLN--DEEFAHNDP	
AF037444	IKKTPGEAEEDRRRMAASKRRLVKMIIIVVVYAVCNLPVHVITLVGD-HNPDIDYNQPH	
	: ** : : : : : : : : . * * . : : : . .	
	***** TM7 *****	
GPRv21	YLTAFYIVECIAMNSMINTLCFVTVKNDTVKYFKKIML-----LHWKASYNGGKS	
AL121755	YLTAFYVVECIAMNSMINTVCFVTVKNNTMKYFKKMML-----LHWRPSQRGSKS	
AF236082	YLTAFYVVECIAMNSMINTLCFVTVRNNTSKYLKRILR-----LQWRASPSGSKA	
U42766	YKLIFTVFHIIAMCSTFANPLLYGWNNSNYRKAFLSAFR-----CEQRLDAIHSEV	
U76254	YKLIFTVFYIIAMCSTFANPLLYGWNNSNYRKAFLSAFR-----CEQRLDAIHSEV	
U42389	YKLIFTVFHIIAMCSTFANPLLYGWNNSNYRKAFLSAFR-----CEQRLDAIHSEV	
U50144	YKLIFTVFHIIAMCSTFANPLLYGWNNSNYRKAFLSAFR-----CEQRLDAIHSEV	
D86238	YKLIFTVFHIIAMCSTFANPLLYGWNNSNYRKAFLSAFR-----CEQRLDAIHSEV	
M81490	LPYVWFAFHWLANSHCCYNPIIYCYMNAFRSGFVQLMHRMPGLRRWCCLRSVGDNRNAT	
AF037444	MNVVNLCAQWLANSHSCYNPFVYFSLSATFRRNLRNTHACRLKQKR-LRQHLSMRSSRA	
	: : ** . * . : : : : . . .	
GPRv21	S-----ADLDLKTIGM---PATEEVDCIRLK-----	
AL121755	S-----ADLDLRTNGV---PTTEEVDICIRLK-----	
AF236082	S-----ADLDLRTTGI---PATEEVDCIRLK-----	
U42766	SVTFKAK-----KNLEVRKNSG---PNDSFTEATNV-----	
U76254	SVTFKAK-----KNLEVRKNSG---PNDSFTEATNV-----	
U42389	SVTFKAK-----KNLEVRKNSG---PNDSFTEATNV-----	
U50144	SVTFKAK-----KHLQVTKNNG---PNDSFTETTIV-----	
D86238	SVTFKAK-----KNLEVKKNNG---PTDSFSEATNV-----	
M81490	SGTGPALPLN--RWNTSTTYISARRKPRATSLRANPLSCGETSPLR-----	
AF037444	DAWDRDTEVYCSAESIPSKVSAGSLHSSNRGAKHVNTSSGEWQCLKEKCLKGVSNOMYL	

Figure 20




Figure 21

```

**
***** TM1 **
1 MEDLFSPSIL PPAPNISVPI LLGWGLNLT GQAPASGPP SRRVRLVFLG VILVVAVAGN 60

*****
***** TM2 *****
61 TTVLCRLCGG GGPWAGPKRR KMDFLVQLA LADLYACGGT ALSQLAWELL GEPRAATGDL 120

*****
@ ***** TM3 ***** ***** TM4 *****
121 ACRFLQLLQA SGRGASAHV VLIALERRA VRLPHGRPLP ARALAALGWL LALLLALPPA 180

*
*****
*** @ ***** TM5
181 FVYRGDSPSP LPPPPPTSL QPGAPPAARA WPGQRRCHGI FAPLPRWHLQ VYAFYEAVAG 240

*****
*****
241 FVAPYTVLGV ACGHLLSVWW RHRPQAPAAA APWSASPGRA PAPSALPRAK VQSLKMSLLL 300

*****
# TM6 ***** ***** TM7 *****
301 ALLFVGCELP YFAARLAAW SSGPAGDWEG EGLSAALRVV AMANSALNPF VYLFFQAGDC 360

361 RLRRQLRKRL GSLCCAPQGG AEDEEGPRGH QALYRQRNPH PHYHARREP LDEGGLRPPP 420

421 PRPRPLPCSC ESAF

```

Figure 22




Figure 23

HSR2R_1	
D49783	
M32701	
U25440	
S57565	
S73473	
M74716	
U64032	MTFRDLLSVTFEGPRPDISAGGSGAGGGAGAGAGAGDTASSESPAVGGVPGAAGGGGGGS
L41147	
GPRv47	
D43633	
HSR2R_1	
D49783	NG TASSFCLODSTACKIT ITV
M32701	MAP NG TASSFCLODSTACKIT ITV
U25440	MIS NG TGSSFCLODPPCRIT VSV
S57565	MAF NG TVPSFCMDFTVYKVT ISV
S73473	MEP NG TVHSCCLODHALKVT ISV
M74716	MAPWPHKNGS LAFWSDAPTLDPASANTSGLPV-VPM-AAAL
U64032	MAPWPHKNGS LAFWSDAPTLDPASANTSGLPV-VPM-AAAL
L41147	VVGAGSGEDHRSSAGEPCGAGGGGE VNGTAAVGGLVSAQSVG VGV
GPRv47	MVP EPGPT ANSTPAWGAGPPSAPGGSG WYAA
D43633	MESSPI PQSSGNSSTLGRVPTPGPSTASGVPEVGLRDV-ASESVLFF
	MMADKTSPIITSDHSISNFSTGLFGPHPTVPPDVGVVTSQSQMKOLFGLF
HSR2R_1	
D49783	VLAVLILITVAGNVVVCLAVGLNRRRLNLTNCFIVSLAITDILLGLLVLPFSAIYQLSCK
M32701	VLAVLILITVAGNVVVCLAVGLNRRRLNLTNCFIVSLAITDILLGLLVLPFSAIYQLSCK
U25440	VLTVLILITVAGNVVVCLAVGLNRRRLNLTNCFIVSLAITDILLGLLVLPFSAIYQLSCK
S57565	ILILILITVAGNVVVCLAVGLNRRRLNLTNCFIVSLAVTDILLGLLVLPFSAIYQLSCK
S73473	VLTTLILITVAGNVVVCLAVGLNRRRLNLTNCFIVSLAATDILLGLLVLPFSAIYQLSFT
M74716	AGALLALATVCGNLLVITAIARTPRLQITNVFVTSLATADLVGGLVMPGATLALTGH
U64032	AGALLALATVCGNLLVITAIARTPRLQITNVFVTSLATADLVGGLVMPGATLALTGH
L41147	FLAAFIITAVAGNLLVILSVACNRHLQTYTNYFIVNLAVADLLSATVLPFSATMEVLGF
GPRv47	ALCVVIALTAANSLLIALICTQPALRNTSHFFLVSLFTSDLMVGLVMPGATLALTGR
D43633	FMLLLDLTAVAGNAAVNAVIAKTPALRKFFVFLCLVDLLAALTLMPLANLSSSALFDM
	CNVTNLIALANTGVMAIARAPHLKKFAFVCHLCAVDVLCAILLMLPLGISSSPFFGT
HSR2R_1	
D49783	WSFGKVFCNIYTSLOVMLCTASILNLFMISLDRYCAVNDPLRYPVLVTPARVAISLVLI
M32701	WSFGKVFCNIYTSLOVMLCTASILNLFMISLDRYCAVNDPLRYPVLVTPARVAISLVLI
U25440	WSFGKVFCNIYTSLOVMLCTASILNLFMISLDRYCAVNDPLRYPVLVTPARVAISLVLI
S57565	WSFGKVFCNIYTSLOVMLCTASILNLFMISLDRYCAVNDPLRYPVLVTPARVAISLVLI
S73473	WPLGATGCELWTSVDVLCVTASIETLCALAYDRYLAVTNPLRYGTLVTKRRARAAYVLV
M74716	WPLGATGCELWTSVDVLCVTASIETLCALAYDRYLAVTNPLRYGTLVTKRRARAAYVLV
U64032	WAFGRAFCDVAAVDVLCCTASILSLCTISVDRYVGYRHSKYPAINTEKAAAIALLL
L41147	WVLARGLCCLWTAFDVMCCSASILNLCISLDRYLLISPLRYKLRTPLRALALVLCAN
GPRv47	ALFGEVACRLYLFLSVCFVSLAIVSYSAINVERYYYVHPNRYEVRNTLGLVASVLCVW
D43633	VVFTILECQVYIFLNVFLWLSILITAIISVERYFYIHPNRYEVKMTINLVIGVMLLI

Figur 24

```

#####
HSH2R_1 VISITLSFLSIHLGWN---SRNETSKGNHTTSKCH---VQVNEVYGLVDGLVTFYLPLLIMCI
D49783 VISITLSFLSIHLGWN---SRNETSKGNHTTSKCH---VQVNEVYGLVDGLVTFYLPLLIMCI
M32701 VISITLSFLSIHLGWN---SRNETSSFNHTIPKCK---VQVNLVYGLVDGLVTFYLPLLIMCI
U25440 VISITLSFLSIHLGWN---SRNETSKDNDTIVKCK---VQVNEVYGLVDGLVTFYLPLLIMCI
S57565 VISITLSFLSIHLGWN---SRNGTRGCGN-DTFKCK---VQVNEVYGLVDGLVTFYLPLLIMCV
S73473 IVSATYSFAPIMSQWVRVGADAEAEQCHSNPRCCS---FASNMPYALLSSSVSYFYPLLVMLF
M74716 IVSATYSFAPIMSQWVRVGADAEAEQCHSNPRCCS---FASNMPYALLSSSVSYFYPLLVMLF
U64032 AVALVYS-NGPLLGWK---EPVPPD-ERFC---GITEEVGAVFSSLCFSYLPNAVIVV
L41147 SLAALASFLPLLGH---ELGHARPPVPGQC---RLLASLPFVLVASGLTFFLPSCAICF
GPRv47 VKALAMASVPVLGRVS-WEEGAPSVPPG---CSLQWHSAYCQLFVVVFAYLYFLLPLLILV
D43633 FKSLLA-LVTLFGWPPYGHQSSIAASH---CSLHASHSRLRGVFAVLFVCIFLAPVVVIFS
: : * : : * :

8
HSH2R_1 TYRIFRVARDAQKRID-HIS-----SWKAATIR-----
D49783 TYRIFKVARDAQKRIN-HIS-----SWKAATIR-----
M32701 TYRIFKVARDAQKRIN-HMG-----SWKAATIG-----
U25440 TYRIFKVARDAQKRIN-HIG-----SWKAATIR-----
S57565 TYRIFKVARDAQKRIN-HIS-----SWKAATIR-----
S73473 VYARVFVAKRQRRLLRRELGRFPPEESPRSPSRSPATVGTPTAS---DCVPSCGR
M74716 VYARVFVAKRQRRFVRRELGRFPPEESPRSPSRSPATVGTPTAS---DCVPSCGR
U64032 MYCRVYVVARSTTRSLAEGVKRERKASEVLR IHCRGAASGADGAPGRGAKHTFRSS
L41147 TYCRILLAARKQAVQVSLTTG-----MASQASETLQVPRTP-R-PGVESADS
GPRv47 VYCSMFVARVAAMQHGCLPTWNETP-----RQRSESLSSR-S-TNVTSSGA
D43633 VYSAVYKVARSAALQVPAVPTWADAS---PAKDRSDSINSQTT---IITRTLP
* : * :

##### TM6 #####
HSH2R_1 -----EHRATVTLAAVMGAFIICWFPYFTAFVYRGLRGDDA INENLEAIVLWLG
D49783 -----EHRATVTLAAVMGAFIICWFPYFTAFVYRGLRGDDA INEYLEAIVLWLG
M32701 -----EHRATVTLAAVMGAFIICWFPYFTAFVYRGLRGDDA INEAFEAVVWLG
U25440 -----EHRATVTLAAVMGAFIICWFPYFTAFVYRGLRGDDA INEYFEDVVLWLG
S57565 -----EHRATVTLAAVMGAFIICWFPYFTAFVYRGLRGDDA INEAVEGIVLWLG
S73473 RPARLLPLG-EHRALRTLGLINGIFSLCWL PFFLANVLRALVGPSPVSGVFIALNWLG
M74716 RPARLLPLG-EHRALRTLGLINGIFSLCWL PFFLANVLRALVGPSPVSGVFIALNWLG
U64032 LSVRLKFSREKKAAKTLAIVGVFVLCWFPFFVLPGLSLFPQLKPSGCVFVIFWLG
L41147 RRLATKHSRKALKASLTGLILLGMFFVTWLPFFVANIVQAVC---DCISPLFDVLTWLG
GPRv47 PQTTPHRTFGGKAAVLLAVGGQFLLCWLPYFSFHLVYALSAQPISTGQVESVVTWIG
D43633 QRLSPERAFSGGKAALTAFIVGQFLVCLPFFIFHLQMSLTGSMKSPGDL EAVNWLAY
: * : * : * : * : * : * :


TM7 #####
HSH2R_1 ANSALNPILYAALNRDFTGYQQLFCCRLANRNSHKTSLSRNASQLSRTQSREPR---Q
D49783 ANSALNPILYAALNRDFTGYQQLFCCRLANRNSHKTSLSRNASQLSRTQSREPR---Q
M32701 ANSALNPILYATLNRDFTAYQQLFRCRPAASHNAQETSLRSNSSQLARNQSREPR---R
U25440 ANSALNPILYAALNRDFTAYHQLFCCRLASHNSHETSRLNNSQLNRSQCQEP---B
S57565 ANSALNPILYAALNRDFTAYQQLFHCKFASHNSHKTSLSRLNNSLLPRSQSREGR---B
S73473 ANSAFNPLIYCR-SPDFRDAFRLL-CSYGGRGPEEP---RVVTFPASPVASR---
M74716 ANSAFNPLIYCR-SPDFRDAFRLL-CSYGGRGPEEP---RVVTFPASPVASR---
U64032 FNSCVNPLIYPCSSREFKRAFLRLRCQCRRRRRRPLWRVYGHWRASAGGPHPOCAL
L41147 CNSTWNPILYPLFNRDFKRALGRFLPCPCPRERQAS-LASPSLRTSHSGPRPGLS---L
GPRv47 FCFTSNPFFYGCNLRQIRGELSKQFVCFKPAPEEELRLPSREGSI EENFLQ---F
D43633 SSFAVNPFFYGLLRQIRDELVKFRRCCVTQVPEIGP---SSLEGSFQENFLQ---F
* : * : * : * :

```

Figure 25

HSH2R_1	QEEKPLKLQVWSGTEVT-----
D49783	QEEKPLKLQVWSGTEVTAPQCATOR-----
M32701	QEEKPLKLQVWSGTEVTAPRCATOR-----
U25440	QEDKPLNLQVWSGTEVTAPQCATOR-----
S57565	QEEKPLKLQVWSGTELTHPQCNPIR-----
S73473	QNS-PLNR--FDGYEGERP-FPT-----
M74716	QNS-PLNR--FDGYEGERP-FPT-----
U64032	SAGAALPGAALALTAAPAPSSAAAPEGQAACAGRRKPPCAFREWRLGPLRRPTTQLRAK
L41147	QQVLPPLPPDSOSDSDACSGSSGLRLTAQLLLPGEATQDPPLPTRAAAANFFNIDPA
GPRv47	LQGTGCPSESWSRPLSPKQEPVDFRIPGQIAEETSEFLEQQLTSDIIMSDSYLRPA
D43633	IQRTSSSSSETHPSFANSNP-RNMQAHKIPGQIPPEQA-----
HSH2R_1	-----
D49783	-----
M32701	-----
U25440	-----
S57565	-----
S73473	-----
M74716	-----
U64032	VSSLSHKIRAGGAQRAEAACALRSEVEAVALSVARDVAEDNTCQAYELADYRNLRETDI
L41147	EPELRPHPLGIPTN-----
GPRv47	ASPRLES-----
D43633	-----

Figure 26



		***** TM1 *
GPRv51	-----	WNQTLNSSGTVESALNYSRGSTVHTAYLVLSLAMFTCLCGMA
M35297		MAGNCSWEAHSTNQNMCPGMSEALELYSRGFLTIEQIATLPPPAVTNYIFLLLCLCGLV
		** . . * *: **** . . * . : : : ****:
	*****	***** TM2 *****
GPRv51		GNSMVIWLLGFRMHRNPFCIYILNLAADLLFLFSMASTLSLETQPLVN-TTDKVHELMK
M35297		GNGLVLWFFGFSIKRTPFSIYFLHLASADGIYLFSAVIALNMGTFLGSPDYVRRVSR
		** : * : * : * : : * . * . * : * : * : * : : * : : * : * : :
	***** TM3 *****	***** TM4 *****
GPRv51		RLMYFAYTVGLSLLTAISTQRCLSYLFPWFKCHRPRHLSANVCGLLWTLCLLMNGLTSS
M35297		IVGLCTFFAGVSLLPAISIERCVSVIFPMWYWRPRKRLSAGVCALLWLLSFLVTSIHNY
		: : : . * : * . * . * : * : * : * : * : : * : * . * : * : . .
	*	***** TM5 *****
GPRv51		FCSKFLKFNE-DRCFRVDMVQAALIMGVLTPLYMTLSSLTFLVWVRRSSQWRRQPTRLFV
M35297		FCMFLGHEASGTACLNMDISLGILLFFLCPLMWLPCLALILHVECRARRRQRS-AKLNH
		** : : . * : : * . * : : : * : * . * : * : * . : : : * : : *
	***** TM6 *****	***** TM7 *****
GPRv51		VVLASVLVFLICSLPLSIYWFVLYNLSLPPENQVLCFSLSRSSSVSSSANPVIYFLVGS
M35297		VVLAIVSVFLVSSIYLGIDWFLFWVFQIP---APFPEYVTDLCICINSSAKPIVYFLAGR
		**** * * : : . * : * * : : : : : : : * . . * : * : * : * : *
GPRv51		RRSHRLPTRSLGTVLQQALRE--EPELEGGETPTVGTNEMGA-----
M35297		DKSQRLNEP-LRVVFQALRDGAEPGDAASSTPNTVTMEMQCPSGNAS
		: * : * * . * : * : * : * : * . . . * . * * .

Figure 28





Figure 29

Y14705	-----MTSAESLLFTSLGPSPPSSGDCRFNEEFKFI LLPSYAVVFLGLAL	***** TM1 **
AJ277752	-----MTSADSLFTSLGPSPPSSGDCRFNEEFKFI LLPSYAVVFLGLAL	
AF031897	-----MDAPVRMFLAPWTPTPTWLGNTTAAAEACVFNEEFKFI LLPSYAVVFLGLAL	
X99953	MTEDIWATSYPTFLTTPYLPKLLMNLNDTEDICVFDEGFKFLLPVSYSAVFNVLGLPL	
AF069555	-----MSMANFTA-----GR-----NSCTFQEEFKQVLLPLVYSVVFLGLPL	
X98283	-----MSMANFTG-----GR-----NSCTFHFEFKQVLLPLVYSVVFLGLPL	
D63665	-----MERDNGTIQAPGLPP-----TTCVYREDFKRLLLPPVYSVVFLVGLPL	
GPRv71	-----NEKVDNNTSQ-----EQ-----GLCQFSEKYKQVYLSLAYSJIFILGLPL	
	* : * : * : *	
Y14705	***** TM2 *****	*****
AJ277752	NAPTLLWFLFLRPLWDATATYMFHLALSDTLVLSLPTLVYVYAARNHWPFGTGLCKFVR	
AF031897	NAPTLLWFLFLRPLWDATATYMFHLALSDTLVLSLPTLVYVYAARNHWPFGTGCKFVR	
X99953	NSWANWIFVSRMRPNWATTYMFHLALSDTLVLSLPTLVYVYADRNHWPFGKVFCIVR	
AF069555	NIAANWIFI AKMRPNWPTTYMFHLALSDTLVLSLPTLVYVYADKNHWPFGVLCCLVR	
X98283	NAVVI GQIWLARKALTRTTIYMLNLATADLLVCSLPLL IYNYTKQDYWPFQDFTCKFVR	
D63665	NAVVI GQIWLARKALTRTTIYMLNLAMADLLVCSLPLL IYNYTKQDYWPFQDFTCKFVR	
GPRv71	NVCVIAQICASRRTLRSAYTYLNLALADLLYACSLPLL IYNYARGDHWPFQDLACRLVR	
	NGTVLWHFWGQTKRWSCATTYLVNLMVADLLYVL-LPFL IITYSLDRWPFQDGLCKLVH	
	* : : : : * : * : * : * : * : *	
Y14705	***** TM3 *****	***** TM4 *****
AJ277752	FLFYWNLYCSVFLTCISVHRYLGICHPLRAIRWGRPR-FASLLCLGVWLVVAGCLVPNL	
AF031897	FLFYWNLYCSVFLTCISVHRYNGICHPLRAIRWGRPR-FAGLLCLGVWLVVAGCLVPNL	
X99953	FLFYANLYSSIFLTCISVHRYNGICHPI RSLKWKTK-HARLICVGVWLVVTCICLPNL	
AF069555	FLFYANLYSSIFLTCISVHRYRGVCHPITSLRRMNAK-HAYVICALVWLVVTCICLPNL	
X98283	FQFYTNLHGSIFLTCISVQRYNGICHPLASWHKKKGKLTWLVCAAYWFI VIAQCLPTF	
D63665	FQFYTNLHGSIFLTCISVQRYNGICHPLASWHKKKGKLTWLVCAAYWFI VIAQCLPTF	
GPRv71	FLFYANLHGSIFLTCISFQRYLGICHPLAPWHKRGGRRAANVVCVWLVVTAQCLPTA	
	FLFYINLYGSILLTLCISVHQLGVCHPLCSLPYRTRR-HAWLGTSTTALVVLQLLPTL	
	* ** ** : * : * : * : * : * : * : * : *	
Y14705	***** TM5 *****	*****
AJ277752	FFVTTNANGTTILCHDTTLPEEFHDYVYFSSAVMVLLFGLPFLITLVCYGLMARRLYRPL	
AF031897	FFVTTNANGTTILCHDTTLPEEFHDYVYFSSIMVLLFGFPFLITLVCYGLMARRLYRPL	
X99953	IFVTTSSKONSTLCHDTTKPEEFHDYVHYSSIMALLFGIPFLIVVVCYGLMARRLYRPL	
AF069555	IFVTVSPKVNTICNDTTRPEDFARYVEYSTAIMCLLFGIPCL IAGCYGLMTRRLMKPI	
X98283	VFASTGTQRNRTVCYDLSPPDRSASYFPGITLTITGFLLPFAAILACYCSMARILCQKD	
D63665	VFASTGTQRNRTVCYDLSPPDRSTSYFPGITLTITGFLLPFAAILACYCSMARILCQKD	
GPRv71	VFAATGQRNRTVCYDLSPPILSTRYLPYGMALTVIGFLLPFTALLACYCRMARRLCRQD	
	AFSHTDYINGQMIWYDNTSQENFDRLFAYGIVLTLSGFLSLLGHFGLFTDQGEFQDARG	
	* .. : * : * : * : * : *	
Y14705	***** TM6 *****	*****
AJ277752	PGAGQS-----SSRLRSLRTIAVVLTVFAVCFVPHITRTIYYQAR-LLQADCHVLNIVNVV	
AF031897	PGAGQS-----SSRLRSLRTIAVVLTVFAVCFVPHITRTIYYLAR-LLNAECRYLNIWNVV	
X99953	FPSPPSPRVPYKRSIKMIIIVLTVFAICFVPHITRTLYYTSR-YFQADQCQLNIINFT	
AF069555	VSGNQQLTPSYKRSIKTIIFVMIAFAICFMPHITRTLYYAR-LLGIKCYALNIVNVT	
X98283	ELIGLAVH-KKKDKAVRMIIIVVIFSISFFPFHLTKTIYLIIVRSSPTLPCPTLQAFAlA	
D63665	ELIGLAVH-KKKDKAVRMIIIVVIFSISFFPFHLTKTIYLIIVRSSASLPCTLQAFAlA	
GPRv71	GPAGPYAQ-ERRSKAARMAYVVAAYFVIFLPHITKTAYLAVRSTPGVSCPYLETFAAA	
	EPHEDRQHSPSQVHPDHTGVNPLHPLFCALPYMSLLLPHLLSAFSGLPALDGSQCGLQ	
	: : : : * : *	

Figure 30

	88888 TM7 888888888	
Y14705	YKYTRPLASANSCLDPVLYLFTGDKYRNQLQQLCRGSK--PKPR-----	TAASSL
AJ277752	YKYTRPLASANSCLDPVLYLFTGDKYRNQLQQLCRGST--PKRR-----	TTASSL
AF031897	YK1TRPLAS INSCLDPI LYFMAGDKYRGRLRRGAAQR--P-R-----	PVPTSL
X99953	YKYTRPLASANSCLDPILYFLANDRYRRRLIRTVRRRSSVPNRRCMHTNHPQTEPHMTAG	
AF069555	YKCTRPFASMN SVLDPILFYFTQRFRESTRYLLDKMS-----	SKWRHD
X98283	YKCTRPFASMN SVLDPILFYFTQRFRESTRYLLDKMS-----	SKWRQD
D63665	YKGTRPFASANSVLDPI LFYFTQKFRRQPHDLLQKLT-----	AKWQRQ
GPRv71	DWEASGECEQLPQPSPVLSFKGGKNRVRLQLKLRQNKLG-----	EHPAGRK
	:*:*	
Y14705	ALVTLHEESISRWADTHQDSTFSAYEGDRL-----	
AJ277752	ALVTLHEESISRWADIHQDSIFPAYEGDRL-----	
AF031897	LALVSPSVDS SVVGGSCCNSE-----SRGMGTVWSRGGQ-----	
X99953	PLPYISAEI PSNGSMVRDENGESREHRVEWTDKEINQMMNRSTIKRNSTOKHDMKE	
AF069555	HCITYGS-----	
X98283	HCISYGS-----	
D63665	RV-----	
GPRv71	RCFGLNRSG-----	
Y14705	-----	
AJ277752	-----	
AF031897	-----	
X99953	NRHGENYLPYVEVVEKEDYETKRENKRTTEQSSKTNAEQDELQTQIDSRKRGKWQLSSK	
AF069555	-----	
X98283	-----	
D63665	-----	
GPRv71	-----	
Y14705	-----	
AJ277752	-----	
AF031897	-----	
X99953	KGAAQENEGHMEPSFEGEGTSTWNLLTPKMYGKKDRLAKNVEEVGYGKEKELQNFPA	
AF069555	-----	
X98283	-----	
D63665	-----	
GPRv71	-----	

Figure 31



111

112

U03866
L31774
D25235
D32202
D32201
AF013261
U81982
U07126
S71323
D63859
AF091890
GPRv72

INTERNATIONAL SEARCH REPORT

International application No.

PCT/JP00/09408

A. CLASSIFICATION OF SUBJECT MATTER

Int.Cl⁷ C12N15/09, C12N1/15, C12N1/19, C12N1/21, C12N5/10, C07K14/705, C07K16/28, C12P21/02, C12Q1/02, C12Q1/68, A61K31/711, A61K48/00, A61P43/00, G01N33/15, G01N33/50

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

Int.Cl⁷ C12N15/00-15/09, C07K14/705

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

GeneBank/EMBL/DBJ/GenSeq

SwissProt/PIR/GenSeq

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	JP, 8-245697, A (Takeda Chemical Industries, Ltd.), 24 September, 1996 (24.09.96) (Family: none)	1-15, 17
A	WO, 98/46620, A1 (MILLENNIUM PHARM INC), 22 January, 1998 (22.01.98) & AU, 9869736, A & US, 5891720, A & EP, 1007536, A1	1-15, 17
A	WO, 99/37679, A1 (MILLENNIUM PHARM INC), 29 July, 1999 (29.07.99) & US, 5945307, A & AU, 9922369, A & EP, 1056777, A1	1-15, 17

☐ Further documents are listed in the continuation of Box C.☐ See patent family annex.

* Special categories of cited documents:
 "A" document defining the general state of the art which is not considered to be of particular relevance
 "E" earlier document but published on or after the international filing date
 "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
 "O" document referring to an oral disclosure, use, exhibition or other means
 "P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
 "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
 "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
 "&" document member of the same patent family

Date of the actual completion of the international search
 27 March, 2001 (27.03.01)

Date of mailing of the international search report
 10 April, 2001 (10.04.01)

Name and mailing address of the ISA/
 Japanese Patent Office

Authorized officer

Facsimile No.

Telephone No.

Form PCT/ISA/210 (second sheet) (July 1992)

INTERNATIONAL SEARCH REPORT

International application No.

PCT/JP00/09408

Box I Observations where certain claims were found unsearchable (Continuation of Item 1 of first sheet)

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.: 16
because they relate to subject matter not required to be searched by this Authority, namely:
The invention as set forth in claim 16 pertains to methods for diagnosis of diseases and thus relates to a subject matter which this International Searching Authority is not required, under the provisions of Article 17(2)(a)(i) of the PCT and Rule 39.1(iv) of the Regulations under the PCT, to search.
2. ☐ Claims Nos.:
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of Item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

The inventions as set forth in claims 1 to 15 and 17 are divided into groups of 9 individual inventions, i.e., inventions relating to DNAs encoding the amino acids of SEQ ID NOS:1 to 4 and 17 to 21, and DNAs having the sequences of SEQ ID NOS:5 to 8 and 22 to 26. These groups of inventions are not considered as relating to a group of inventions so linked as to form a single general inventive concept.

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☒ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:
Claims 1 to 15 and 17 (inventions relating to the DNA encoding the amino acid sequence of SEQ ID NO:1 and the DNA having the sequence of SEQ ID NO:5)

Remark on Protest ☐ The additional search fees were accompanied by the applicant's protest.
☐ No protest accompanied the payment of additional search fees.

Form PCT/ISA/210 (continuation of first sheet (1)) (July 1992)

THIS PAGE BLANK (USPTO)